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Stellingen behorende bij het proefschrift
Out of Balance
Neurocognitive mechanisms underlying 
depression in Parkinson’s disease
I. Depressieve klachten bij de ziekte van Parkinson worden vaak niet 
onderkend (dit proefschrift)
II. Veranderingen in het dopaminerge systeem dragen bij aan het ontstaan 
van depressieve klachten bij patiënten met de ziekte van Parkinson (dit 
proefschrift)
III. Parkinson patiënten met depressieve klachten (in de voorgeschiedenis) 
zijn slechter in het leren van beloning (dit proefschrift)
IV. Parkinson patiënten met depressieve klachten zijn gevoeliger voor 
de negatieve effecten van dopaminerge medicatie op cognitie (dit 
proefschrift)
V. Door dokters voorgeschreven dopaminerge medicatie verandert de 
manier waarop Parkinson patiënten beslissingen nemen (dit proefschrift)
VI. Beloning als motivator kan Parkinson patiënten helpen om Parkinson 
specifieke cognitieve problemen te overwinnen (dit proefschrift) 
VII. Als onze hersenen simpel genoeg zouden zijn om ze volledig te begrijpen, 
dan zouden wij te simpel zijn om dat te kunnen (Ian Stewart, 1994)
VIII. Chronisch ziek zijn vraagt om chronisch optimisme (Loesje.nl)
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General introduction
Over two-hundred years ago, in 1817, James Parkinson described for the first time in his 
“Assay on the shaking Palsy” a series of patients with the disease that now carries his 
name [1]. Parkinson’s disease is a classical example of a neuropsychiatric disorder. Besides 
the characteristic motor symptoms - bradykinesia, rigidity and tremor -, numerous patients 
with Parkinson’s disease also experience non-motor symptoms, including many psychiatric 
symptoms. The most common are cognitive deficits, apathy, anxiety and depression [2, 
3]. Over the years, a tremendous amount of work has been done to unravel its cause, 
the underlying pathology, the neural and chemical brain alterations contributing to its 
symptomatology and how to best treat patients. Many significant findings have been done, 
such as the discovery of dopaminergic treatment and deep brain stimulation. However, a 
lot still remains unknown. Thus far, Parkinson’s disease cannot be cured or prevented. The 
most important role for clinicians (and other health care professionals) is to support the 
patient, provide tools to enable patients (and their families) to cope with the disease and 
try to minimize symptoms, for instance via medication. With this thesis, I aim to contribute 
to enhancing our understanding and improving diagnosis and treatment of one of the 
symptoms that most severely impacts the quality of life of many patients and their caregivers, 
namely depression [4, 5]. 
Depression in Parkinson’s disease
Depression is one of the most common non-motor symptoms of Parkinson’s disease with 
prevalence rates varying between 2.7% and 90%. The prevalence of clinically significant 
depressive symptoms is estimated around 35% [5]. Depression can occur during every 
disease stage and also precede the motor symptoms, being the first symptom of the disease 
[6, 7]. The neuropathology underlying Parkinson’s disease has been argued to contribute to 
the enhanced depression vulnerability (Box 1). Besides degeneration of the dopaminergic 
system, also other neurotransmitter systems already degenerate in early stages of Parkinson’s 
disease [8]. Alterations in the serotonergic, noradrenergic and dopaminergic system are all 
likely to contribute to depression in Parkinson’s disease. Neuropathological studies have 
shown that noradrenergic neurons in the locus coeruleus and serotonergic neurons in the 
raphe nucleus degenerate in Parkinson’s disease, with more severe degeneration in patients 
who suffer(ed) from depression [9, 10]. Moreover, via nuclear neuroimaging - a technique 
that uses radioactive ligands to visualize binding sides in the brain - it was shown that 
depressive symptoms correlated with lower dopamine and noradrenalin transporter binding 
in several limbic regions, including the ventral striatum [11]. The link between dopamine 
and depression in Parkinson’s disease stems from several lines of evidence, starting with 
observations in clinical practice. When Parkinson’s disease progresses, dopaminergic 
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treatment inevitably leads to the development of response fluctuations. Response 
fluctuations refer to fluctuations in motor symptoms during the day related to dopaminergic 
treatment; periods when dopaminergic medication is effective (ON) are alternated by periods 
when dopaminergic medication effects wear off and motor symptoms reappear (OFF). In the 
majority of patients, these motor fluctuations are, to some extent, accompanied by mood 
fluctuations [12, 13]. Thus, experiencing increased anxiety, apathy or depressive symptoms 
during OFF periods, with improvement of symptoms during ON periods. Secondly and 
perhaps not surprisingly given the aforementioned, it has been shown that dopaminergic 
medication has an antidepressant effect in Parkinson’s disease patients [14, 15]. Finally, 
several nuclear neuroimaging studies revealed a link between depressive symptoms in 
Parkinson’s disease and dopamine transporter availability. Dopamine transporter availability 
is thought to be a biomarker of dopamine neuron degeneration. These studies revealed that 
lower striatal dopamine transporter availability, and thus putatively lower striatal dopamine 
levels, especially in the ventral striatum, were associated with more severe depressive 
symptoms [11, 16-19]. Together, these findings suggest that depression in Parkinson’s disease 
is associated with a hypodopaminergic state, especially of the (ventral) striatum [11, 16, 17]. 
Whereas the link between dopamine and depression in Parkinson’s disease has been clearly 
established, the exact underlying neurocognitive mechanisms still remain unclear. 
Box 1. Neuropathology underlying Parkinson’s disease
Parkinson’s disease is one of the most common neurodegenerative disorders with an estimated 
prevalence of over 400 per 100.000 individuals over the age of 60 [20]. The prevalence 
increases with age, but approximately 10-15 % of patients is diagnosed with Parkinson’s disease 
under the age of 40 [20]. As such, Parkinson’s disease has a tremendous impact on society. 
Neuropathologically, Parkinson’s disease is characterized by the formation of Lewy neuritis and 
intraneuronal Lewy bodies, which mainly consist of the misfolded protein alpha-synuclein. The 
Lewy body pathology spreads via a specific pattern [8]. First the olfactory bulb, the dorsal IX/X 
motor nucleus, the caudal serotonergic raphe nuclei and the noradrenergic locus coeruleus 
are affected. Hereafter, dopaminergic neurons in the pars compacta of the substantia nigra 
degenerate, leading to massive dopamine depletion in the basal ganglia, causing the motor 
as well as some of the cognitive and motivational symptoms that characterize Parkinson's 
disease. During late stage Parkinson’s disease, Lewy body pathology spreads further, affecting 
several cortical areas. In accordance with the neuropathological staging, in the pre-motor 
phase, many Parkinson’s disease patients already experience non-motor symptoms, such 
as constipation, loss of smell, REM-sleep behaviour disorder, anxiety and depression [21]. In 
the new clinical diagnostic criteria, these (and other) non-motor symptoms can contribute to 
establishing a clinical Parkinson’s disease diagnosis [22].   
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Depression; a neurocognitive disorder
Around the 1960s, theories started to evolve that aimed to understand and explain 
depression. These theories focused on depression from two different angles. First there 
was the “monoamine hypothesis of depression”, which stated that an imbalance in specific 
neurotransmitters (i.e. monoamines) causes the core symptoms of depression, namely 
dysphoria (low mood) and anhedonia (a decreased ability to experience pleasure) [23]. 
Around the same time, Beck proposed his cognitive model of depression. This model 
conceptualizes depression as a state in which self reinforcing dysfunctional negative 
schemata – fixed internal models of the self, the world and the future, that are instantiated 
by early adverse experiences – come to dominate every aspect of an individual’s information 
processing [24]. More recently, attempts have been made to reconcile these two approaches, 
converging onto a cognitive neuropsychological model of depression [25-27]. This cognitive 
neuropsychological model conceptualizes core depressed mood and anhedonia, as learned 
states brought forth by dysfunctional negative schemata, instantiated over long periods by 
affective information processing biases. Alterations in monoamine transmission are thought 
to underlie these negative affective processing biases [25, 27-29].
How we perceive information is strongly related to our mood. Individuals who suffer 
from depression, or are at risk of depression, process information in a perturbed manner. 
Processing of negative information is enhanced, while processing of positive information is 
diminished [28, 29]. These so called negative affective biases are observed across several 
cognitive domains, such as emotion recognition, emotional attention, emotional memory and 
reward and punishment processing during for instance learning and decision making [25, 26, 
29]. The cognitive neuropsychological model of depression assigns a causal role to these 
negative affective biases in the development, maintenance and treatment of depression. 
As such, understanding the nature of these biases could help to better treat and eventually 
prevent depression. With respect to depression in Parkinson’s disease, specifically reward 
(and punishment) processing has critically implicated striatal dopamine and as such is 
likely to play a key role. This is the focus of this thesis. Specifically, this thesis aims to 
elucidate dopamine’s role in (aberrant) reward (and punishment) processing in depression in 
Parkinson’s disease, with a focus on three cognitive domains that have critically implicated 
striatal dopamine, namely learning, decision making and incentive motivation.
Dopamine and the reward system 
Extensive neurophysiological experiments in animals and neuropharmacological, genetic 
and neuroimaging studies in humans have revealed that dopamine neurons in the ventral 
tegmental area (VTA) and in the substantia nigra (SN) lie at the centre of the brains’ reward 
circuit [30-35]. These dopamine neurons project from the VTA to the nucleus accumbens 
(the mesolimbic pathway) and frontal cortex (the mesocortical pathway) and from the SN to 
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the striatum (the nigrostriatal pathway). Over the years, several theories evolved trying to 
explain dopamine’s role in reward processing, starting with the hedonia or “liking” hypothesis 
[36]. According to this hypothesis, dopamine in the nucleus accumbens serves as a pleasure 
neurotransmitter, translating sensory inputs into hedonic responses. Indeed, it has been 
shown that many rewards activate the mesolimbic dopamine system, such as food, sex, 
social and cognitive rewards [37-39]. However, subsequent studies revealed that dopamine 
is not necessary nor sufficient to generate a liking response [33, 40]. Current theories have 
assigned a key role to the endocannabinoid, opioid and GABA-ergic circuits in the brain in 
mediating this liking response [41, 42].
Hereafter, two other theories evolved regarding dopamine’s role in reward processing; 
namely learning theory and incentive salience theory. Learning theory is based on ground-
breaking neurophysiological work by Schultz and colleagues who investigated firing rates of 
single dopamine neurons in the VTA of macaques during classical (i.e. Pavlovian) conditioning 
[31]. They showed that, before conditioning, dopamine neurons strongly increased firing in 
response to the (unexpected) reward, but not in response to the cue. However, over time, 
when cue-outcome associations were acquired, dopamine neurons strongly increased firing 
in response to the cue, but not the received reward. Finally, when the predicted reward 
was omitted, firing decreased below baseline at the time of outcome presentation. These 
findings indicated that dopamine neurons via these phasic bursts and dips do not respond 
to reward per se, but rather signal a prediction error, encoding the difference between 
the predicted reward and the received reward. A prediction error can either be positive or 
negative: Positive when the received reward exceeds the prediction and negative when the 
received reward is less than predicted. More recent views postulate that dopamine neurons 
encode subjective rather than objective reward values [43]. This is based on observations 
that dopamine neurons show some degree of temporal discounting – the phenomenon that 
outcome values are diminished or discounted by imposed delays [44, 45]. In other words, 
an immediate reward is generally considered subjectively more valuable than a delayed 
reward. Current views and (computational) models on dopamine’s role in (reward) learning 
and value-based decision making (see for example [46]) are based on these concepts and 
also form the basis of the work described in chapters 3, 4 and 5 of this thesis. 
In incentive salience theory a full reward is considered not only to have a “liking” and a 
“learning” component, but also a “wanting” component. Incentive salience theory assigns 
an important role to dopamine neurons in signalling specifically this “wanting” component 
of reward [33, 47, 48]. In this theory, the above described prediction error signals are 
thought to reflect a conditioned wanting response or “desire”, translating learned cue-
outcome associations into motivation, action and approach behaviour. This theory is based 
on several observations. First, although it has been shown that reward (prediction error) 
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learning is clearly affected by dopaminergic manipulations [49-51], it has also been shown 
that normal reward learning can take place in the absence of dopamine. For instance, 
genetically modified dopamine deficient mice with clear Parkinsonian symptoms are still able 
to demonstrate reward learning [52, 53]. Second, dopaminergic stimulation has been shown 
to specifically increase this wanting component of reward. For example, genetically modified 
hyperdopaminergic mice do not learn stimulus-reward association faster, stronger or more 
persistent, but rather seem to “want” the rewards more [54, 55]. Finally, the dopamine 
system plays a key role in integrating and translating physiological states and learned cue-
outcome associations into a context dependent “subjective” reward value which dynamically 
modulates behaviour. How valuable a specific reward is, strongly depends on the current 
physiological state. When hungry, food is subjectively more valuable than water, but when 
thirsty, water is subjectively more valuable then food. Both work in animals and humans has 
shown that induced changes in physiological states, such as via appetite modulation, affect 
the subjective value of an incentive (i.e. the conditioned stimulus) [48, 56, 57]. Dopamine’s 
role in incentive motivation forms the basis of the work described in chapter 6. 
The dopamine overdose hypothesis
Early studies investigating effects of dopaminergic medication on cognition in Parkinson’s 
disease already indicated that dopaminergic medication can improve as well as impair 
cognitive performance. For instance, Gotham and colleagues observed beneficial effects 
of dopaminergic medication on alternating fluency, but detrimental effects on associative 
conditional learning [62]. Subsequent studies in patients with early stage Parkinson’s disease 
revealed that effects of dopaminergic medication on cognitive function depend on dopamine 
levels in the underlying neurocircuitry (Box 2). Specifically, it was shown that dopaminergic 
medication in Parkinson’s disease improves cognitive functions that are associated with 
the severely dopamine depleted dorsal (cognitive) cortico-striatal circuit, such as task-set 
switching and working memory, but impairs cognitive functions that are associated with 
the less affected ventral (limbic) cortico-striatal circuit, such as reversal learning and risky 
choice [63-67]. These findings have led to the dopamine overdose hypothesis which 
states that dopaminergic medication doses necessary to ameliorate motor and cognitive 
functions associated with the severely depleted dorsal striatum might detrimentally overdose 
dopamine levels in relatively intact brain regions, such as the ventral striatum [62, 64]. 
Further support for this hypothesis came from imaging studies showing that dopaminergic 
medication in Parkinson’s disease modulates the relatively intact ventral striatum during 
reversal learning [68] and that dopaminergic medication-induced impairments in reversal 
learning are associated with greater striatal dopamine release [69].
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Box 2. Cortico-striatal circuits
The basal ganglia are a group of subcortical nuclei deep in the brain. They do not project 
directly to the spinal cord, but are interconnected with the cerebral cortex trough various 
loops that involve the striatum (putamen, caudate nucleus and nucleus accumbens), the 
pallidum (globus pallidus pars interna and externa) and specific nuclei of the thalamus. The 
striatum receives excitatory inputs from the cerebral cortex and send its outputs, via the 
thalamus, back to the cortex forming so called cortico-striatal circuits. Animal tracing work 
has shown that these cortico-striatal circuits are organized in multiple segregated functional 
circuits reciprocally connecting different parts of the striatum with different parts of the cortex 
following a ventromedial to dorsolateral gradient [58, 59] (Figure 1). The ventromedial striatum 
is interconnected with orbitofrontal and limbic regions and involved in reward processing, 
emotion and motivation (limbic loop). The dorsomedial striatum is interconnected with the 
dorsolateral prefrontal cortex and involved in cognitive processes (cognitive loop). The 
dorsolateral striatum is interconnected with the motor cortex and involved in motor function 
and action selection (motor loop). The striatum receives dense dopaminergic projections from 
the ventral tegmental area and substantia nigra. Neuropathological studies revealed that 
dopamine depletion is not uniform across the entire striatum in Parkinson’s disease patients, 
but shows a spatial temporal progression [60]. The dorsolateral striatum (e.g. motor loop) is 
more severely affected than the dorsomedial striatum (e.g. cognitive loop), which again is 
more severely affected than the ventromedial striatum (e.g. limbic loop). 
MotorCognitiveLimbic
DA
Orbitofrontal
cortex
Motor
cortexDorsolateral
prefrontal
cortex
Figure 1. The three main cortico-striatal circuits: (i) motor loop (blue), (ii) cognitive loop (orange) 
and (iii) limbic loop (red). All circuits are innervated by dopaminergic neurons from the midbrain 
(substantia nigra and ventral tegmental area). The arrow thickness represents the relative 
dopaminergic denervation  and subsequent dysfunction in the related circuits in Parkinson’s 
disease.  DA = dopamine. Adapted from [61].
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Similar overdosing effects have been shown for the mesocortical dopamine projections. 
These studies used individual differences in catecholamine-O-methyltransferase (COMT) 
polymorphisms as a proxy for prefrontal cortical dopamine levels [70, 71]. COMT enzyme activity 
regulates prefrontal dopamine levels and polymorphisms in the COMT gene modulate COMT 
activity: The methione (Met) variant is associated with lower COMT activity compared with the 
valine (Val) variant [72]. In a non-Parkinson population it was shown that an increasing number 
of Met alleles, and putatively higher prefrontal dopamine levels, was associated with enhanced 
cognitive performance [73]. By contrast, Met homozygous patients with Parkinson’s disease, 
especially those who received dopaminergic medication, showed impaired performance 
on the Tower of London test of planning [70]. These findings were explained in the context 
of prefrontal dopamine up regulation in early stage Parkinson’s disease and an additional 
“overdosing” by dopaminergic medication. Indeed, and in line with observations that prefrontal 
dopamine levels decrease during more advanced disease stages, it was shown that this 
pattern of results was reversed when the same patients were retested several years later [74]. 
Together these findings provide strong evidence for an overdosing account of detrimental 
effects of dopaminergic medication in patients with Parkinson’s disease. This hypothesis 
has implications for disorders that affect baseline dopamine levels, such as depression. 
As mentioned above, depression in Parkinson’s disease is considered to reflect a 
hypodopaminergic state, especially of ventral striatal dopamine levels. Following the 
overdose hypothesis, patients with Parkinson’s disease and comorbid depression should 
be less likely to experience detrimental effects of dopaminergic medication on cognitive 
tasks that are associated with the ventral cortico-striatal circuit. This hypothesis is tested in 
chapters 3 and 4 (in the domain of learning) and in chapter 5 (in the domain of risky choice). 
Box 3. Direct and indirect pathways in the basal ganglia
Dopamine plays an important role in modulating activity and plasticity in the direct and indirect 
pathways of the basal ganglia. The two pathways are affected differentially by dopamine due to 
the selective expression of D1 and D2 receptors in the direct and indirect pathways, respectively. 
Moreover, downstream effects of D1 and D2 receptors differ. While D1 activation by dopaminergic 
stimulation increases the responsiveness of striatal neurons to sustained cortical glutamatergic 
inputs (i.e. facilitating transmission), stimulation of post-synaptic D2 receptors by dopamine 
reduces excitability of striatal neurons to cortical glutamatergic inputs (i.e. reduces transmission). 
This specific distribution of D1 and D2 receptors in the direct and indirect pathway in combination 
with the contrasting effects of dopamine on these specific receptor subtypes allows dopamine 
to dynamically modulate the balance between direct and indirect pathway activity. Increases in 
dopamine have a net effect of increasing activity in the direct (GO) pathway and decreasing activity 
in the indirect (NOGO) pathway, while decreases in dopamine have a net effect of increasing 
activity in the indirect (NOGO) pathway and decreasing activity in the direct (GO) pathway (Figure 1).
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Box 3. Continued
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Figure 1. Schematic overview of the direct (‘GO’) and indirect (‘NOGO’) pathways of the basal 
ganglia. A. Normal situation. B. Low dopamine levels (Parkinson’s disease without medication). 
C. High dopamine levels (Parkinson’s disease with detrimental overdosing by dopaminergic 
medication). Adapted from [61]. 
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Reward and punishment learning
In Parkinson’s disease, dopaminergic medication has been shown to impair reversal 
learning - the ability to flexibly adjust behaviour when previously learned reward 
contingencies reverse. To explain these detrimental “overdosing” effects of dopaminergic 
medication on reversal learning, Frank and colleagues developed a neurocomputational 
model of the basal ganglia based on the work described above by Schultz and colleagues 
[75]. They simulated dopamine bursts during a positive prediction error and dopamine 
dips during a negative prediction error. The model showed that dopamine bursts during 
(unexpected) rewards promote reward learning via increased activity in the D1 (GO) 
pathway, while dopamine dips during (unexpected) punishments promote punishment 
learning via increased activity in the D2 (NOGO) pathway (see Box 3 for an overview of 
the direct and indirect pathways of the basal ganglia). Using a probabilistic selection 
task, they showed that dopaminergic medication induces a shift in the balance between 
learning from reward versus punishment. When patients were tested OFF dopaminergic 
medication, they were impaired in learning from reward, whereas when tested ON 
dopaminergic medication, they were impaired in learning from punishment [76]. The 
model correctly predicted these effects of dopaminergic medication. Low dopamine 
levels during the OFF state reduced the ability to generate a dopamine burst (i.e. the 
encoding of a positive prediction error) during positive reward, impairing reward learning, 
whereas high dopamine levels during the ON state diminished the phasic dopamine 
dip (i.e. the encoding of a negative prediction error) during punishment (or a reward 
omission), impairing punishment learning. 
Hereafter, it has consistently been shown, both in healthy individuals as well as in patients 
with Parkinson’s disease, that the balance between learning from reward and punishment 
critically depends on striatal dopamine levels [49-51, 77]. The task used in chapter 3 of 
this thesis was specifically designed to assess the effects of dopaminergic medication on 
prediction error signalling during reward and punishment reversal learning [49, 50]. 
Depression is characterized by negative affective biases, which includes negative learning 
biases. For instance, depressed individuals (without Parkinson’s disease) adjust their 
behaviour faster after perceiving misleading negative feedback [78] and are more likely 
to show a catastrophic response to failure – a deterioration in performance after making 
an error [79]. Moreover, depressed individuals (without Parkinson’s disease) fail to develop 
a positive response bias [80, 81] and exhibit impaired reward-based learning [82]. Ventral 
striatal dysfunction plays a critical role in aberrant reward processing in depression. With 
functional MRI it was shown that depressed individuals (without Parkinson’s disease) exhibit 
attenuated ventral striatal responses to rewarding outcomes [83-85], including during reward-
based learning (using the exact same task as employed in chapter 3 of this thesis) [82]. 
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Moreover, animal models of depression revealed that a depressive-like state is accompanied 
by decreases in firing rate of VTA dopaminergic neurons [86]. 
Thus, striatal dopamine levels modulate the balance between learning from reward versus 
punishment. Parkinson’s disease patients without medication show impairments in learning 
from reward, with an opposite pattern when tested ON medication. Depression in Parkinson’s 
disease is hypothesized to reflect a (ventral) striatal hypodopaminergic state. And finally, 
depressed individuals (without Parkinson’s disease) show impaired reward and enhanced 
punishment learning (comparable to Parkinson’s disease patients when tested OFF medication). 
Based on this literature, I predicted depression in Parkinson’s disease to be accompanied by 
an impairment in reward versus punishment-based learning, especially during the OFF state 
and that this deficit would be remedied by dopaminergic medication. By contrast, I predicted 
non-depressed patients to exhibit normal reward versus punishment-based learning OFF 
medication and a detrimental overdosing effect, impairing punishment versus reward-based 
learning ON medication. I predicted that these differences between depressed and non-
depressed patients and the effects of dopaminergic medication would be accompanied by 
modulation of activity in the striatum. These hypotheses are tested in chapter 3. A combined 
medication withdrawal approach with cognitive functional MRI was used to assess the 
underlying neural correlates (Box 4).  
Box 4. Functional Magnetic Resonance Imaging (fMRI)
Functional Magnetic Resonance Imaging (fMRI) is an imaging technique that is widely used to 
investigate cerebral activity in vivo. This technique uses the differential magnetic properties 
of oxygenated and deoxygenated haemoglobin in blood. The resulting net-difference signal 
(blood-oxygen-level-dependent signal or BOLD signal) has been proven to be a reliable proxy 
of neural activity and postsynaptic excitatory activity [130]. During fMRI scanning, participants 
are typically asked to perform a task designed to assess a specific cognitive process. This 
enables quantification of oxygenation, and thereby neural activity, in response to the task 
performed. fMRI has a relatively high spatial resolution with a precision of 1 to 3 mm allowing 
for relatively accurate localization of BOLD signal changes. By contrast, due to the nature of 
the BOLD response, the temporal resolution of fMRI is relatively low. However, when taking 
into account the temporal characteristics of the BOLD response and optimizing the timing of 
stimulus representation within the task, it is possible to measure rapid ‘event-related’ changes 
in BOLD response. Because neural activity is considered to reflect a combination of stimulus 
and/or task-related activity and unrelated ongoing neural activity, activity is usually studied in 
terms of the relative difference in BOLD signal between different conditions [130]. In the study 
described in chapter 3 I contrasted BOLD signal during unexpected rewards and unexpected 
punishments. These contrast maps were obtained for each individual and in a subsequent 
step used for analysis purposes. 
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Decision making
In day to day life, we continuously make decisions that entail some degree of risk. Should I 
rush through a busy street or take the long way via a crosswalk? Should I take my umbrella 
when going outside or take my changes that it will not rain any time soon? The lay concept of 
risk refers to hazards that cause anxiety or fear and/or are associated with (some degree of) 
uncertainty. In neuro-economics, risk is distinguished from uncertainty [87]. Decisions under 
risk entail options that have well-specified outcome probabilities, whereas decisions under 
uncertainty entail options whose outcomes are (to some degree) uncertain. An influential 
theory explaining decision making under risk is prospect theory [88, 89]. One of the core 
concepts of prospect theory is loss aversion, the relative weighting of gains and losses 
during risky choice. In the general population, losses loom larger than equivalent gains. For 
example, most people would reject a gamble for which they gain $50 if a fair coin lands 
heads and lose $50 if a fair coin lands tails. Typically, losses have at least twice the impact 
of equivalent gains, so that people would require a 50% chance of gaining at least $100 to 
make up for a 50% chance of losing $50. 
Dopamine plays a critical role in reward based decision making. It is well-known that 
dopaminergic medication enhances risky choice. This has been demonstrated in both healthy 
controls as well as patients with Parkinson’s disease and in experimental animals [67, 90-94]. 
In Parkinson’s disease, the most well-known example of detrimental effects of dopaminergic 
medication on risky choice are impulse control disorders – behavioural addictions induced 
by the administration of dopaminergic medication [95, 96]. Even though it is well known that 
dopaminergic medication enhances risky choice, the underlying mechanisms have remained 
unclear. When keeping in mind that dopamine induces shifts in the balance between learning 
from reward versus punishment [49, 76], the concept of loss aversion is of particular interest, 
since recent theoretical work extended these value-dependent effects of dopaminergic 
medication from learning to choice [46]. However, if dopamine enhances risky choice via a 
mechanism similar to that observed in the domain of learning, i.e. enhancing risky choice 
via decreasing loss aversion, has not been investigated yet. This hypothesis is tested in 
chapter 5. 
Analogue to learning, negative affective biases in depression have also been described in 
the domain of decision making [97]. For instance, depressed individuals (without Parkinson’s 
disease) show fewer advantageous card selections [98], they learn to avoid risky responses 
faster [99] and exhibit decision strategies that aim to minimize losses rather than maximize 
gains [100, 101]. Finally, functional MRI scanning during risky choice revealed enhanced 
loss encoding and decreased gain encoding during risky choice in individuals with a major 
depression compared with healthy controls [102, 103]. 
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Based on the above outlined literature I hypothesized that: (i) Depressed patients with 
Parkinson’s disease exhibit enhanced loss aversion in comparison with non-depressed 
patients. (ii) Dopaminergic medication increases risky choice in non-depressed as well as 
depressed Parkinson’s disease patients. And (iii) dopaminergic medication increases risky 
choice via a mechanism of decreasing loss aversion. These hypotheses are tested in chapter 5. 
To specifically assess the underlying neurocomputational mechanisms, I employed a 
computational modelling approach (Box 5). 
Box 5. Computational modelling
Cognitive neuroscience aims to understand the biological (and neural) processes that underlie 
all kind of mental processes, such as acquiring new knowledge, memory, language and 
decision making. Specific experiments are designed to assess specific aspects of cognition. 
For instance, if you want to investigate whether gender affects risk taking behaviour, you 
can compare a group of female and male students and their choices on a gambling task. 
Standard analysis (i.e. performing a 2-sample t-test), can tell you if male compared with female 
participants choose to gamble more often, but it doesn’t give any information about the 
underlying decision process. Is it that male students are just more attracted to gambling, are 
they more sensitive to potential gains or less sensitive to potential losses, or is it a combination 
of factors. Computational models aim to capture these underlying latent variables that cannot 
be directly observed from behaviour. 
Computational models can be divided into data driven models and theory driven models. 
Data driven models are not explicitly programmed, but are algorithms that are able to make 
data driven predictions and decisions through building a model based on sample inputs. By 
contrast, theory driven models encapsulate a theoretical, often mechanistic, understanding 
of the process that is assessed. The computational model used in chapter 5 of this thesis is 
a theory driven model based on a well-known theory of decision making, namely prospect 
theory. Theory driven models have the advantage that the acquired knowledge can be directly 
mapped onto what is already known. 
Theory driven computational models do have some pitfalls. The most important one is that 
they only model what you tell them to model. Models are, by necessity, a simplification of the 
real process. If the simplifying assumptions are wrong, then this inevitably affects the model 
results. A clear advantage of a simpler model is that it is easier to understand. However, if 
a model is too simple, it will not capture all the relevant variables to generate the observed 
behaviour. More complex models (i.e. models with more freedom to generate the observed 
behaviour) will usually explain the data better, but might result in over fitting - even modelling 
random noise. To deal with this problem,  a model comparison is often conducted, which 
involves comparing several candidate models to identify the most suitable model based on 
an assessment of how likely a model would be to generate behaviour while at the same time 
penalizing for model complexity.
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Incentive motivation
Already in the 1920s Souques described a phenomena called kinesia paradoxa; the ability 
of Parkinson’s disease patients who were akinetic and wheelchair bound to suddenly 
move fluently and with normal speed in response to an urgent situation [104]. These early 
descriptions contributed to the idea that the motor symptoms of Parkinson’s disease, 
especially bradykinesia, actually reflect a motivational deficit and in keeping with this 
observation, the disorder has also more recently been referred to as a prototypical disorder 
of the will [105].
As outlined above, mesolimbic dopamine plays a critical role in incentive motivation [33, 106-
108]. Both work in primates and humans, including patients with Parkinson’s disease, have 
implicated the ventral striatum in reward anticipation and the processing of incentive cues 
[109-111]. Ample evidence exists that dopamine manipulations affect motivated behaviour. 
For instance, studies in rodents revealed that administration of dopamine enhancing drugs 
in the ventral striatum increases cue-evoked reward motivation [112, 113], while the opposite 
was shown with administration of dopamine receptor blocking agents [114]. 
In line with the characterization of Parkinson’s disease as a disorder of the will, it has been 
shown that Parkinson’s disease is associated with decreased incentive motivation for motor 
decisions as well as decreased willingness to exert motor effort [115-118]. Intriguingly however, 
in the cognitive domain, Parkinson’s disease has been associated with, if anything, enhanced 
incentive motivation of cognitive control [119, 120]. This enhanced incentive motivation of 
cognitive control has been shown to co-vary with dopamine cell loss in the striatum of patients 
with Parkinson’s disease [119]. Patients with the most severe degeneration of dopaminergic 
neurons, and putatively the lowest striatal dopamine levels, showed the greatest beneficial 
effect of reward anticipation on cognitive control. These findings concur with observations 
in healthy young volunteers who showed a similar negative correlation between an index 
of striatal dopamine, dopamine synthesis capacity as measured with 6-[(18)F]-fluoro-L-m-
tyrosine positron emission tomography (FMT-PET), and motivated cognitive control [121]. In 
these healthy controls, higher striatal dopamine in the left caudate nucleus was associated 
with greater detrimental effects of reward motivation on cognitive control. Together, these 
findings suggest a linearly negative relationship between striatal dopamine and motivated 
cognition, with higher dopamine levels impairing motivated cognitive control and lower 
dopamine levels enhancing motivated cognitive control. 
Now the question raises how to reconcile this enhanced motivation of cognitive control in 
Parkinson’s disease with the frequent co-occurrence of depression in Parkinson’s disease – a 
disorder that typically affects motivation. Depressed individuals (without-Parkinson’s disease) 
exhibit decreased reward motivation during effort-based decision-making [122, 123], require 
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more time to respond to happy than to sad words on an affective Go/NoGo task [124] and 
exhibit a diminished ability to develop a response bias towards rewarding stimuli [80, 81, 125]. 
Specifically anhedonia, one of the core features of depression, has been linked to diminished 
incentive motivation. For instance, anhedonia ratings have been shown to correlate with 
impairments in positive response bias development as well as with a decreased willingness 
to work for reward [122, 125-127]. In line with striatal dopamine’s role in incentive motivation, 
this decreased sensitivity to incentive cues in depression has been linked to ventral striatal 
dysfunction [85, 128].
Together these findings raised the following questions: Are the earlier observed findings 
of motivational enhancement of cognitive control in Parkinson’s disease restricted to 
non-depressed patients? And second, given the proposed key role for dopamine, is this 
motivational enhancement of cognitive control modulated by dopaminergic medication? 
These hypothesis are tested in chapter 6.  
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Outline of the thesis
The overarching aim of the research presented in this thesis is to contribute to enhancing 
our understanding of the mechanisms contributing to depression in Parkinson’s disease, 
ultimately aiming to improve adequate recognition, treatment and eventually prevention 
of depression (in Parkinson’s disease). One chapter is devoted explicitly to improving 
recognition and treatment of depression in Parkinson’s disease in current clinical practice. 
The other chapters focus on enhancing our understanding of the underlying mechanisms, 
with a focus on the role of dopamine in reward (and punishment) processing across three 
cognitive domains; learning, decision making and incentive motivation.
Chapter 2 provides the clinician with a practical overview based on current available evidence 
how to diagnose and treat depression in patients with Parkinson’s disease, ultimately aiming 
to improve the quality of life of patients (and their caregivers) who are (currently) suffering 
from depression in Parkinson’s disease.  
Chapter 3 and 4 investigate the effect of dopamine and depression on (reward-based) learning 
in Parkinson’s disease. Previous research has shown that dopaminergic medication can either 
improve or impair learning as a function of baseline dopamine levels [62, 64, 65]. More recent 
work revealed that dopamine specifically modulates the balance between learning from reward 
and punishment, improving reward–based learning and/or impairing punishment-based 
learning [49, 76]. According to current modelling work, these drug effects reflect dopamine-
induced shifts in the balance between activity in the direct and indirect pathways of the basal 
ganglia [75]. Depression (without Parkinson’s disease) has been associated with an imbalance 
in learning from reward and punishment [25, 29]. Depressed individuals exhibit impaired 
reward and enhanced punishment learning. In chapter 3 a controlled medication withdrawal 
procedure combined with functional MRI (Box 4) was employed in Parkinson’s disease patients 
with and without depression to assess whether depression in Parkinson’s disease is associated 
with an imbalance in learning from reward and punishment. This procedure allowed us to 
investigate the effect of dopaminergic medication on reward-based versus punishment-based 
learning as well as the underlying neural mechanisms. The study described in chapter 4 was 
part of the ParkFit study [129]. This dataset allowed me to conduct a mediation analysis in a 
uniquely large sample of Parkinson’s disease patients, enabling to assess whether previously 
described detrimental (overdosing) effects of dopaminergic medication-dose on learning in 
Parkinson’s disease are mediated by current depression severity. The results of the studies in 
chapter 3 and 4 enhance our understanding of how depression in Parkinson’s disease affects 
(reward-based) learning, how this relates to dopaminergic medication (state and dose) and 
sheds light on the underlying neural correlates.
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Chapter 5 focuses on the mechanisms underlying dopamine-induced increases in risky 
choice in Parkinson’s disease patients with and without depression. Dopaminergic-
medication is known to increase risky choice in Parkinson’s disease [67, 95]. However, the 
underlying mechanisms have remained unclear. I employed a neurocomputational approach 
(Box 5) to investigate the effects of dopaminergic medication on specific components of 
risky choice in Parkinson’s disease patients with and without depression. This enabled 
me to specifically assess the underlying computational mechanisms. The results of this 
study further enhance our understanding of the mechanisms underlying dopamine-induced 
increases in risky choice in Parkinson’s disease patients with and without depression and 
illustrate the potential of a computational psychiatric approach to advance our understanding 
of cognition in (depression in) Parkinson’s disease. 
Chapter 6 investigates the effect of incentive motivation on cognitive control in Parkinson’s 
disease patients with and without depression. Motor deficits in Parkinson’s disease have 
been argued to reflect a motivational deficit [105]. By contrast, motivation for cognitive 
control is paradoxically enhanced in Parkinson’s disease [119]. Depression is associated with 
motivational impairments. However, whether motivational enhancement of cognitive control 
in Parkinson’s disease is abolished in patients with co morbid depression has not been 
investigated yet. To this end, I compared effects of reward anticipation on task-switching 
in Parkinson’s disease patients with and without depression. A medication withdrawal 
procedure was employed to investigate the effects of dopaminergic medication on motivated 
cognitive control. The results of this study further enhance our understanding of the effects of 
reward motivation on cognitive control in Parkinson’s disease with and without depression, 
thereby advancing our knowledge of the potential of reward motivation to overcome the 
specific cognitive deficits associated with Parkinson’s disease. 
Finally, in chapter 7 I will present an overview of the results and interpretation of the findings 
presented in this thesis. 
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Abstract
Depression is a frequent non-motor symptom of Parkinson’s disease (PD). Prevalence rates 
of depression in PD vary widely across studies (between 2.7% and 90%). The prevalence of 
clinically significant depressive symptoms is estimated around 35%. Even though depression 
can have an immense impact on the quality of life of affected patients and their caregivers, 
depressive symptoms in PD frequently remain unrecognized and, as a result, treatment is 
often not initiated. In this review article we give an overview of the diagnostic challenges and 
pitfalls, including the factors that putatively contribute to the underdiagnosis of depression. 
We also discuss current ideas with respect to the underlying pathophysiology. Finally, we 
offer a treatment approach based on currently available evidence.  
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Introduction
James Parkinson was the first to acknowledge an association between Parkinson’s disease 
(PD) and depressed mood. In his “Essay on the Shaking Palsy” he cites his colleague Dr. 
Maty, who referred a patient with the following words: “A more melancholy object I never 
beheld”. We now realize that depression is one of the most frequently observed non-motor 
symptoms of PD. In fact, depression as a non-motor symptom has a place in the new clinical 
diagnostic criteria for PD.[1] Depression has an immense impact on the quality of life of 
patients and their caregivers, even during early disease stages.[2] Even though depressive 
symptoms are associated with more severe cognitive and motor problems, an increased 
mortality risk and earlier withdrawal from the workforce, depression in PD frequently remains 
unrecognized.[3, 4] 
To improve the quality of life of PD patients and their caregivers, and to reduce the impact on 
society, there is need for improved diagnosis and better treatment of depression in PD. In this 
paper we will discuss the diagnostic challenges and pitfalls, as well as the pathophysiological 
backgrounds. We also offer a recommended treatment approach for depression in PD. 
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Diagnosing depression
Epidemiology and diagnostic criteria
Diagnostic criteria for a major or minor depressive episode, dysthymic disorder and 
adjustment disorder with depressed mood have been formulated within the DSM-IV (Table 
1). Prevalence rates of depression in PD vary widely across studies (between 2.7% and 90%). 
The prevalence of clinically significant depressive symptoms is estimated around 35%.[5] 
Most patients have mild symptoms that can be classified as a mild depressive episode, 
dysthymic disorder or adjustment disorder with depressed mood. The prevalence of major 
depression in PD ranges from 2.3% to 55.6% (estimated average 19%).[5] A subgroup of 
patients experiences clinically relevant depressive symptoms that are restricted to OFF 
periods (i.e. during episodes of the day when the dopaminergic drug effects have worn 
off). This subgroup of depression does not meet the criteria of a mild of major depressive 
episode, dysthymic disorder or adjustment disorder with depressed mood, as in these cases 
depressive symptoms are often of shorter duration (i.e. restricted to OFF periods). These 
depressive symptoms are classified as subsyndromal depression.[6] 
Comparing depression in the general population with depression in PD there are some 
subtle differences. For instance, PD patients report less often feelings of guilt and feelings 
of worthlessness, but more often experience indecisiveness.[7] In addition, the risk of suicide 
in patients with PD is lower compared with that in the general population - 0.08% in patients 
with PD compared with 0.8% in the general population.[8] Case reports have suggested 
an enhanced suicide risk in PD patients after deep brain stimulation (DBS). However, more 
recent evidence suggests no clear increase in suicide ideation and behaviours after DBS.
[9] But note that the strongest predictor of suicide after DBS is the existence of depressive 
symptoms. Therefore, careful monitoring for depression is warranted after DBS. 
Diagnostic challenges and pitfalls
Depressive symptoms in patients with PD frequently remain unrecognized. Of the 44% 
of patients attending a routine appointment that actually had depression, only 21% were 
identified as such by their Neurologist.[10] This underdiagnosis is attributable to several 
factors (Table 2). 
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Table 1. DSM-IV criteria for diagnosing a depressive disorder
A: The following symptoms are present during two consecutive weeks and represent a change 
from baseline: at least 5 in case of a major depressive episode and at least 2 in case of a minor 
depressive episode. At least criteria 1 or criteria 2 should be met. Each criterion should be present 
nearly every day: 
- Depressed mood most of the day
- Decreased interest or pleasure in most activities, most of each day 
- Significant weight change (5%) or change in appetite
- Insomnia or hypersomnia 
- Psychomotor agitation or retardation 
- Fatigue or loss of energy
- Feelings of worthlessness or excessive or inappropriate guilt 
- Diminished ability to think or concentrate, or more indecisiveness 
- Recurrent thoughts of death or suicide, or has suicide plan 
B: The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning.
C: The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, 
a medication) or a general medical condition (e.g., hypothyroidism). 
D: The Major Depressive Episode is not better accounted for by Schizoaffective Disorder and is not 
superimposed on Schizophrenia, Schizophreniform Disorder, Delusional Disorder, or Psychotic 
Disorder Not Otherwise Specified.
E: There has never been a Manic Episode, a Mixed Episode, or a Hypomanic Episode.
First, treating physicians frequently don’t recognize depressive symptoms in patients with PD, 
or at least not in time. This is actually quite understandable, because depressive symptoms 
grossly overlap with symptoms related to PD.[6] For example, psychomotor retardation with 
slowing of movements, a stooped posture and lack of facial expression can occur during a 
depressive episode, but also resemble the motor features that characterize PD. Physicians 
therefore literally need to search “behind the mask” (the poker face) to identify the depressed 
mood. Also, cognitive changes that typically occur during a depressive episode, such as 
diminished attention and mental slowing, can occur in PD patients irrespective of depression. 
Moreover, sleep disturbances and fatigue are well known features of both depression and PD 
itself. Therefore, depression should not only be considered in patients with depressed mood 
or anhedonia (i.e. decreased interest or pleasure), but also in patients with (unexplained) 
motor impairment, cognitive deterioration or sleep disturbances. To prevent underdiagnosis 
of depression in PD, an inclusive approach is advocated. With an inclusive approach, no 
distinction is made between symptoms that are putatively attributable to PD or attributable 
to depression. This approach has been validated to diagnose a major or mild depressive 
episode or dysthymic disorder in patients with PD.[11] 
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Second, it can be difficult to distinguish depression from other non-motor symptoms of 
PD, such as apathy, anxiety or psychotic features. In patients with PD, apathy, anxiety 
and psychosis can occur in isolation, and separately from depression. However, they are 
also well-known accompaniments of depression. The prevalence of apathy in PD varies 
between 20 and 60%, depending on disease severity (the prevalence increasing with 
greater disease severity). Distinguishing apathy from depression is important, because 
apathy requires a different treatment approach. Apathy is defined by reduced goal-directed 
behaviour as a result of a lack of motivation, enthusiasm and blunted emotion. Note that 
anhedonia – a decreased ability to experience pleasure – can be a core feature of both 
apathy and depression. The key clinical difference between depression and apathy is the 
lack of subjective suffering in apathetic patients (low or absent) compared with patients 
that have a depression (high degree of subjective suffering). For a comprehensive review 
on apathy in PD, please see reference [12]. The prevalence of anxiety disorders in PD is 
approximately 30%. The most common anxiety disorders are generalized anxiety disorder, 
social phobia, anxiety not otherwise specified, specific phobia and panic disorder. Of all 
PD patients, approximately 20% suffers from depression and comorbid anxiety.[13] Note 
that, similar to depression, both apathy and anxiety can be seen during OFF periods in 
patients with motor fluctuations. This suggests that the neurobiological substrates underlying 
depression, anxiety and apathy in PD partly overlap.[14] With respect to psychotic symptoms, 
one should acknowledge that a depressive episode in PD can be accompanied by psychotic 
symptoms, but these are mainly mood-congruent (e.g. nihilistic delusions and delusions of 
guilt). Psychotic features (like paranoia) in PD are more often related to cognitive decline 
and the use of (dopaminergic) medication than to a depressive episode.
Finally, another important factor contributing to underdiagnosis is the underreporting of 
depressive symptoms by patients themselves. In a large study, incorporating data of over 
1,000 patients, approximately 50% of patients had clinically relevant depressive symptoms 
as measured with the Beck Depression Inventory. By contrast, only 1% of these patients 
volunteered depressive symptoms, signalling a striking degree of underreporting.[15] The 
causes underlying this underreporting have not been elucidated yet and warrant further 
investigation. This study does, however, highlight the importance of a pro-active approach by 
the treating physician or nurse with respect to diagnosing depression in PD, and particularly 
emphasizes the need to conduct a careful hetero-anamnesis (interviewing a close caregiver). 
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Table 2. How to improve the diagnosis of depression
Pro-active approach by the treating physician/nurse (including routinely conducting a careful hetero-
anamnesis in an immediate caregiver)
Consider depression in patients with (unexplained) motor or cognitive deterioration and/or sleep 
disturbances 
Be aware of overlap between PD symptoms and depressive  symptoms 
- Motor symptoms (lack of facial expression, stooped posture, slowing of movements)
- Somatic symptoms (fatigue, lack of energy)
- Cognitive features (diminished attention, mental slowing)
Use an inclusive approach to diagnose depression (no distinction between symptoms attributable 
to PD or to depression) 
Distinguish depression (high degree of subjective suffering) from apathy (low to absent subjective 
suffering)
Distinguish psychotic features accompanying depression (mood-congruent) from psychotic features 
related to dopaminergic treatment and/or cognitive decline (more common, not mood-congruent)
Screening questionnaires can be useful; the use of adjusted cut-off scores is recommended
Diagnostic tools
Although a formal diagnosis should be made based on DSM-criteria, in clinical practice, 
screening tools might be useful for the first detection of a depression. A taskforce from 
the Movement Disorders Society investigated which questionnaires are most suitable 
to assess depression in PD.[16] In this study, several questionnaires were compared 
and recommendations were made (differentiating screening purposes from severity 
assessments) (Table 3). Note that while the MADRS and HAM-D were originally developed 
to assess depression severity, they have also been validated for screening purposes in PD. 
All these questionnaires incorporate somatic items that overlap with symptoms related to 
PD, therefore the use of adjusted cut-off scores is recommended (Table 3).  
We acknowledge that the administration of self-rated questionnaires in a busy clinical practice 
is not always possible. Although this has as such not been validated in clinical practice yet, 
a useful approach when screening for depression might be to pose the question related 
to the depression-item of the new Unified Parkinson Disease Rating Scale.[17] Specifically, 
clinicians could ask the following: “Over the past week have you felt low, sad, hopeless 
or unable to enjoy things?” If yes, determine the duration and impact by asking: “Was this 
feeling for longer than one day at a time?” And: “Did it make it difficult for you to carry out 
your usual activities or to be with people?” If the patient experiences depressive symptoms, 
always determine if there is a relationship with their dopaminergic medication schedule and/
or motor symptoms.
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The use of modern technology such as wearable sensors or the use of Apps is not common 
practice yet (neither in general, nor for the specific purpose of monitoring depression). 
However, recent studies are beginning to show some promising results. In the field of 
depression, App technology might improve treatment adherence and the quality of clinical 
consultations. Moreover, it has great potential to improve monitoring of motor as well as non-
motor symptoms. New technologies might become available in the near future, with the aim 
of further improving diagnosis, monitoring and treatment of depression in PD.
Table 3. Questionnaires validated to assess depression in PD
Questionnaires suited for screening purposes Number of somatic 
items
Recommended 
cut-off score
Hamilton Depression Rating Scale (HAM-D) 
Beck Depression Inventory (BDI)
Hospital Anxiety and Depression Scale (HADS)
Montgomery Asberg Depression Rating Scale (MADRS)
Geriatric Depression Scale (GDS)
***
**
*
**
*
<10
<14
<11
<15
<5
Questionnaires suited to assess depression severity and changes over time
Hamilton Depression Rating Scale (HAM-D) 
Beck Depression Inventory (BDI)
Montgomery Asberg Depression Rating Scale (MADRS)
Zung Self-Rating Depression Scale (SDS)
Number of somatic items: *25%; **25–50%; ***50%
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Pathophysiology
Knowledge about the underlying mechanisms of depression in PD is increasing, but far from 
complete. A multifactorial model currently appears to be most suitable. Factors that contribute 
include an individual underlying (genetic) vulnerability to depression, the occurrence of life 
events, individual coping abilities, psycho-social factors and disease-specific factors. As in the 
general population, a positive family history of depression, a personal history of depression 
and lower education levels contribute to an enhanced depression risk. Moreover, a diagnosis 
of PD can lead to reactive depression and to anxieties about the disease course, possible 
future disabilities and concerns about future perspectives. That disease-specific factors 
contribute stems from observations that many PD patients already experience depressive 
symptoms in the years before being diagnosed with PD.[18] Therefore, depression is 
considered one of the premotor symptoms.[19]
Several studies support the idea that changes in the dopamine system play a role in PD-
related depression. For example, clinical studies revealed that approximately 75% of patients 
with motor fluctuations also experience prominent OFF-period related depressive symptoms.
[20] Moreover, pharmacological trials showed that dopaminergic medication exerts an 
antidepressant effect (see below). Involvement of the dopamine system in PD-related 
depression has also been shown using nuclear neuroimaging studies. Depressed PD patients 
have lower striatal dopamine transporter (DAT) binding compared with non-depressed 
patients.[21] Lower DAT-binding is thought to reflect more severe neurodegeneration of 
striatal dopaminergic neurons resulting in lower striatal dopamine levels.
In addition to dopamine, other neurotransmitters putatively contribute as well, and 
these include noradrenalin, acetylcholine and serotonin. Although evidence is scarce, 
neuropathological and neuroimaging studies have shown that noradrenergic neurons in 
the locus coeruleus and serotonergic neurons in the raphe nucleus degenerate in patients 
with PD, with more severe degeneration in PD patients who suffer(ed) from depression.[14] 
The exact contribution of each of these neurotransmitter systems to depression in PD needs 
to be elucidated in future research. 
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Treatment
Here we review studies that were specifically designed to assess treatment effects on 
depressive symptoms in patients with PD. Based on available evidence, we propose a 
flowchart with recommended treatment steps. Meta-analyses of randomized placebo-
controlled trials were used; otherwise recommendations are based on randomized (placebo)-
controlled studies. Lower class evidence studies were only included if this was the only 
available evidence. 
General recommendations
Before initiating treatment, it is important to evaluate the severity of depressive symptoms and 
to assess if there are any suicidal ideations or concrete plans. We advocate the importance 
of a multidisciplinary team approach in all PD patients with depression (See flowchart). 
Depending on the severity, this could mean involving an experienced nurse, general 
practitioner, psychologist and/or psychiatrist. In cases with severe depressive symptoms, 
especially when there is an enhanced suicide risk, psychiatric consultation is strongly 
recommended. The recommendation of a multidisciplinary team approach is largely based 
on our personal conviction, but is also partially supported by clinical studies (acknowledging 
the challenge that multiple models exist, and that evaluations of multidisciplinary care are 
difficult to perform). Recent work suggests that some forms of multidisciplinary care may 
contribute to better quality of life and a greater reduction of depressive symptoms.[22] 
General interventions recommended for treating depression include verbal and written 
psycho-education, information about self-help, support groups, sleep hygiene, the need for 
behavioural activation, and involvement and support of family members/carers.[23] The latter 
is even more important when depression occurs in the setting of another chronic disease 
(such as PD): although effects were small, a recent meta-analysis showed that involving 
family members in the treatment of depression is effective in reducing depression among 
patients with chronic disease.[24] Only few studies have specifically examined the effect of 
psychosocial interventions in depression in PD, the majority of which had small sample sizes 
so no firm conclusions could be drawn. 
Below, several possible clinical interventions for depression in PD are discussed. The 
treatment choice in general should be guided by various factors - including the severity 
and duration of the depressive episode, previous course and response to treatment, 
potential adverse effects, the likelihood of adherence to treatment, and the patient’s own 
preferences.[23] 
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Depression related to motor fluctuations or general undertreatment
The next step in our treatment algorithm is to decide whether or not depression is related 
to motor fluctuations or is associated with general undertreatment. If depressed mood 
is related to motor fluctuations or associated with undertreatment of motor symptoms, 
optimizing dopaminergic treatment is the first step. Although (based on clinical experience) 
it appears plausible that levodopa has an antidepressant effect, this has never been 
investigated in randomized placebo controlled trials. One small sample size (n=8) placebo-
controlled study showed a short-term effect of levodopa infusion on mood and anxiety.
[25] The antidepressant effect of dopamine receptor agonists, especially pramipexole, has 
been shown via a few randomized clinical trials.[26, 27] Dopamine receptor agonists and 
levodopa have never been compared directly with respect to its effect on depression. How to 
optimize dopaminergic treatment mainly depends on the (dopaminergic) medication that the 
patient already uses and on other individual patient characteristics (see Table 4). In general, 
established strategies to treat motor symptoms can be followed. If a patients doesn’t use a 
dopamine receptor agonist and there are no contraindications, one should consider adding 
this to the treatment regime. Note however, that the antidepressant effect of dopamine 
receptor agonists (and maybe also levodopa) is relatively small.[26, 27] Therefore, in case of 
severe depressive symptoms a different treatment approach is advocated (see below). When 
prescribing dopamine receptor agonists to PD patients with depression, strict monitoring for 
impulse control disorders (ICDs) such as hypersexuality, binge-eating, compulsive shopping 
and pathological gambling is warranted. Over and above, PD patients with depression seem 
more vulnerable to develop ICD.[28]
Advanced treatments, such as continuous jejunal levodopa infusion or deep brain stimulation, 
can also be considered in patients with motor fluctuations who have accompanying non-
severe mood fluctuations. Although, no clinical trials have been done assessing depressive 
symptoms as primary outcome in patients that received advanced treatments, indirect 
evidence suggests that also depressive symptoms are likely to improve.[29, 30] In these 
patients however, extra careful psychiatric (pre- and post intervention) evaluation as well as 
strict follow-up monitoring is strongly advocated. Moreover, it should be noted that a current 
severe depression is a contraindication for deep brain stimulation. Depression on its own is 
not an indication for advanced treatment.
Depression unrelated to motor fluctuations or motor symptom deterioration
Treatment choice of depressive symptoms unrelated to motor fluctuations or motor symptom 
deterioration mainly depends on depression severity. This approach can also be used in PD 
patients with depressive symptoms that are (or initially were) related to motor fluctuations of 
motor symptom deterioration, but persist despite optimization of dopaminergic treatment. 
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Figure 1. Flow chart treatment recommendations. *When prescribing antidepressants, always take 
possible side effects into account and be aware of drug interactions (see table 4). CBT, cognitive–
behavioural therapy; ECT, electroconvulsive therapy; SSRIs, selective serotonin reuptake inhibitors; 
TCA, tricyclic antidepressants; DBS, deep brain stimulation; NB, nota bene.
Severe depressive symptoms
If depressive symptoms are severe, we suggest considering treatment with antidepressants. 
Although evidence is still scarce, two recent meta-analyses suggest that antidepressant 
medication might be effective in treating depression in patients with PD (Table 5).[31, 32] 
These meta-analyses included randomized placebo-controlled clinical trials that assessed 
treatment effects in patients with PD and a clinical diagnosis of depression (mostly major 
depression).[33-37] Inclusion criteria, sample sizes, interventions and outcome measures are 
reported in table 5. Note that both meta-analyses encountered methodological difficulties, 
the number of included studies was limited and sample sizes were small. The meta-analyses 
by Troeung et al revealed a non-significant pooled effect of treatment with antidepressants 
over placebo. However, the pooled effect of treatment with tricyclic antidepressants (TCA) 
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(desipramine and nortriptyline) revealed a significant antidepressant effect (with medium 
effect size). No such effect was observed for selective serotonin reuptake inhibitors (SSRI) 
(citalopram, sertraline, paroxetine). In the meta-analyses by Rocha et al, both SSRIs and 
TCAs were not superior to placebo. However, TCAs were superior to SSRIs.[31] Therefore, 
treatment with TCAs (nortriptyline and desipramine) is favoured slightly over treatment with 
SSRIs. Comparison of an SSRI (sertraline) with a dopamine receptor agonist (pramipexole) 
revealed no significant difference in antidepressant effect between these two.[27] No 
direct comparison of dopamine receptor agonists and TCAs has been done. Based on the 
effect sizes of the separate studies (see also table 5), the antidepressant effect of TCAs is 
seemingly larger than that of dopamine receptor agonists.[26, 31, 32] Therefore, in case of 
severe depression, we prefer antidepressants (especially TCAs) over dopamine receptor 
agonists. If treatment fails and the patient doesn’t receive a dopamine receptor agonist yet, 
adding a dopamine receptor agonist to the medication regime should be considered. When 
prescribing antidepressants or dopamine receptor agonists, contraindications and possible 
adverse effects should always be taken into account and closely monitored (Table 4). Both 
dopamine receptor agonists and antidepressants frequently cause sleep disturbances. While 
dopamine receptor agonists and TCAs most often cause excessive (daytime) sleepiness, 
SSRIs can induce increased sleepiness as well as insomnia. For a patient with depression 
and comorbid sleeping difficulties, sleepiness can also be regarded as a potentially positive 
side effect, by prescribing a dopamine receptor agonist or TCA prior to bedtime. In practice, 
we suggest to take a dopamine receptor agonist and/or TCA ante noctum and an SSRI in the 
morning, unless the SSRI causes excessive daytime sleepiness. In that case, we suggest to 
take the SSRI ante noctum as well. Other frequent side effects of both dopamine receptor 
agonists and antidepressants, specifically TCAs, are cognitive disturbances and psychotic 
symptoms. These side effects are less commonly observed with SSRIs. Therefore, SSRIs are 
preferred when treating depression in patients with comorbid cognitive impairment.
With respect to other antidepressants: venlafaxine, a combined serotonin and noradrenalin 
reuptake inhibitor, was not more efficacious than treatment with SSRIs, and atomoxetine 
– a noradrenalin reuptake inhibitor – was not superior to placebo.[36, 38] Thus far, no 
randomized placebo-controlled trials have investigated the effect of newer antidepressants 
such as buproprion – a combined reuptake inhibitor of dopamine, serotonin and noradrenalin. 
As such, there is not much evidence supporting efficacy of these antidepressants in PD.
When initiating treatment, we recommend to keep the following motto in mind: Start slow, 
then go. At first, carefully monitor for potential side effects. If the medication is well tolerated, 
then start to increase the dosage. For dopamine receptor agonists, we suggest to increase 
the dosage every 1-2 weeks until a response is observed. If the patient does not respond to 
pramipexole 3 mg/day or ropinirol 15 mg/day, we would suggest not to increase the dosage 
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further.[26] The dosage of TCAs should be increased gradually, every other week, until the 
therapeutic range has been reached (monitor serum drug levels). The start dosage of SSRIs 
is usually the therapeutic dosage. Both TCAs and SSRIs should be continued for 6 weeks 
when the therapeutic dosage has been reached to assess its efficacy.[23]
Table 4. Antidepressant medications, contraindications and adverse effects 
Type of medication Contraindications Potential adverse effects
Dopamine receptor 
agonists 
Caution is warranted in older PD 
patients (>70 years of age), PD 
patients with cognitive impairment 
and/or psychotic symptoms and 
orthostatic hypotension
Impulse control disorders, cognitive 
dysfunction, hallucinations, 
orthostatic hypotension, gastric 
complaints, excessive daytime 
sleepiness
TCAs* Caution is warranted in PD patients 
with urinary retention, orthostatic 
hypotension, (angle-closure) 
glaucoma and cardiovascular 
disorders (especially tachycardia) 
Cognitive dysfunction, excessive 
daytime sleepiness, orthostatic 
hypotension, tachycardia, gastric 
complaints, dry mouth, urinary 
retention, headache
SSRIs** Caution is warranted in PD 
patients who use MAO-B inhibiters 
(selegeline or rasagiline) due to 
the risk of developing a serotonin 
syndrome 
Sleep disturbances, gastric 
complaints, dry mouth, erectile 
dysfunction, dizziness, headache, 
musculoskeletal pain, pharyngitis, 
less often cognitive dysfunction
* TCAs = tricyclic antidepressants
** SSRIs = selective serotonin reuptake inhibitors
Besides treatment with medication, additional cognitive behavioural therapy should always 
be considered. In one large randomized controlled trial, cognitive behavioural therapy (CBT) 
was compared with clinical monitoring.[39] In this study with one-month follow-up, CBT 
was more efficacious in treating depressive symptoms than clinical monitoring (Table 5). 
No direct comparison has been done between treatment of depressive symptoms in PD 
with CBT or medication (antidepressants or dopaminergic medication). One advantage of 
CBT is that it doesn’t have any adverse effects. Moreover, the mechanism of action of CBT 
differs from that of medication. Therefore, a combination of CBT and medication potentially 
has a greater effect. Note however, that CBT requires no language barriers and sufficient 
cognitive capacity.
If all above mentioned treatment options fail and the patient still suffers from severe 
depressive symptoms, electroconvulsive therapy (ECT) should be considered. The efficacy 
of ECT for treating depression in PD has not been investigated in randomized controlled 
trials. However, data from one retrospective study, analyzing 25 PD patients with depression 
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who underwent ECT, demonstrated a significant reduction in depressive symptoms after ECT 
treatment.[40] Interestingly, ECT might also have additional beneficial effects on PD motor 
symptoms. It is regarded safe in patients with PD (without deep brain stimulation) and as 
such should be considered in case of severe and treatment-resistant depression. 
Mild depressive symptoms
If depressive symptoms are mild, we suggest starting with cognitive behavioural therapy 
(CBT). We advocate CBT over medication mainly because CBT doesn’t have potential 
adverse effects. If CBT is not feasible or ineffective, one could consider adding a dopamine 
receptor agonist or antidepressant (TCAs are favoured slightly over SSRIs) to the medication 
regime. See text above and table 5 for available evidence, and table 4 for contraindications 
and most common side effects. 
Conclusion
Depression in PD can highly influence the quality of life of both affected patients and their 
caregivers, but is largely underdiagnosed and frequently undertreated. This paper reviews 
the diagnosis, diagnostic pitfalls and diagnostic clues, pathophysiology and a broad spectrum 
of treatment options, thus providing the clinician with tools to improve the quality of life of 
their patients and patient’s caregivers.
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Table 5. Randomized placebo-controlled clinical trials
Study Inclusion criteria Design Results Meta-analyses
CBT*
- Dobkin 
ea. 2011 
PD + major depression, 
dysthymia or depression 
not otherwise specified 
according to the DSM-IV 
criteria 
Randomized-controlled trial of 10 weekly CBT 
sessions (n=41) versus clinical monitoring (n=39)
Primary outcome: change in HAM-D score 
CBT versus clinical monitoring (p<0.001)
CBT: HAM-D baseline 20.9; endpoint 13.6 
Clinical monitoring: HAM-D baseline 19.4; 
endpoint 19.3
AD**
- Devos 
ea. 2008
PD + major depression 
according to the DSM-IV + 
MADRS ≥ 20
Double-blind randomized-controlled trial of 30 days 
treatment with desipramine (n=17), citalopram (n=15) 
or placebo (n=16)
Primary outcome: change in MADRS score
Desipramine versus placebo (p<0.05)
Citalopram versus placebo (p<0.05)
Desipramine versus citalopram  (ns)
Desipramine: MADRS baseline 29; endpoint 9
Citalopram: MADRS baseline 25; endpoint 11
Placebo: MADRS baseline 27; endpoint 18
- Rocha ea. 2013
Antidepressants versus placebo 
(CI 0.98-1.87, ns)
TCAs versus placebo 
(CI 0.57-2.52, ns)
SSRIs versus placebo 
(CI 0.57-2.52, ns)
TCAs versus SSRIs 
(CI 1.06-2.99, significant)
- Leentjens 
ea. 2003
PD + major depression 
according to the DSM-IV
Double-blind randomized-controlled trial of 10 weeks 
treatment with sertraline(n=6)or placebo (n=6)
Primary outcome: change in MADRS score
Sertraline versus placebo (ns)
Sertraline: MADRS baseline 20; endpoint 11 
Placebo:  MADRS baseline 19; endpoint 8
- Menza 
ea. 2009
PD + major depression or 
dysthymia according to the 
DSM-IV
Double-blind randomized-controlled trial of 8 weeks 
treatment with paroxetine (n=18), nortriptyline (n=17) 
or placebo (n=17)
Primary outcome: change in HAM-D score
Paroxetine versus placebo (ns)
Nortriptyline versus placebo (p<0.01)
Paroxetine versus nortriptyline (p=0.08)
Paroxetine: HAM-D baseline 18.8; endpoint 12.5 
Nortriptyline: HAM-D baseline 21.1; endpoint 10.8 
Placebo: HAM-D baseline 19.3; endpoint 15.9
- Troeung ea. 2013
Antidepressants versus placebo 
(CI -1.33 –3.08, ns)
TCAs versus placebo 
(d=1.35, CI 0.19-2.52, significant)
SSRIs versus placebo 
(d=0.57, CI -1.33 –2.47, ns)- Richard 
ea. 2012
PD + major depression, minor 
depression or dysthymia 
according to the DSM-IV or  
subsyndromal depression
Double-blind randomized-controlled trial of 12 weeks 
treatment with paroxetine (n=42), venlafaxine (n=34) 
or placebo (n=39)
Primary outcome: change in HAM-D score
Paroxetine versus placebo (p<0.001)
Venlafaxine versus placebo (p<0.05)
Paroxetine versus  venlafaxine (ns)
Paroxetine: HAM-D baseline 22.2; endpoint  9.2 
Venlafaxine: HAM-D baseline 21.2; endpoint 10.2
Placebo: HAM-D baseline 21.4; endpoint 14.6 
- Wermuth 
ea. 1998 
PD + major depression 
according to the DSM-III 
Double-blind randomized-controlled trial of 52 weeks 
treatment with citalopram (n=18) or placebo (n=19)
Primary outcome: change in HAM-D score 
Citalopram versus placebo (ns)
Citalopram: HAM-D baseline 16.6; endpoint 3.5 
Placebo:  HAM-D baseline 16.2; endpoint 9.8 
DA***
- Barone 
ea.  2010 
PD + GDS ≥5 and UPDRS 
part 1 depression item score 
≥2 
Double-blind randomized-controlled trial of 12 weeks 
treatment with pramipexole (n=139) or placebo (n=148)
Primary outcome: change in BDI score 
Pramipexole versus placebo (p<0.05)
Pramipexole: baseline BDI 18.7, endpoint 13.1 
Placebo: BDI baseline 19.2,  endpoint 15.0 
* CBT = Cognitive behavioural therapy
** AD = Antidperessants
*** DA = Dopamine receptor agonists
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Table 5. Randomized placebo-controlled clinical trials
Study Inclusion criteria Design Results Meta-analyses
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SSRIs versus placebo 
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Double-blind randomized-controlled trial of 8 weeks 
treatment with paroxetine (n=18), nortriptyline (n=17) 
or placebo (n=17)
Primary outcome: change in HAM-D score
Paroxetine versus placebo (ns)
Nortriptyline versus placebo (p<0.01)
Paroxetine versus nortriptyline (p=0.08)
Paroxetine: HAM-D baseline 18.8; endpoint 12.5 
Nortriptyline: HAM-D baseline 21.1; endpoint 10.8 
Placebo: HAM-D baseline 19.3; endpoint 15.9
- Troeung ea. 2013
Antidepressants versus placebo 
(CI -1.33 –3.08, ns)
TCAs versus placebo 
(d=1.35, CI 0.19-2.52, significant)
SSRIs versus placebo 
(d=0.57, CI -1.33 –2.47, ns)- Richard 
ea. 2012
PD + major depression, minor 
depression or dysthymia 
according to the DSM-IV or  
subsyndromal depression
Double-blind randomized-controlled trial of 12 weeks 
treatment with paroxetine (n=42), venlafaxine (n=34) 
or placebo (n=39)
Primary outcome: change in HAM-D score
Paroxetine versus placebo (p<0.001)
Venlafaxine versus placebo (p<0.05)
Paroxetine versus  venlafaxine (ns)
Paroxetine: HAM-D baseline 22.2; endpoint  9.2 
Venlafaxine: HAM-D baseline 21.2; endpoint 10.2
Placebo: HAM-D baseline 21.4; endpoint 14.6 
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PD + major depression 
according to the DSM-III 
Double-blind randomized-controlled trial of 52 weeks 
treatment with citalopram (n=18) or placebo (n=19)
Primary outcome: change in HAM-D score 
Citalopram versus placebo (ns)
Citalopram: HAM-D baseline 16.6; endpoint 3.5 
Placebo:  HAM-D baseline 16.2; endpoint 9.8 
DA***
- Barone 
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PD + GDS ≥5 and UPDRS 
part 1 depression item score 
≥2 
Double-blind randomized-controlled trial of 12 weeks 
treatment with pramipexole (n=139) or placebo (n=148)
Primary outcome: change in BDI score 
Pramipexole versus placebo (p<0.05)
Pramipexole: baseline BDI 18.7, endpoint 13.1 
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* CBT = Cognitive behavioural therapy
** AD = Antidperessants
*** DA = Dopamine receptor agonists
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Abstract
Background: Depression is one of the most common and debilitating non-motor symptoms 
of Parkinson’s disease (PD). The neurocognitive mechanisms underlying depression in PD 
are unclear and treatment is often suboptimal. 
Methods: We investigated the role of striatal dopamine in reversal learning from reward and 
punishment by combining a controlled medication withdrawal procedure with functional 
magnetic resonance imaging (fMRI) in 22 non-depressed PD patients and 19 PD patients 
with past or present depression. 
Results: PD patients with a depression (history) exhibited impaired reward versus punishment 
reversal learning as well as reduced reward versus punishment-related BOLD signal in the 
striatum (putamen) compared with non-depressed PD patients. No effects of dopaminergic 
medication were observed. 
Conclusions: The present findings demonstrate that impairments in reversal learning from 
reward versus punishment and associated striatal signalling depend on the presence of (a 
history of) depression in PD.
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Introduction
Patients with Parkinson’s disease (PD) experience not only motor symptoms, such as 
bradykinesia and rigidity, but also non-motor symptoms among which depression is one 
of the most frequent and debilitating [1]. Despite such a high prevalence and impact, the 
mechanisms underlying depression in PD are unclear and accordingly, treatment is often 
suboptimal. 
Depression has been associated with an imbalance in the impact of reward and/or punishment 
on learning, behaviour and cognition [2-7]. For example, patients with depression exhibit both 
enhanced impact of punishment as well as reduced impact of reward on learning [8-10]. 
Notably, negative affective biases are also observed in individuals at risk for depression in 
several cognitive domains, including learning, putatively representing a vulnerability factor 
[4, 11, 12]. In this study, we asked whether similar biases in learning from reward versus 
punishment contribute to depression in PD. 
This question is particularly relevant given evidence that PD is accompanied by dopamine-
dependent changes in the balance between reward- versus punishment-based learning, 
which involves dopaminergic prediction error coding in the striatum [13]. Multiple studies 
have shown that dopaminergic medication in PD reduces punishment-based learning, but, 
if anything, enhances reward-based learning [14-20]. According to current modelling work, 
these drug effects reflect dopamine-induced shifts in the balance between activity in the 
direct and indirect pathways of the basal ganglia [21]. Despite consistent medication effects, 
discrepancy exists between studies with regard to the pattern of performance on such 
tasks of PD patients OFF medication. While some studies report unaltered performance in 
the OFF state compared with healthy controls [14, 15, 19, 20], other studies report impaired 
reward versus punishment-based learning [16-18, 22]. The pattern of impaired reward versus 
punishment learning in PD patients OFF medication resembles that described above in 
depressed individuals (non-PD) [2, 3] and concurs generally with suggestions that striatal 
dopamine depletion contributes to depression in PD. For instance, nuclear neuroimaging 
studies revealed that depression in PD is accompanied by decreased dopamine transporter 
binding, especially in ventral striatal regions, compared with non-depressed patients [23-25]. 
Functional MRI studies in depressed individuals (non-PD) have shown attenuated ventral 
striatal functioning across various tasks [26-28], including reward-based learning [9]. Based 
on this evidence, we hypothesized that the presence of impaired reward versus punishment 
learning in PD patients OFF medication depends on the presence of (a history of) depression 
and associated ventral striatal dysfunction. 
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Specifically, we predicted that depressed PD patients, OFF medication, would exhibit a greater 
imbalance between learning from reward versus punishment and greater abnormalities 
in ventral striatal BOLD signal than non-depressed PD patients. Moreover, this negative 
learning bias and associated ventral striatal dysfunction in depressed PD patients would 
be remedied by dopaminergic medication. Thus, we expected dopaminergic medication to 
normalize reward versus punishment learning and associated ventral striatal BOLD signal 
in depressed patients, while impairing punishment versus reward learning and associated 
ventral striatal BOLD signal in non-depressed patients (cf[15]). 
To test these hypotheses, we investigated effects of dopaminergic medication withdrawal 
in PD patients with and without a depression (history), using pharmacological fMRI and a 
well-established reversal learning paradigm specifically designed to disentangle reward- 
from punishment-based reversal learning. Previous fMRI work with this paradigm has shown 
that both unexpected reward and unexpected punishment elicit a prediction error signal in 
the striatum [29]. Moreover, this paradigm has been shown to be sensitive to dopaminergic 
manipulation in healthy volunteers as well as PD [15, 30-32] and to depression (non-PD)[9]. 
Here we build on this prior work to advance our understanding of the neurochemical and 
neurocognitive mechanisms of depression in PD. 
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Materials and Methods
Participants and general procedure
Twenty-five healthy controls, 24 depressed and 23 non-depressed PD patients were 
recruited. Data from 2 healthy controls, 5 depressed and 1 non-depressed patient were 
excluded from the analysis for several reasons (supplement). One depressed patient was 
claustrophobic and unable to perform the task inside the MRI scanner. Three PD patients (2 
depressed and 1 non-depressed) were outliers (mean error rates across the task as a whole 
>3SD from the group mean). Two healthy controls were excluded because of a lifetime history 
of depression. Therefore, results are based on datasets from 19 depressed patients, 22 
non-depressed patients and 23 healthy controls. We aimed for a sample size of 20 patients 
per group. This was based on general recommendations by Thirion and colleagues [33], 
who suggest that 20 subjects per group is an appropriate sample size for cognitive fMRI 
studies with a between-group design, and on previous studies that have been done using 
the same task and drug manipulation (sample sizes varied between 10 and 15 subjects per 
group [9, 15]). 
This study was part of a larger project investigating the neurobiological mechanisms of 
depression in PD. All participants gave informed consent as approved by the local research 
ethics committee (CMO region Arnhem - Nijmegen, The Netherlands, nr. 2012/43) and 
were compensated for participation. Patients were recruited from the Parkinson Centre at 
the Radboud university medical centre, Nijmegen, the Netherlands, and were diagnosed 
with idiopathic PD according to the UK Brain Bank criteria by a neurologist specialized 
in movement disorders (Prof. B.R. Bloem, Dr. R.A. Esselink, Dr. B. Post). All patients used 
dopaminergic medication (non-depressed: levodopa n=10, dopamine receptor agonists n=2, 
combination of both n=10; depressed: levodopa n=14, dopamine receptor agonists n=2, 
combination of both n=3). Patient groups were matched for amounts of daily dopaminergic 
medication use (levodopa equivalent dose [34], t(39)=1.22, p=0.23) as well as amounts of 
daily dopamine receptor agonist use (t(39)=1.47, p=0.15). Six depressed patients used 
antidepressants (Paroxetine n=2, Escitalopram n=1, Citalopram n=1 and Nortriptyline n=2). 
All patients were on stable medication regimes during the course of the study, except for 
one patient who used Duloxetine for 4 weeks between the two testing days. The drug was 
prescribed to treat pain and discontinued 4 weeks before the second testing day. 
Exclusion criteria were clinical dementia (Mini Mental State Examination <24 [35]), psychiatric 
disorders other than depression, neurological co-morbidity and hallucinations. Patients 
were assigned to the depressed group if they met the DSM-IV criteria, based on structured 
psychiatric interviews conducted during an intake session (MINI-plus [36]), for a major or 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 64
Chapter 3
64
minor depressive episode, dysthymic disorder or adjustment disorder with depressed mood 
within five years before PD diagnosis up until now. A depression history is significantly 
more common in PD patients compared with age-matched controls, with odds ratios 
varying between 1.5 and 3.1 [37]. The criterion of five years was based on a previous report 
suggesting that depression occurring within five years before PD diagnosis is more likely to 
be PD-related [38]. From here on, we refer to these patients as depressed patients, although 
it should be noted that this group consists of patients with current (n=5), but mostly past 
depression (n=14) (see supplementary table S1 for more information about current and past 
psychiatric diagnoses). None of the patients in the non-depressed group had suffered from 
depression during their lifetime. Groups were matched for age, gender, IQ (Dutch version 
of the National Adult Reading Test [39]), disease severity (Unified Parkinson Disease Rating 
Scale part III [40]) and amounts of dopaminergic medication (Levodopa Equivalent Dose 
[34])(Table1). 
Patients were assessed on two occasions - once ON and once after withdrawal from their 
dopaminergic medication for at least 18 hours (24 hours for controlled-release dopamine 
receptor agonists)(OFF). Antidepressants were not withdrawn. The order of OFF and ON 
sessions was counterbalanced in each group (Table1). Healthy controls were only tested 
once. Current depressive symptoms were measured using the Beck Depression Inventory 
(BDI). Testing days always started in the morning between 8:30-10:30 am. 
Table 1. Patient characteristics
 
 
Depressed
n = 19
Non-depressed
n = 22
Gender, men 
Age, years
NART-IQ
MMSE
Handedness, right
Response hand, right
UPDRS-III (OFF)
LED (mg/day)
LED agonists (mg/day)
BDI (averaged)
First session ON
Days between sessions
12
58.4 (5.3)
96.0 (11.5)
28.5 (1.3)
16
5
23.3 (9.4)
527 (240)
55 (114)
8.7 (5.0)
9
24.1 (28.6)
14
61.1 (7.6)
97.8 (15.0)
28.6 (1.2)
18
14
21.9 (6.8)
626 (277)
110 (127)
4.3 (2.3)
13
21.5 (20.2)
Values represent number of patients or mean (SD). NART = National Adult Reading Test, MMSE = 
Mini Mental State Examination, UPDRS = Unified Parkinson Disease Rating Scale, LED = Levodopa 
Equivalent Dose, BDI = Beck Depression Inventory, averaged across the ON and OFF session in 
patients.  
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 65
Reward learning deficits
65
03
Task
We used a deterministic reversal learning paradigm (Figure 1) similar to that used in 
previous studies [9, 15, 31]. The task was presented on a screen visible via a mirror 
attached on the head coil in the MRI scanner. On each trial, participants were shown 2 
simultaneously presented vertically adjacent stimuli, 1 scene and 1 face. One of these stimuli 
was associated with reward, the other with punishment. By trial and error, subjects had 
to learn these deterministic stimulus-outcome associations. Unlike classical instrumental 
reversal learning paradigms, subjects did not choose between stimuli, but had to predict 
whether the highlighted stimulus was associated with reward or punishment. Patients 
responded with their least affected side, 11 healthy controls were asked to respond with 
their left hand as well. Response mappings were counterbalanced across subjects. Stimuli 
were presented until a response was made, after which the actual outcome was shown. If 
subjects did not respond in time, a “Too late” message was presented. Stimulus-outcome 
contingencies reversed after 4-6 consecutive correct predictions. Reversals were signalled 
by either an unexpected reward (presented after a highlighted stimulus that was previously 
associated with punishment) or an unexpected punishment (presented after a highlighted 
stimulus that was previously associated with reward). Unexpected outcomes were only 
presented after a correct prediction was made according to the current contingency 
ruling-out the possibility of reversal anticipation. Moreover, participants were informed that 
reversal anticipation was not possible within the structure of this task. The same stimulus 
was always highlighted again on the first trial after an unexpected outcome to ensure that 
a contingency reversal would always be paired with a reversal in motor response. Patients 
were familiarized with the task during the intake session and performed a practice block 
on each testing day. 
On each testing day, subjects completed 2 experimental blocks of 230 trials. Each 
experimental block contained a short break of 30s. The number of reversals depended on 
task performance and thus varied across participants. The average number of reversal trials 
for reward and punishment was 29(±6) and 29(±5), respectively, across groups and did not 
differ between groups or drug sessions. 
Behavioural analysis
Error rates and reaction times were analyzed with a mixed ANOVA with GROUP as a 
between-subject factor and REVERSAL (reversal, non-reversal), VALENCE (reward, 
punishment) and DRUG (OFF and ON medication) as within-subject factors. Comparison of 
patient data with healthy control data can be found in the supplement. Errors were defined 
as misses or incorrect predictions. Errors on reversal trials were defined as incorrect 
predictions on the trial immediately following an unexpected outcome. All other trials 
were defined as non-reversal trials, including trials that were followed by an unexpected 
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outcome. Note that unexpected outcomes only followed a correct prediction. Error rates 
were arcsine transformed (2*arcsin(√x)) as is appropriate when variance is proportionate 
to the mean.
Unexpected punishment
Condition: Unexpected punishment
Highlighted stimulus:             F      S      F      F      F     S      F
Correct prediction:    rw    pn    rw    rw    pn    rw    pn
Outcome:     R      P      R     P      P      R     P
Trial type:     ER   EP   ER           EP   ER   EP 
B
+
- €100 
A
ITI 1500-6000 ms.
Response 
deadline 1500 ms. Outcome presentation
500 ms.
Figure 1. Task overview. A Two stimuli (a face and a scene) were simultaneously presented. 
One of the stimuli was highlighted with a black border. Participants were asked to predict 
if the highlighted stimulus was followed by reward (green happy smiley and “+€100” sign) 
or punishment (red sad smiley and “-€100” sign). Following the participants’ prediction, 
the actual outcome was presented (100% deterministic). B Example sequence of trials. 
In this example the face stimulus was associated with expected reward (ER) and the 
scene stimulus was associated with expected punishment (EP). After a series of 4 to 6 
consecutive correct responses, the stimulus-outcome associations reversed, signalled by 
either unexpected reward or unexpected punishment. 
Image acquisition and analysis
A Siemens TIM-Trio 3-T MRI scanner with a 32-channel head-coil was used to acquire 
structural and functional MRI images. Functional images were acquired using a multi-
echo echoplanar imaging sequence (38 axial slices, ascending slice acquisition 
order, voxel size=3.3x3.3x2.5mm, matrix=64x64, repetition time (TR)=2.32s, echo time 
(TE)=9.0/19.3/30.0/40.0ms, flip angle=90°). Multi-echo images were acquired in order to 
benefit from reduced susceptibility artefacts at low echo times [41]. Structural images were 
acquired using a T1-weighted MP-RAGE sequence (192 slices, voxel size=1.0×1.0×1.0mm, 
matrix=256x256, TR=2.3s, TE=3.03s, flip-angle=8°).
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Images were preprocessed and analyzed using SPM8 (Welcome Department of Cognitive 
Neurology, London). Images were realigned to the first volume using data from the shortest 
TE to estimate realignment parameters. After realignment, a weighted summation was 
performed to combine all four TEs into a single dataset [41]. To this aim, 30 “resting-state” 
images, acquired before the start of the actual experiment, were used to estimate BOLD 
contrast-to-noise ratio maps for each TE. These maps were used to calculate an optimal 
voxel-wise weighting between the four echoes using in-house software, maximizing the 
contribution of each echo according to its contrast-to-noise ratio. Combined images were 
checked for spiking artefacts, slice-time corrected to the middle slice, coregistered to the 
structural image, normalized to the standard Montreal Neurological Institute template, re-
sampled into 2.5x2.5x2.5mm isotropic voxels and smoothed with an isotropic Gaussian 
kernel of 8mm full-width at half-maximum. 
A first-level general linear model (GLM) was estimated that incorporated separate regressors 
for each possible outcome (modelled as event at time of outcome presentation, convolved 
with a canonical hemodynamic response function (HRF)): unexpected punishment, 
unexpected reward, correctly predicted expected punishment, correctly predicted expected 
reward, incorrectly predicted expected outcomes and misses. An additional epoch regressor 
modelled the 30s break. Twenty-nine noise regressors were added to the GLM: 24 motion 
regressors (6 derived from the realignment procedure, their first derivatives (n=6) and those 
squared (n=12)), 3 parameters to model global intensity changes (time series of the mean signal 
from white matter, cerebral spinal fluid and out-of brain segments) and 2 regressors to control 
for BOLD signal changes related to (changes in) tremor amplitude; an electromyography 
amplitude regressor and its first derivative both convolved with a canonical HRF [42]. Time 
series were high-pass filtered (cut-off 128sec) to remove low-frequency signals and an AR(1) 
model was applied to adjust for serial correlations. The 2 experimental blocks from 1 session 
were modelled within one GLM. Preprocessing and estimation of the GLM was performed 
separately for each drug session.
Individual contrast maps were generated at the first level for each drug session. The main 
contrast of interest was [unexpected reward – unexpected punishment]. We calculated 
individual ‘drug-difference maps’ (OFF-ON) and ‘drug-average maps’ ((OFF+ON)/2). These 
contrast maps were taken to a second-level random-effects analysis. To compare drug-
effects between depressed and non-depressed patients, we submitted individual ‘drug-
difference maps’ to a second level two-sample T-test. To assess the main effect of drug, 
we submitted individual ‘drug-difference maps’ to a second level one-sample T-test and to 
assess the main effect of group, we submitted individual ‘drug-average maps’ to a second 
level two-sample T-test. Response hand was added as a covariate of no-interest to control 
for differences in response hand between groups (Table 1). 
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Statistical inference was performed at the voxel level using a family-wise error (FWE) corrected 
threshold of p<0.05 within an a priori defined small-volume of interest corresponding to 
the bilateral striatum (psv_fwe). To this end, we combined the bilateral caudate nucleus and 
putamen regions extracted from the AAL atlas into one single region of interest [43]. For 
additional whole brain analyses, statistical inference was performed at the cluster level 
using an FWE-corrected threshold of p<0.05 across the whole-brain (pwb_fwe) combined with 
a cluster-forming threshold of p<0.001 uncorrected. Marsbar software was used to extract 
mean parameter estimates and assess brain-behaviour correlations. 
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Results
Patient and disease characteristics
As expected, patient groups differed significantly in depressive symptoms (BDI averaged 
across the 2 drug sessions, F(1,39)=13.22, p=0.001, ηp2=0.25) (Table 1), although BDI scores of 
the depressed patient group still fell within the normal range (mean 8.7±5.0). 
Table 2. Error rates 
Trial type Depressed patients Non-depressed patients
EP OFF
UP OFF
ER OFF
UR OFF
0.07 (0.13)
0.06 (0.17)
0.08 (0.10)
0.12 (0.21)
0.07 (0.10)
0.07 (0.10)
0.09 (0.08)
0.06 (0.12)
EP ON
UP ON
ER ON
UR ON
0.07 (0.08)
0.07 (0.15)
0.07 (0.06)
0.14 (0.14)
0.10 (0.11)
0.09 (0.10)
0.10 (0.06)
0.09 (0.12)
Median error rate (interquartile range) per group and drug session. EP = expected punishment, UP = 
unexpected punishment, ER = expected reward, UR = unexpected reward. 
Behavioural results
Task performance in general was very good (Table 2). Comparison of error rates in non-
depressed and depressed PD patients revealed a significant REVERSAL*VALENCE*GROUP 
interaction (F(1,39)=4.17, p=0.048, ηp2=0.10). Breakdown of this interaction revealed a significant 
REVERSAL*VALENCE interaction in depressed (F(1,39)=8.55, p=0.009, ηp2=0.32), but not in 
non-depressed patients (p=0.4). The significant interaction in depressed patients was driven 
by an effect of VALENCE on reversal trials (F(18)=4.86, p=0.041, ηp2=0.21). Depressed patients 
made more errors on reward compared with punishment reversal trials. There was also a 
significant effect of REVERSAL on reward trials (F(18)=5.12, p=0.036, ηp2=0.22), indicating 
that depressed patients made more errors on reward reversal trials compared with reward 
non-reversal trials. There was no effect of VALENCE on non-reversal trials (p=0.6). There 
were no other significant interactions with GROUP or DRUG and no significant main effects 
of GROUP, DRUG, REVERSAL or VALENCE (Figure 2). There were no session order effects. 
Analyses of reaction times are reported in the supplement. 
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Dopamine receptor agonists
In contrast to previous studies (cf[15]) we did not observe valence-specific effects of 
dopaminergic medication on reversal learning. Because previous literature suggests that 
valence-specific drug effects might be driven by patients on dopamine receptor agonists 
[15], we performed a supplementary analysis including dopamine receptor agonist use 
(AGONIST) as additional between-subject factor. However, this analysis revealed no 
significant interactions with GROUP, DRUG or AGONIST as factor(s) and no significant main 
effects of GROUP, DRUG or AGONIST. 
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Figure 2. Error rates on reversal trials [unexpected reward - unexpected punishment] (in blue) and 
non-reversal trials [expected reward - expected punishment] (in red) as a function of group (depressed 
and non-depressed PD patients). Error bars represent standard errors of the mean. *p<0.05, ** p<0.01, 
***p<0.001
Imaging results
We were primarily interested in valence-specific striatal BOLD signal changes during 
unexpected outcomes in depressed versus non-depressed PD patients. Supplementary 
analyses on outcome-general reversal-related brain signal changes and on valence-specific 
brain signal changes during expected outcomes are presented in the supplement (Figure 
S1 and S2). First, given the behavioural results, we assessed group differences using a 
two-sample T-test on individual ‘drug-average maps’ contrasting unexpected reward and 
punishment. This analysis revealed a significant effect of GROUP on striatal BOLD signal 
elicited by unexpected reward versus unexpected punishment (right putamen, x=30, y=-14, 
z=12, T=5.05, psv_fwe=0.008) (Figure 3A). Decomposing this interaction in each group separately 
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revealed that unexpected reward induced significantly greater increases in striatal BOLD signal 
than unexpected punishment in non-depressed patients (right putamen, x=30, y=-14, z=12, 
T=5.11, psv_fwe=0.037; left putamen, x=-28, y=-4, z=12, T=4.95, psv_fwe=0.049). This effect was 
not observed in depressed patients (Figure 3A). There were no differences in striatal BOLD 
signal elicited by either unexpected reward or unexpected punishment (contrasted against 
baseline) between depressed and non-depressed patients, indicating that the observed 
difference in valence-specific striatal BOLD signal during unexpected outcomes was driven 
by the difference between reward and punishment. Moreover, a supplementary analysis, 
for which we subtracted the response to expected rewards and punishments from that to 
unexpected rewards and punishments, revealed a similar result: a significant group effect 
on striatal BOLD signal elicited by [(unexpected reward - expected reward) – (unexpected 
punishment – expected punishment)] (right putamen, x=30, y=-14, z=12, T=4.99, psv_fwe=0.009). 
The effect was restricted to the striatum: there were no other effects elsewhere in the brain as 
revealed by whole brain analysis. There was no GROUP*DRUG interaction nor a main effect of 
DRUG on striatal BOLD signal elicited by unexpected reward versus unexpected punishment, 
suggesting that the above reported effects did not differ between drug sessions. 
In the depressed PD group, we performed brain-behaviour correlations. Specifically, we 
extracted individual beta values from the striatal cluster (right putamen) showing a significant 
GROUP*VALENCE interaction in the voxel-wise analysis reported in Figure 3A. Behaviourally, 
error rates on punishment reversal trials were subtracted from error rates on reward reversal 
trials. We used non-parametric statistics (Spearman correlation) for this subgroup analysis, given 
the relatively low sample size (n = 19). There was a significant correlation between these two 
measurements (rho=-.525, p=0.021) (Figure 3B). Patients who made more errors on reward 
versus punishment reversal trials also exhibited reduced striatal BOLD signal in response to 
unexpected reward versus unexpected punishment. In depressed PD patients, there was no 
significant correlation between BDI scores and impairments in valence-specific reversal learning 
(rho=0.135, p=0.58) and no significant correlation between BDI scores and valence-specific BOLD 
signal changes in the striatum during unexpected outcomes (rho=-0.025, p=0.92).
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Figure 3. BOLD signal during reward- versus punishment-based reversal learning. A Valence-specific 
BOLD signal in the striatum during unexpected outcomes [unexpected reward (UR) – unexpected 
punishment (UP)] for the contrast [non-depressed - depressed patients] and for both groups separately 
(non-depressed patients and depressed patients). Data presented at p<0.001 uncorrected (blue) and 
at p<0.005 uncorrected (red). Note that peak activations in the putamen survive an FWE-corrected 
threshold of p<0.05 in our anatomically defined striatal volume of interest. B  Brain-behaviour 
relationship among depressed PD patients. This plot shows a significant correlation (rho=-.525, 
p=0.021) between differential error rate  and striatal BOLD signal for the contrast [unexpected reward 
(UR) – unexpected punishment (UP)]. Beta values were extracted from the striatal voxels showing a 
significant GROUP*VALENCE interaction in the voxel-wise analysis (i.e. 9 voxels in the right putamen 
that survived the family-wise error corrected threshold of p<0.05 within our small-volume of interest).
Antidepressants
Six depressed PD patients used antidepressants. In order to rule out their potentially 
confounding effect, we performed an additional analysis excluding patients who used 
antidepressants (i.e. non-depressed group n=22, depressed group n=13). Analysis of error 
rates revealed a qualitatively similar although not significant REVERSAL*VALENCE*GROUP 
interaction (F(1,33)=3.83, p=0.059, ηp2=0.10). Decomposition of this 3-way interaction revealed 
a significant REVERSAL*VALENCE interaction in the depressed group (F(12)=7.26, p=0.020, 
ηp2=0.38), but not in the non-depressed group (F(21)=0.72, p=0.41, ηp2=0.03). 
We also performed additional analyses of the imaging data after excluding the patients 
who used antidepressants. Comparing non-depressed patients with depressed patients 
revealed a similar result as reported above, i.e. a significant group effect on striatal BOLD 
signal elicited by unexpected reward versus unexpected punishment (right putamen, x=30, 
y=-14, z=12, T=4.70, psv_fwe=0.028). 
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Discussion
In line with our hypothesis, we demonstrate that a depression (history) in PD is accompanied 
by impaired reward (versus punishment) reversal learning and an attenuation of the 
differential striatal response to unexpected reward versus unexpected punishment. Whereas 
unexpected reward induced significantly greater increases in striatal BOLD signal than 
unexpected punishment in non-depressed patients, this was not observed in depressed 
patients. However, in contrast to our other hypothesis, we did not observe an effect of 
dopaminergic medication on reversal learning or striatal BOLD signal.
In depression, impaired reward processing and attenuated striatal function has been shown 
previously across multiple facets of cognition [26-28, 44]. The present effect concurs 
directly with a finding from previous work, using the same paradigm, showing reduced 
reward-based reversal learning and reduced striatal signalling (albeit in a slightly more 
anterior region) in depressed individuals (non-PD) [9]. This is the first study demonstrating 
impaired reward (versus punishment) reversal learning and an attenuated differential striatal 
response to unexpected reward versus punishment in depressed versus non-depressed 
PD patients. It might be noted that the pattern of alteration observed at the behavioural 
level was partly different from that observed at the neural level. Whereas learning deficits 
in depressed PD patients were relatively selective for reward, the impairment observed at 
the striatal BOLD level concerned the differential response to unexpected reward versus 
punishment. Yet, we believe these two findings to be related. Indeed, in depressed patients, 
the degree of impairment in the differential striatal response to unexpected reward versus 
punishment correlated with the degree of impairment in learning from unexpected reward 
versus punishment. Together, these results provide evidence that abnormal signalling in the 
striatum, the key region affected by PD, also contributes to depression-related deficits in PD. 
There is discrepancy in extant literature with respect to the integrity of reward and/or 
punishment learning in PD patients OFF medication. Some studies have reported OFF state 
performance to be unaltered compared with controls [14, 15, 19, 20], whereas other studies 
have revealed impaired reward relative to punishment learning/performance [16-18, 22]. The 
current data suggest that these discrepancies might reflect differences in the inclusion of 
patients with or without a depression (history). As such, our observations demonstrate that 
(striatal) reward learning deficits in PD depend on the presence of a depression (history) 
and highlight the importance of taking into account depression history in PD patients when 
investigating reward (versus punishment) learning.  
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The present study demonstrates attenuated brain responses to reward versus punishment 
in depressed PD patients in a posterior striatal region. This contrasts with some previous 
studies in depressed individuals (non-PD) showing blunted striatal responses in more 
anterior striatal regions [9, 26, 44]. This discrepancy might reflect the effect of PD in our 
study. Critically, a similar posterior striatal locus of reward versus punishment prediction 
error coding has been previously shown using the same paradigm in healthy subjects [29]. 
This was argued to reflect recruitment of instrumental mechanisms in the context of reward 
[29]. Accordingly, the present effect might reflect an inability of depressed patients to recruit 
reward-guided instrumental actions [45, 46]. 
In contrast to our hypothesis, and contrary to previous studies [15-18, 20], we did not 
observe valence-specific drug effects. We are puzzled by this lack of effect and provide 
two possible accounts. First, valence-specific drug effects on (reversal) learning have been 
shown primarily with dopamine receptor agonists and antagonists [15, 17, 20, 30-32]. In 
contrast to previous studies, in our sample only less than half of the patients used dopamine 
receptor agonists (17/41). Moreover, most patients in our sample (15/17) used controlled-
release dopamine receptor agonists for which one might argue that the withdrawal period 
was too short. However, the behavioural pattern (across both patient groups) observed in 
the current study was more akin to that seen in previous studies when patients were in an 
OFF rather than an ON state, suggesting that the effects of controlled-release dopamine 
receptor agonists on valence-specific (reversal) learning might not be comparable to those 
of regular dopamine receptor agonists. A second, not mutually exclusive possibility is that 
our failure to observe the predicted medication effect might reflect a ceiling effect: in the 
present study patients performed extremely well, and much better than did the patients in 
our previous study [15]. The median error rate OFF (across patients groups) for unexpected 
punishment was 0.06 and 0.08 for unexpected reward in the current study, while it was 
0.12 for unexpected punishment and 0.20 for unexpected reward in our previous study [15]. 
Thus, it is possible that there was insufficient dynamic range for any medication-induced 
improvement in valence-specific learning to surface. 
A potential caveat of the present study is the heterogeneous sample of depressed PD 
patients, which included patients with current as well as past depression. Although the sample 
sizes of both patients groups (n=19 and n=22) were large enough for a cognitive fMRI study 
with a between-group design [33], we lacked sufficient power for comparing PD patients with 
current (n=5) versus past (n=14) depression. Negative (learning) biases have been shown in 
never-depressed individuals at risk for depression [11, 12]. Moreover, outside the domain of 
learning, it has been shown that negative affective biases can persist after remission of a 
depressive episode (see for review Roiser et al., 2012). However, the hypothesis that negative 
learning biases persist (or diminish) with remission of a depressive episode has never been 
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investigated. The present results should therefore be validated in a follow-up study that 
includes a larger group of depressed PD patients enabling comparison of patients with past 
and current depression. In addition, six depressed patients used antidepressants. It is well 
known that other neurotransmitters than dopamine, such as serotonin, can influence reward 
versus punishment learning [47, 48]. However, a supplementary analysis after excluding 
patients who used antidepressants revealed similar behavioural as well as neural findings, 
increasing our confidence in the results.
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Supplement
Results
Reaction times
Mean reaction times were based on correctly predicted trials. Comparison of non-depressed 
and depressed PD patients revealed no significant interactions with GROUP as a between-
subject factor, but there was a significant DRUG*REVERSAL interaction (F(1,39)=5.65, p=0.022) 
across groups. This interaction was driven by a simple main effect of DRUG on reversal 
trials (F(1,39)=6.89, p=0.012). Patients responded more slowly on reversal trials when they 
were tested ON versus OFF medication. There was no drug effect on non-reversal trials 
(p=0.2). There was also a main effect of REVERSAL (F(1,39)=5.69, p=0.022). Patients responded 
significantly faster on reversal trials compared with non-reversal trials. And a main effect 
of DRUG (F(1,39)=5.50, p=0.024). Patients responded significantly faster when they were ON 
versus OFF medication. There were no significant interactions with VALENCE as factor en 
no significant main effects of GROUP or VALENCE. 
Comparison with healthy controls
We compared error rates in patients and healthy controls. For patients we averaged error 
rates across the two drug sessions (because there were no drug effects). Two mixed 
ANOVAs were conducted with REVERSAL (reversal, non-reversal) and OUTCOME (reward, 
punishment) as within-subject factors and GROUP as a between subject factor. One 
comparing non-depressed patients with healthy controls and one comparing depressed 
patients with healthy controls. Comparison of non-depressed patients with healthy controls 
revealed no differences in outcome-specific reversal learning, indicated by a non-significant 
REVERSAL*OUTCOME*GROUP interaction (p=1). There was a trend towards an interaction 
when comparing depressed patients and healthy controls, but this did not quite reach 
significance (REVERSAL*OUTCOME*GROUP, F(1,40)=2.98, p=0.092).
We compared reaction times in healthy controls with all patients pooled together (because 
there were no group differences). Separate repeated-measures ANOVAs were conducted 
for both drug sessions, because we did observe drug effects in patients: one comparing the 
OFF session of patients with healthy controls and one comparing the ON session of patients 
with healthy controls. There were no effects of GROUP, indicating that patients did not differ 
from healthy controls in terms of reaction times during either drug session.   
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 77
Reward learning deficits
77
03
We then compared imaging data between patients and healthy controls, depressed and non-
depressed patients separately (averaged across drug sessions). These analyses revealed 
no significant group differences.
Outcome-general reversal related brain signal
Unexpected outcomes (collapsed across reward and punishment, both patient groups 
and drug sessions) revealed significant BOLD signal changes (p<0.05 cluster-level FWE-
corrected threshold across the whole-brain combined with a cluster-forming threshold of 
p<0.001 uncorrected) in the bilateral anterior insular cortex, the bilateral middle frontal cortex 
and the anterior cingulate cortex relative to expected outcomes (Figure S1 and Table S2). 
Valence-specific BOLD signal changes during expected outcomes
Whole brain analyses revealed differences in BOLD signal changes during expected 
outcomes [expected reward – expected punishment] between depressed and non-
depressed patients. There was a significant (p<0.05 cluster-level FWE-corrected threshold 
across the whole-brain combined with a cluster-forming threshold of p<0.001 uncorrected) 
group difference in BOLD signal in the bilateral ventral anterior cingulate cortex (x=12, y=48, 
z=10, T=4.58, pwb_fwe=0.012). Decomposition of this interaction revealed that expected reward 
induced significantly greater increases in BOLD signal in the ventral anterior cingulate cortex 
than expected punishment in depressed patients (x=-1, y=48, z=8, T=4.64, pwb_fwe<0.001). This 
effect was not observed in non-depressed patients (Figure S2). 
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Figure S1. Outcome-general reversal related BOLD signal. Outcome-general, reversal-related 
[unexpected outcomes – expected outcomes] increases in BOLD signal. Results presented at a 
p<0.05 cluster-level FWE-corrected threshold across the whole-brain combined with a cluster-forming 
threshold of p<0.001 uncorrected.
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z=10
=0.001
=0.005
Non-depressed patients             Depressed patients
             [Depressed - Non-depressed]
Figure S2. BOLD signal during expected outcomes. Valence-specific [expected reward – expected 
punishment] BOLD signal changes in the ventral anterior cingulate cortex for the contrast [depressed 
- non-depressed patients] and for both groups separately (non-depressed patients and depressed 
patients). Data presented at p<0.001 uncorrected (blue) and at p<0.005 uncorrected (red). The group 
difference in the ventral anterior cingulated cortex survives a p<0.05 cluster-level FWE-corrected 
threshold across the whole-brain combined with a cluster-forming threshold of p<0.001 uncorrected.
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Discussion
In addition to the between-group difference in striatal BOLD signal elicited by unexpected 
outcomes reported in the main text, we also observed between-group differences in 
BOLD signal elicited by expected outcomes in the ventral anterior cingulate cortex (ACC). 
Specifically, in contrast to non-depressed patients, depressed patients exhibited significantly 
greater increases in ventral ACC BOLD signal elicited by expected reward relative to expected 
punishment. The ventral ACC is part of the brain’s limbic system and tightly connected with 
for instance the amygdala, hypothalamus and nucleus accumbens [49, 50]. Aberrant ventral 
ACC function has been a consistent finding in depressed individuals (non-PD) ([51, 52], for 
a meta-analysis see [53]). Interestingly, enhanced activation of the ventral ACC has been 
particularly observed in studies where depressed individuals or individuals with a remitted 
depression performed at the same level as healthy controls [54-57] and was hypothesized 
to reflect over-recruitment of these areas as compensatory mechanism [53]. Similarly in our 
sample, enhanced recruitment of the ventral ACC in patients with a PD-related depression 
(history) was accompanied by unimpaired performance on expected reward relative to 
expected punishment trials. Together, this would concur with the hypothesis that patients 
with PD-related depression (history) exhibit a general reward learning deficit, which surfaces 
more readily on reversal trials due to its higher demands for learning. Thus, it is possible 
that over-recruitment of the ventral ACC enables them to overcome this deficit during the 
less demanding non-reversal trials, while they fail to do so during the more demanding 
reversal trials. 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 81
Reward learning deficits
81
03
Table S1. Depression diagnosis and antidepressant use
Subject Age DD* Current 
diagnosis
Past diagnosis AD**  
use
1 62 2,51 Dysthymic disorder around PD diagnosis 0
2 60 2,51 Adjustment disorder with depressed mood 
after receiving PD diagnosis
0
3 59 12,76 Minor depressive disorder around PD 
diagnosis
0
4 59 2,84 Minor depressive disorder around PD 
diagnosis
0
5 54 1,84 Minor depressive 
disorder
0
6 54 5,08 Minor depressive disorder after receiving PD 
diagnosis
0
7 46 1,75 Minor depressive disorder 3 years before PD 
diagnosis
0
8 63 2,92 Minor depressive disorder 2 years before PD 
diagnosis
0
9 64 4,09 Major depressive disorder during puberty, 
MDD 1 year before PD diagnosis
0
10 65 7,26 Minor depressive disorder after receiving PD 
diagnosis
0
11 58 8,01 Minor depressive disorder 6 months before 
PD diagnosis
0
12 56 7,26 Major depressive disorder 6 years after PD 
diagnosis
0
13 54 2,75 Minor depressive 
disorder
Postnatal depression 0
14 64 5,34 Major depressive disorder around PD 
diagnosis
1
15 55 3,51 Minor depressive disorder after PD diagnosis 1
16 51 2,51 Major depressive 
disorder
1
17 64 6,76 Major depressive 
disorder
Four past major depressive episodes, first 
episode at 44 years of age, 2 episodes within 
5 years before PD diagnosis, one episode 4 
years after diagnosis
1
18 58 7,34 Minor depressive disorder at 38 years of age, 
minor depressive disorder 6 years after PD 
diagnosis
1
19 65 14,52 Minor depressive 
disorder
1
* DD = disease duration Parkinson’s disease (years from diagnosis)
** AD = antidepressant
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Table S2. Outcome-general reversal related brain signal
Label MNI coordinates 
(x, y, z) 
T Cluster size 
(K) 
Left anterior insula 
Right anterior insula 
Right middle frontal gyrus 
Left inferior frontal gyrus 
Left precentral gyrus 
Left paracingulate gyrus 
Left middle frontal gyrus 
Right thalamus
Left frontal pole
-30  23  0
34  20  -2
47  28  25
44  20  35
42  8  55
52  13  38
42  13  35
-53  16  8
-48  23  30
-56  10  20
-46  6  30
-6  16  50
-46  28  25
43  6 40
7  -22  0
-36  50  8
20.85
18.56
13.89
11.69
11.42
11.04
10.89
13.82
12.34
11.75
13.27
12.72
12.61
12.51
11.51
11.21 
14332 
Left superior parietal lobule
Left lateral occipital cortex
Right superior parietal lobule
Left supramarginal gyrus 
Right angular gyrus
Left angular gyrus
Left precuneus cortex
Left superior parietal lobule 
Right precuneus cortex
Right lateral occipital cortex
-30  -57  40
-33  -60  42
34  -52  40
-50  -47  50
-43  -44  45
-50  -40  50
-48  -40  45 
-58  -52  30
37  -54  45
54  -47  30
-38  -52  45
-48  -52  38 
-8  -67  48
-33 -50  42
7  -67  50
12  -70  55 
14.30
13.81
13.63
13.56
13.47
12.98
12.61
11.37
13.34
12.49
12.84
12.19
13.09
12.93
11.36
11.16 
7873 
Right middle temporal gyrus
 
Right inferior temporal gyrus 
Right temporal occipital fusiform cortex 
62  -27  -8
57  -27  -8
60  -47  -12
40  -54  -20 
10.01
9.97
6.79
4.29 
835 
Left posterior cingulate gyrus -3  -30  28 7.31 219 
Right anterior cingulate gyrus 
Left anterior cingulate gyrus 
4  8  28
-6  6  30 
5.49
4.43 
37 
Left intracalcarine cortex -13  -74  10
-10  -87  2 
4.21
3.90 
67 
Right intracalcarine cortex 14  -67  10
2  -74  10 
3.86
3.32 
19 
Outcome-general reversal-related [unexpected outcomes – expected outcomes] increases in BOLD 
signal across patient groups and drug sessions. Peaks at p<0.001 uncorrected.
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Abstract
Background: Parkinson’s disease is accompanied by medication-induced learning deficits, 
which have been attributed to putative overdosing of intact ventral frontostriatal circuitry. 
However, there is large individual variability in the effects of dopaminergic medication on 
learning. 
Objectives: We assessed whether learning deficits in patients with Parkinson’s disease on 
dopaminergic medication depend on depression, which implicates, among other things, 
abnormal dopamine transmission in the ventral striatum. 
Methods: The association between depression status and reversal learning impairment 
was assessed in 569 non-demented patients with Parkinson’s disease, who were tested on 
dopaminergic medication. 
Results: Consistent with the overdose hypothesis, higher dopaminergic medication dose 
was associated with greater reversal learning impairment. Seventeen percent of this effect 
was explained by current depression severity. Patients on high medication doses exhibited 
poorer reversal learning compared with patients on low medication doses, but only if they 
had high current depression ratings. 
Conclusions: These findings suggest that patients with Parkinson’s disease and concurrent 
depression are more vulnerable to the detrimental effects of high dopaminergic medication 
dose on learning than non-depressed patients and highlight the need for stricter monitoring 
of cognitive side effects with dopaminergic treatment in depressed patients. 
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Introduction
Many patients with Parkinson’s disease (PD) experience non-motor symptoms, such as 
depression and/or cognitive deficits [1]. Both have a highly significant negative impact on 
quality of life [2, 3]. While dopaminergic treatment ameliorates many of the motor symptoms, 
the effects of dopaminergic drugs on cognitive functions in PD are more complex. In this 
study we asked whether cognitive effects of dopaminergic medication in PD depend on 
depression status.
PD patients are well known to exhibit various forms of cognitive inflexibility, including difficulty 
with attentional set-shifting and reversal learning [4-9]. These different forms of cognitive 
flexibility are thought to implicate distinct neuromodulators, with dopamine being particularly 
strongly implicated in reversal learning, but not attentional set-shifting. Indeed reversal 
learning has been found to be impaired by administration of dopaminergic medication [4, 9, 
10], while attentional set shifting was repeatedly left unaltered by dopaminergic medication 
[4, 7, 11]. Gotham et al were the first to put forward the dopamine overdose hypothesis to 
account for the detrimental effects of dopaminergic medication on cognitive function [12]. This 
hypothesis was later substantiated by work of others [4, 5, 9, 10] and states that dopaminergic 
medication doses necessary to ameliorate motor and cognitive functions associated with 
the severely depleted dorsal striatum might detrimentally overdose dopamine levels in 
relatively intact brain regions, such as the ventral striatum. Consistent with this hypothesis 
are observations that dopaminergic medication in PD modulates the relatively intact 
ventral striatum during reversal learning [13], and that dopaminergic medication-induced 
impairments in reversal learning are associated with greater striatal dopamine release [14]. 
One implication of this hypothesis is that the detrimental effects of dopaminergic medication 
on reversal learning in PD might be restricted to patients with intact levels of ventral striatal 
dopamine, not extending to patients with deficient dopamine transmission in the ventral 
striatum (a hypothesis made explicit in [15]). 
Depression is well known to be accompanied by reward-related motivational and learning 
abnormalities and strongly implicates ventral striatal dopamine dysfunction [16-19]. More 
specifically, nuclear imaging studies with patients with PD have revealed lower striatal 
dopamine transporter binding, specifically in ventral striatal regions, in depressed compared 
with non-depressed PD patients [20-22]. Depressive symptoms in PD occur more frequently 
when dopaminergic medication effects wear OFF and can be ameliorated (to some degree) 
by dopaminergic medication [23, 24]. Therefore, according to the overdose hypothesis, 
PD patients with concurrent depression might be expected to be less likely to experience 
overdosing effects of dopaminergic medication. 
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To address the question whether medication-related deficits in reversal learning in PD 
depend on depression status, we investigated the association between dopaminergic 
medication dose and reversal learning impairment in a large sample of PD patients (n=569) 
with various degrees of depressive symptoms. The task employed was the well-established 
CANTAB intradimensional/extradimensional set-shifting paradigm (ID/ED) [6]. This task has 
been shown to be sensitive to attentional set-shifting impairments in PD (cf [4, 6, 25]) and 
to reversal learning impairments in depressed individuals (non-PD) [26]. Based on previous 
literature [4, 7, 9-11], we predicted an association between dopaminergic medication dose and 
reversal learning impairment, but not between dopaminergic medication dose and attentional 
set-shifting impairment. Moreover, based on the association between depression and ventral 
striatal dopamine dysfunction and following the overdose hypothesis, we predicted that an 
association between dopaminergic medication dose and reversal learning impairment would 
be greater in patients with lower depression ratings. 
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Methods
Participants and experimental design
The data used in this study are part of a large dataset obtained during the ParkFit study, a 
randomized clinical trial that assessed the effectiveness of a behavioural change program 
to promote physical activity in PD patients [27]. Data used in the current study were 
measurements obtained during baseline, i.e. before start of the intervention. Patients were 
eligible for inclusion in the ParkFit study if they met the following criteria: a diagnosis of 
idiopathic Parkinson’s disease according to the UK brain bank criteria [28], Hoehn and Yahr 
stage ≤3 and a sedentary lifestyle. Patients were excluded if they met one of the following 
criteria: unclear diagnosis (e.g. no gratifying, sustained response to dopaminergic therapy), 
Mini-Mental State Examination <24 (MMSE) [29], unable to complete Dutch questionnaires, 
severe co-morbidity, daily institutionalized care or deep brain stimulation. In total, 586 
patients were included in the ParkFit study. The measurements of interest for the current 
study were: performance on the intradimensional/extradimensional set-shifting task (ID/ED, 
see task) [6], ratings on the depression subscale of the Hospital Anxiety and Depression 
Scale questionnaire (minimum score 0, maximum score 21) (HADS) [30] and amounts of 
dopaminergic medication, operationalized as total daily levodopa equivalent dose (LED). 
Daily levodopa equivalent dose (LED) was calculated, pooling different drugs according 
to the following formula: apomorphine x10 + regular levodopa x1 + slow release levodopa 
x0.7 + bromocriptine x10 + ropinirol x20 + pergolide x100 + pramipexole x100 + [regular 
levodopa dose+ (slow release levodopa x0.7)] x0.2 if taking entacapone [31]. The HADS is 
a recommended tool to evaluate depressive symptoms in PD patients, with the advantage 
of having little overlap with the core symptoms of the disease. Furthermore, the internal 
consistency and test-retest reliability in PD patients are good [30]. 
The study was approved by the local ethics committee (CMO region Arnhem-Nijmegen) and 
all participants gave written informed consent. The study has been registered at clinicaltrials.
gov (nr NCT00748488). 
Task
Participants completed the CANTAB intradimensional/extradimensional set-shifting task (ID/
ED) [6] (Figure 1). The task was administered using a touch screen computer. Participants 
were tested while taking their normal dopaminergic medication. Participants were confronted 
with four rectangular boxes. On each trial, two of these boxes randomly contained a stimulus 
(two different shapes). The subjects were instructed to find out by trial and error which one 
of these stimuli was correct. After indicating their choice by touching one of the shapes 
on the screen, auditory and visual feedback was provided (100% deterministic). After 
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six consecutive correct responses (i.e. the learning criterion), the task proceeded to the 
next stage. This first simple discrimination stage (SD) was followed by the first reversal 
stage (simple discrimination reversal, SDR) during which stimuli remained the same, but 
contingencies changed; the previously incorrect shape now became the correct one. In 
stage 3, a second dimension was introduced (lines), initially adjacent to the first dimension 
(compound discrimination with separate dimensions, C-D) and during stage 4 overlapping 
the first dimension (compound discrimination with overlapping dimensions, CD). These 
compound discrimination stages were followed by another reversal stage (compound 
discrimination reversal, CDR), during which contingencies reversed again, but still within 
the same dimension (shapes). During stage 6, new compound stimuli were introduced, again 
with the same two dimensions (shapes and lines). Subjects were still required to respond to 
the previously relevant dimension (intra-dimensional shift, IDS). The next stage was again 
a reversal stage, during which contingencies changed, but still within the same dimension 
(intra-dimensional reversal, IDR). In stage 8 of the task, subjects were required to shift their 
responding to the previously irrelevant dimension (e.g. lines) and to find out which one of 
the two stimuli in this dimension was correct (extra-dimensional shift, EDS). The last stage 
of the task was again a reversal stage during which contingencies reversed, but this time in 
the other dimension, that is, lines (extra-dimensional reversal, EDR). 
Statistical analysis
Task stage pass-rate was assessed as a measure of general task performance. Correlation 
analyses were conducted to assess the association between dopaminergic medication dose 
and performance on the attentional set-shifting and reversal learning stages of the task. 
The number of errors on the EDS stage was used as a measure of extra-dimensional (or 
attentional) set-shifting performance. The average number of errors on the four reversal 
stages (2, 5, 7 and 9) was used as a measure of reversal learning performance. If subjects 
failed to reach the criterion of 6 correct consecutive responses after 50 trials, the task 
terminated automatically. Therefore, not all subjects performed all stages of the task. 
Following prior work [26, 32, 33], we used adjusted error scores, calculated by adding 
25 for each stage that was not attempted due to failure of earlier stages. This number 
corresponds to the average number of errors made when patients fail to reach criterion at 
a certain stage of the task.
Mediation analyses were performed to assess whether the correlation between dose and 
reversal learning performance and between dose and attentional set-shifting performance 
depended on current depression severity (2 separate models). In the mediation model, error 
rates were entered as the dependent variable (Y), the amount of dopaminergic medication 
as the independent variable (X) and scores on the depression subscale of the HADS as the 
mediator variable (M). 
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Figure 1. Task overview. Schematic overview of stage 4 to 9 of the ID/ED task. A = compound 
discrimination with overlapping dimensions (CD, stage 4), B = compound discrimination reversal (CDR, 
stage 5), C =  intra-dimensional shift (IDS, stage 6), D = intra-dimensional reversal (IDR, stage 7), E = 
extra-dimensional shift (EDS, stage 8), F = extra-dimensional reversal (EDR, stage 9). Participants had 
to learn by trial-and-error to select the correct stimulus (contingencies were deterministic). After six 
consecutive correct responses, the task proceeded to the next stage. The stimulus in the box with 
the highlighted white border is the correct stimulus (not shown to the participant). In stage 4 to 7 (i.e. 
A, B, C and D) the shape of the stimuli determines which stimulus is correct, in stage 8 and 9 (i.e. E 
and F) the line overlapping the shape determines which stimulus is correct.
All analyses were carried out using IBM SPSS Statistics software, version 21. For correlation 
analyses, we used two-tailed Pearson correlations. To test the equality of two correlation 
coefficients with one shared variable, we used the method introduced by Steiger [34] 
which is implemented in an online tool (Lee & Preacher). This tool converts each correlation 
coefficient into a z-score (Fisher’s r-z transformation), which is used to compute the 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 94
Chapter 4
94
asymptotic covariance of the estimates. These quantities are then used in an asymptotic 
z-test. Mediation analysis was performed using PROCESS macro for SPSS [35]. This macro 
uses ordinary least squares regression to estimate model parameters. A bootstrapping 
procedure was included to assess the significance of the mediation effect. By resampling 
with replacement of the original group sample, this procedure creates 5000 new group 
samples that are used to obtain bias-corrected 95% confidence intervals (CI). If this interval 
does not include zero, the mediation effect is considered statistically significant. We used 
the ratio of the indirect effect (mediation effect) to the direct effect of X on Y as an estimate 
of the effect size [36]. All tests were two-tailed and significance was determined at p<0.05. 
Table 1. Patient characteristics
Total number of patients 569
Gender (men) 370
Age (years) 66 (41-76)
Disease duration (years) 3.8 (0.1-24.8)
Hoehn & Yahr 2 (1-3)
% using dopaminergic medication 88.8%
LED (mg/day) 480 (0-2610)
% using dopamine receptor agonists 56.7%
LED agonists (mg/day) 75 (0-900)
MMSE 28 (24-30)
HADS
- Depression subscale
- Anxiety subscale
9
4
5
(0-36)
(0-19)
(0-17)
Values presented are medians (ranges)
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Results
Study population
Patient characteristics are presented in Table 1. More information with respect to the 
types of dopaminergic medication patients used can be found in Table 2. In 15 patients, 
measurements of interest were not available: 10 patients did not perform the ID/ED task, 3 
patients did not complete the HADS and from 4 patients UPDRS scores were not available. 
Therefore, reported results are based on data from 569 patients.
Eighty-nine percent of patients used dopaminergic medication and the median daily 
dopaminergic dose (LED) was 480 mg/day. The other patients were drug-naïve. The median 
total HADS score was 9 (ranging from 0 to 36), with 42% of patients exhibiting depressive 
symptoms evidenced by scores higher than the cut-off score to screen for depression in PD 
(>10) [30]. This corresponds with previous studies investigating the prevalence of depression 
in PD [37]. 
Table 2. Dopaminergic medication
Type of medication Number of 
patients
Average daily dose 
(range)
Apomorphine 3 26 (15-40)
Levodopa/carbidopa regular 176 492 (62.5-2000)
Levodopa/carbidopa slow release 63 460 (125-1250)
Levodopa/benserazide dispers 37 331 (60-1750)
Levodopa/benserazide regular 96 401 (50-2000)
Levodopa/benserazide slow release 25 435 (125-1375)
Entacapone 30 900 (400-1600)
Pergolide 13 3 (1.5-4.5)
Bromocriptine 0 0
Ropinirol 174 11 (0.75-27)
Pramipexole 135 2 (0.125-9)
Effect of dopaminergic medication on attentional set-shifting and reversal learning
The percentage of patients that reached criterion at each stage of the task is plotted in Figure 
2. The average number of errors and adjusted errors per stage of the task are presented in 
table 3. As shown previously [4, 6, 25] there was a clear drop in the proportion of patients 
reaching criterion at the EDS stage of the task. 
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Figure 2. Proportion of patients reaching criterion at each of the 9 stages of the ID/ED task. SD = 
simple discrimination, SDR = simple discrimination reversal , C-D = compound discrimination with 
separate dimensions, CD = compound discrimination with overlapping dimensions, CDR = compound 
discrimination reversal, IDS = intra-dimensional shift, IDR = intra-dimensional reversal, EDS = extra-
dimensional shift, EDR = extra-dimensional reversal.
Not surprisingly, dopaminergic medication dose (LED) correlated positively with UPDRS-III 
scores (motor part of the Unified Parkinson Disease Rating Scale, used as a measure of 
disease severity) (r(567)=0.117, p=0.005) and with age (r(567)=0.095, p=0.024) and negatively 
with MMSE (r(567)=-0.125, p=0.003). There was no association between LED and IQ estimates 
(r(567)=0.067, p=0.13). In all analyses we controlled for age, MMSE and scores on the UPDRS 
part-III. (Because UPDRS-III does not capture disease severity completely, we also performed 
the analyses replacing UPDRS-III by PDQ-39 scores (Parkinson’s disease questionnaire-39, 
[38]) as measure of self-reported disease severity. Results remained the same).
The (partial) correlation between LED and reversal errors was highly significant (r(564)=0.124, 
p=0.003), indicating that higher dopaminergic medication dose was significantly associated 
with more reversal errors, consistent with an overdose effect. This (partial) correlation also 
remained significant when we correlated pre-EDS stage reversal errors and dopaminergic 
medication dose (adjusted: r(564)=0.118, p=0.005, unadjusted: r(564)=0.115, p=0.006), indicating that 
the detrimental effect of dopaminergic medication on reversal learning could not be explained 
by an effect of adjusted error scores on the last reversal stage in patients who failed the EDS 
stage of the task. The (partial) correlation between LED and EDS errors was not significant 
(r(564)=0.041, p=0.32). This correlation remained non-significant after excluding patients who 
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did not perform the EDS stage of the task (r(500)=0.010, p=0.82) (similar for unadjusted and 
adjusted errors). Moreover, as an additional control analysis, we also performed a correlation 
analysis correlating IDS stage errors (as measure of pre-EDS stage attentional set-shifting) and 
dopaminergic medication dose in all patients who performed the IDS stage of the task (n=511). 
This analysis also revealed a non-significant (partial) correlation (r(506)=-0.012, p=0.79) (similar for 
unadjusted and adjusted errors), strengthening our belief that the null finding is true. Moreover, 
the (partial) correlation of medication dose with reversal errors was significantly stronger than 
that with EDS errors (Fisher test z=2.09, p=0.037) (Figure 3). 
Table 3. Mean number of errors
Mean errors (range)
in patients who failed 
to reach criterion
Mean errors  
(range)
(in all patients, n=569)
Mean errors adjusted 
(range)
(in all patients, n=569)
Stage 1 – SD Not applicable 0.90 (0 – 16) 0.90 (0 – 16)
Stage 2 – SDR 24.38 (19 – 29) (n=8) 2.96 (1 – 29) 2.96 (1 – 29)
Stage 3 – C-D 25.36 (11 – 33) (n=27) 3.17 (0 – 33) 3.52 (0 – 33)
Stage 4 – CD 19.88 (4 – 26) (n=8) 0.91 (0 – 26) 2.40 (0 – 26)
Stage 5 – CDR 24.54 (16 – 35) (n=13) 2.61 (0 – 35) 4.46 (0 – 35)
Stage 6 – IDS 21.00 (21 – 21) (n=2) 0.77 (0 – 24) 3.18 (0 – 25)
Stage 7 – IDR 23.67 (16 – 32) (n=6) 1.67 (0 – 32) 4.18 (0 – 32)
Stage 8 – EDS 27.55 (18 – 36) (n=187) 13.70 (0 – 36) 16.47 (0 – 36)
Stage 9 – EDR 26.16 (19 - 33) (n=25) 2.75 (0 – 33) 13.73 (0 – 33) 
Given prior literature suggesting that the detrimental cognitive effects of dopaminergic 
medication might be greatest with dopamine receptor agonist [10], we also performed 
additional analyses to assess whether the correlation between dopaminergic medication 
dose and reversal learning errors was driven by an effect of dopamine receptor agonists. 
To this end we correlated dopamine receptor agonist dose and reversal learning errors in 
a subgroup of patients who used dopamine receptor agonists (n=322) (r(317)=0.137, p=0.014) 
and in the group as a whole (r(564)=0.066, p=0.116). These findings suggest that, although 
dopamine receptor agonists contribute to the detrimental effect of dopaminergic medication 
dose on reversal learning, they do not solely explain this effect. 
The mediating effect of depression severity
Regression analyses revealed that the total direct effect of dopaminergic medication dose 
on reversal errors was significant (B=0.002, 95%CI=0.001-0.003) (Figure 4A). There was also 
a significant positive relationship between dopaminergic medication dose and depression 
scores (B=0.001, 95%CI=0.001-0.002) and between depression scores and reversal errors 
(B=0.215, 95%CI=0.086-0.344). Most critically, bias-corrected bootstrapped 95% confidence 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 98
Chapter 4
98
intervals of the indirect path (e.g. mediation effect) revealed that the correlation between 
dopaminergic medication dose and reversal learning was mediated by current depression 
severity (B=0.0003, bias-corrected 95%CI=0.001–0.006) (Figure 4B).
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Figure 3. Correlation between performance and LED. Correlation between dopaminergic medication 
dose and reversal errors (grey line) (r(564)=0.124, p=0.003) and correlation between dopaminergic 
medication dose (LED) and EDS errors (black line) (r(564)=0.041, p=0.32). Correlations are significantly 
different (z=2.09, p=0.037). Reversal errors are defined as the average number of errors on reversal 
stages (2, 5, 7 and 9) of the ID/ED task; EDS stage errors are the number of errors on the EDS stage 
of the ID/ED task. For illustration purposes, number of errors were z-scored. 
Current depression severity explained 17% of the total effect of dopaminergic medication 
dose on reversal learning. This mediation effect remained significant after controlling for age, 
MMSE and scores on the UPDRS part-III (B=0.0002, bias-corrected 95%CI=0.0001–0.0004). 
Moreover, if we replace the number of reversal errors by the number of pre-EDS stage 
reversal errors (average number of reversal errors on stages 2, 5 and 7 of the task), results 
remained the same. 
Regression analyses revealed no significant direct effect of dopaminergic medication dose 
on attentional set-shifting performance (B=0.002, 95%CI=-0.001-0.004). 
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Figure 4. Mediation analysis. Schematic model of current depression severity mediating the 
relationship between dopaminergic medication and reversal errors. A The total direct effect of 
dopaminergic medication dose on reversal errors (c). B Current depression severity mediating the 
effect of dopaminergic medication dose on reversal errors. c-c’ represents the indirect (mediating) 
effect (with % mediation). c’ represents the direct effect of dopaminergic medication dose on reversal 
errors when adjusting for the indirect (mediating) effect of depression severity. *p < 0.05, **p  < 0.01, 
*** p  < 0.001 
For illustration purposes, we plotted the average number of reversal errors by median 
splitting the patients into four subgroups as a function of dopaminergic medication dose and 
depression severity (Figure 5). Parametric comparisons of these groups revealed a significant 
difference in reversal errors between patients with high HADS scores and high medication 
dose and those with high HADS scores and low medication dose (t(266)=-3,50, p=0,001), but 
an effect of medication dose was not seen for the low HADS patients (t(299)=-0,75, p=0,46). 
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Figure 5. Effect of LED and HADS on reversal learning. Average number of reversal errors. Patients 
were divided into four categories based on amount of dopaminergic medication (LED median split) 
and current depression severity (HADS depression median split). 
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Discussion
We show in a large sample of PD patients that current depressive symptoms mediate the 
association between dopaminergic medication dose and reversal learning impairment. Consistent 
with the overdose hypothesis, higher amounts of dopaminergic medication were associated with 
greater impairments in reversal learning. Critically, and in contrast to our hypothesis, mediation 
analyses revealed that this association is greatest in patients who exhibit the highest depression 
scores. 
Dopaminergic medication in PD patients was previously found to impair reversal learning [4]. 
The current study complements these previous findings by showing in a much larger sample of 
PD patients that the association between dopaminergic medication dose and reversal learning 
impairment is significantly greater than that between medication dose and attentional set-shifting. 
The obvious caveat of this large sample study is that it did not involve manipulation of medication 
state. As in any other study in which patients are tested only on their medication [9], any association 
between medication dose and task impairment might also reflect disease severity, which often 
covaries with medication dose. Indeed there was also a significant correlation between disease 
severity and reversal learning impairment. However, in all our analyses we carefully controlled 
for this. As such, the finding that the association with reversal learning is greater than that with 
attentional set-shifting cannot be accounted for by disease severity. Instead, a medication 
account of the disproportionate association is more plausible. 
The present study also significantly extends previous literature by suggesting that the detrimental 
effects of dopaminergic medication on reversal learning are more severe in patients with higher 
depression scores, a finding that is generally in line with previous studies showing reversal 
learning deficits in depressed compared with non-depressed individuals (without PD) [26, 39, 40]. 
Our finding raises the hypothesis that previously observed detrimental effects of dopaminergic 
medication on reversal learning in PD patients were driven by patients with concurrent depressive 
symptoms, but direct comparison of the effects of medication withdrawal in depressed and non-
depressed PD patients in future studies is necessary to establish this definitively. 
In the present study, as has been shown before [41], depression in PD was associated with 
the use of higher amounts of dopaminergic medication. This might seem surprising, given 
that dopaminergic medication has been shown to (partly) ameliorate depressive symptoms 
in patients with PD. However, it is possible that patients with high depression ratings receive 
higher amounts of dopaminergic medication because of their depression. We argue that 
depression ratings would have been even higher if patients were assessed OFF their 
dopaminergic medication.
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In prior work, we have put forward the “overdose” hypothesis to explain the detrimental 
effects of dopaminergic medication on cognitive function in PD. According to this 
hypothesis, dopaminergic medication doses necessary to restore dopamine levels in 
the severely depleted dorsal striatum might detrimentally overdose dopamine levels in 
the relatively spared ventral striatum [4, 9, 12, 15]. One might predict, according to this 
hypothesis, that detrimental effects of dopaminergic medication on cognitive function 
would be greater in non-depressed patients with putatively intact levels of ventral striatal 
dopamine than in depressed patients who have been argued to exhibit ventral striatal 
dopamine depletion [20-22]. However, the present data provide evidence to the contrary, 
and suggest that patients with ventral striatal dysfunction (i.e. those who suffer from 
depression) are in fact more likely to experience detrimental effects of dopaminergic 
medication on reversal learning. 
The mechanisms underlying enhanced vulnerability of depressed PD patients to the 
detrimental effects of dopaminergic medication remain to be established. Reward-based 
learning is well established to depend on striatal dopamine [42, 43], suggesting that the 
detrimental effects of dopaminergic medication might well originate within the striatum. This 
idea is supported by functional MRI work showing that dopaminergic medication modulates 
ventral striatal BOLD signaling during reversal learning and reward-related performance in 
PD patients [13, 44, 45]. Moreover, dopaminergic medication-related impairment in reversal 
learning was shown to be associated with striatal dopamine release [14] and individual 
differences in reversal learning have been shown to depend on a common polymorphism 
affecting striatal dopamine transmission [46]. Dopamine levels within the striatum are 
regulated by auto-regulatory mechanisms, such as the dopamine D2/D3 auto-receptor and 
the presynaptic dopamine transporter (DAT). Depression in PD is accompanied by decreased 
striatal DAT [20-22, 47] and decreased D2/D3 receptor availability [48]. Thus, the ventral striatal 
hypodopaminergic state of depression in PD might well be accompanied by deficient auto-
regulatory mechanisms, rendering depressed PD patients more susceptible to overdosing 
effects. An alternative possibility, given the implication of serotonin in depression, is that 
the detrimental effects of dopaminergic medication reflect maladaptive interaction between 
dopaminergic medication and deficient serotonin transmission [49-51]. The observation that 
the mediating effect of depression remained significant after controlling for disease severity 
(amongst other variables), suggests that presynaptic dopamine dysfunction in the ventral 
striatum, associated with depression, might be more relevant for explaining medication-
induced cognitive impairments than is presynaptic dopamine dysfunction in dorsal striatum, 
associated with PD severity. Future research is warranted to elucidate the mechanisms 
underlying disproportionate medication-induced learning impairment in depressed versus 
non-depressed PD patients. 
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Of course, reversal learning and depression are also well known to implicate other major 
neuromodulators than dopamine, such as serotonin [52]. Unfortunately, we cannot rule 
out completely the possibility that the effects of interest of dopaminergic medication on 
reversal learning reflect use of serotonergic antidepressants in the patients with the higher 
depression ratings, because data regarding the use of antidepressant medication were not 
available. However, we do think it is unlikely that the effect of interest (the mediating effect of 
depression on the link between dopaminergic medication and reversal learning) reflects use 
of serotonergic drugs because of the following reasons. First, the non-dopaminergic drugs 
that were most likely used by the patients with high depression ratings are selective serotonin 
reuptake inhibitors. Chronic (although not necessarily acute [53]) administration of such 
SSRIs is generally thought to increase serotonin transmission, which has been associated 
with improvement rather than impairment of reversal learning [54-56] (for review see [57]). 
As such, the possibly increased chronic use of SSRIs by our patients with high depression 
ratings is unlikely to mediate a positive correlation between dopaminergic medication and 
reversal learning errors. Second, on a related note, although serotonin has been argued 
previously to mediate detrimental effects of dopaminergic medication in Parkinson’s 
disease [58], this effect would be in the opposite direction, with dopaminergic medication 
impairing cognitive function via decreasing (rather than increasing) serotonin. As such, any 
serotonin-increasing effect of any SSRIs would therefore counteract the observed negative 
link between dopaminergic medication dose and reversal learning. Indeed, the observation 
that the effects of dopaminergic medication can resemble those of serotonin depletion 
has strengthened pervasive ideas about motivational opponency between dopamine and 
serotonin. This observation renders an account of our effect of interest in terms of serotonin-
enhancing drugs unlikely. Furthermore, it might be noted that noradrenergic drugs are 
also often used to treat patients with depression. Again, we think an account in terms of 
noradrenalin is also unlikely, given previous studies showing that noradrenergic drugs, like 
atomoxetine, did not alter reversal learning [53]. And lastly, another type of medication that is 
frequently used to treat PD patients are anticholinergics which are known to impair cognitive 
function. However, it has been shown that specifically depression, but not anticholinergics, 
affect learning in PD [59]. As such, we also believe that our findings cannot be explained by 
potential use of anticholinergics by our patients. The failure to obtain data regarding non-
dopaminergic medication is a shortcoming of the study and future work should address the 
role of, for example, antidepressants in the negative association between dopaminergic 
medication and cognitive impairment. 
The present results have implications for clinical practice, warranting stricter monitoring 
of cognitive side effects during dopaminergic treatment in PD patients with concurrent 
depression. 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 104
Chapter 4
104
References
1. Khoo, T.K., et al., The spectrum of nonmotor symptoms in early Parkinson disease. Neurology, 2013. 
80(3): p. 276-281.
2. Lawson, R.A., et al., Severity of mild cognitive impairment in early Parkinson’s disease contributes 
to poorer quality of life. Parkinsonism & Related Disorders, 2014. 20(10): p. 1071-1075.
3. Schrag, A., Quality of life and depression in Parkinson’s disease. Journal of the Neurological 
Sciences, 2006. 248(1-2): p. 151-157.
4. Cools, R., et al., Enhanced or impaired cognitive function in Parkinson’s disease as a function of 
dopaminergic medication and task demands. Cerebral Cortex, 2001. 11(12): p. 1136-1143.
5. Cools, R., et al., Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain, 2001. 124: p. 
2503-2512.
6. Downes, J.J., et al., Impaired extra-dimensional shift performance in medicated and unmedicated 
Parkinson’s disease - Evidence for a specific attentional dysfunction. Neuropsychologia, 1989. 
27(11-12): p. 1329-1343.
7. Kehagia, A.A., R.A. Barker, and T.W. Robbins, Neuropsychological and clinical heterogeneity of 
cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurology, 2010. 
9(12): p. 1200-1213.
8. Kehagia, A.A., et al., Switching between abstract rules reflects disease severity but not dopaminergic 
status in Parkinson’s disease. Neuropsychologia, 2009. 47(4): p. 1117-1127.
9. Swainson, R., et al., Probabilistic learning and reversal deficits in patients with Parkinson’s 
disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. 
Neuropsychologia, 2000. 38(5): p. 596-612.
10. Cools, Altamirano, and D’Esposito, Reversal learning in Parkinson’s disease depends on medication 
status and outcome valence. Neuropsychologia, 2006. 44(10): p. 1663-1673.
11. Lewis, S.J.G., et al., Dopaminergic basis for deficits in working memory but not attentional set-
shifting in Parkinson’s disease. Neuropsychologia, 2005. 43(6): p. 823-832.
12. Gotham, A.M., R.G. Brown, and C.D. Marsden, Frontal cognitive function in patients with Parkinson’s 
disease ON and OFF levodopa. Brain, 1988. 111: p. 299-321.
13. Cools, et al., L-DOPA disrupts activity in the nucleus accumbens during reversal learning in 
Parkinson’s disease. Neuropsychopharmacology, 2007. 32(1): p. 180-189.
14. Clatworthy, P.L., et al., Dopamine Release in Dissociable Striatal Subregions Predicts the Different 
Effects of Oral Methylphenidate on Reversal Learning and Spatial Working Memory. Journal of 
Neuroscience, 2009. 29(15): p. 4690-4696.
15. Cools, Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in 
Parkinson’s disease. Neuroscience and Biobehavioral Reviews, 2006. 30(1): p. 1-23.
16. Eshel, N. and J.P. Roiser, Reward and Punishment Processing in Depression. Biological Psychiatry, 
2010. 68(2): p. 118-124.
17. Pizzagalli, D.A., Depression, Stress, and Anhedonia: Toward a Synthesis and Integrated Model, in 
Annual Review of Clinical Psychology, Vol 10, T.D. Cannon and T. Widiger, Editors. 2014. p. 393-423.
18. Barch, D.M.P., D; Luking, K Mechanisms Underlying Motivational Deficits in Psychopathology: 
Similarities and Differences in Depression and Schizophrenia. Current Topics in Behavioral 
Neuroscience, 2016. 27: p. 411-49.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 105
Dopamine dose-related reversal learning deficits
105
04
19. Admon, R., et al., Dopaminergic Enhancement of Striatal Response to Reward in Major Depression. 
American Journal of Psychiatry, 2017. 174(4): p. 378-386.
20. Weintraub, D., et al., Striatal dopamine transporter imaging correlates with anxiety and depression 
symptoms in Parkinson’s disease. Journal of Nuclear Medicine, 2005. 46(2): p. 227-232.
21. Remy, P., et al., Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation 
in the limbic system. Brain, 2005. 128: p. 1314-1322.
22. Vriend, C., et al., Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT 
binding in the caudate nucleus. J Neurol Neurosurg Psychiatry, 2013.
23. Maricle, R.A., et al., Mood response to levodopa infusion in early Parkinson’s disease. Neurology, 
1998. 50(6): p. 1890-1892.
24. Barone, P., et al., Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s 
disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, 2010. 9(6): p. 573-
580.
25. Owen, A.M., et al., Extradimensional versus intradimensional set shifting performance following 
frontal-lobe excisions, temporal-lobe excisions or amygdalo-hippocampectomy in man. 
Neuropsychologia, 1991. 29(10): p. 993-1006.
26. Potter, G.G., et al., Association of attentional shift and reversal learning to functional deficits in 
geriatric depression. International Journal of Geriatric Psychiatry, 2012. 27(11): p. 1172-1179.
27. van Nimwegen, M., et al., Design and baseline characteristics of the ParkFit study, a randomized 
controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase 
physical activity in Parkinson patients. Bmc Neurology, 2010. 10.
28. Gibb, W.R.G. and A.J. Lees, The relevance of the Lewy body to the pathologenesis of idiopathic 
Parkinons disease. Journal of Neurology Neurosurgery and Psychiatry, 1988. 51(6): p. 745-752.
29. Folstein, M.F., S.E. Folstein, and P.R. McHugh, Mini-Mental State - Practical method for grading 
cognitive state of patients for clinician. Journal of Psychiatric Research, 1975. 12(3): p. 189-198.
30. Schrag, A., et al., Depression rating scales in Parkinson’s disease: Critique and recommendations. 
Movement Disorders, 2007. 22(8): p. 1077-1092.
31. Esselink, R.A.J., et al., Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in 
PD - A randomized trial. Neurology, 2004. 62(2): p. 201-207.
32. Dolan, M., The neuropsychology of prefrontal function in antisocial personality disordered offenders 
with varying degrees of psychopathy. Psychological Medicine, 2012. 42(8): p. 1715-1725.
33. Weiland-Fiedler, P., et al., Evidence for continuing neuropsychological impairments in depression. 
Journal of Affective Disorders, 2004. 82(2): p. 253-258.
34. Steiger, J.H., Tests for comparing elements of a correlation matrix. Psychological Bulletin, 1980. 
87(2): p. 245-251.
35. Preacher and Hayes, SPSS and SAS procedures for estimating indirect effects in simple mediation 
models. Behavior Research Methods Instruments & Computers, 2004. 36(4): p. 717-731.
36. Preacher and Hayes, Asymptotic and resampling strategies for assessing and comparing indirect 
effects in multiple mediator models. Behavior Research Methods, 2008. 40(3): p. 879-891.
37. Reijnders, J., et al., A systematic review of prevalence studies of depression in Parkinson’s disease. 
Movement Disorders, 2008. 23(2): p. 183-189.
38. Peto, V., et al., The development and valdiation of a short measure of functioning and well-being 
for individuals with Parkinsons disease. Quality of Life Research, 1995. 4(3): p. 241-248.
39. Murphy, F.C., et al., Neuropsychological impairment in patients with major depressive disorder: the 
effects of feedback on task performance. Psychological Medicine, 2003. 33(3): p. 455-467.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 106
Chapter 4
106
40. Taylor Tavares, J.V., et al., Neural basis of abnormal response to negative feedback in unmedicated 
mood disorders. Neuroimage, 2008. 42(3): p. 1118-26.
41. Dissanayaka, N.N.W., et al., Factors associated with depression in Parkinson’s disease. Journal of 
Affective Disorders, 2011. 132(1-2): p. 82-88.
42. Maia, T.V. and M.J. Frank, From reinforcement learning models to psychiatric and neurological 
disorders. Nature Neuroscience, 2011. 14(2): p. 154-162.
43. Collins, A.G.E. and M.J. Frank, Opponent Actor Learning (OpAL): Modeling Interactive Effects of 
Striatal Dopamine on Reinforcement Learning and Choice Incentive. Psychological Review, 2014. 
121(3): p. 337-366.
44. Aarts, E., et al., Greater striatal responses to medication in Parkinson’s disease are associated with 
better task-switching but worse reward performance. Neuropsychologia, 2014. 62: p. 390-397.
45. Dodds, C.M., et al., Methylphenidate has differential effects on blood oxygenation level-dependent 
signal related to cognitive subprocesses of reversal learning. Journal of Neuroscience, 2008. 
28(23): p. 5976-5982.
46. den Ouden, H.E.M., et al., Dissociable Effects of Dopamine and Serotonin on Reversal Learning. 
Neuron, 2013. 80(4): p. 1090-1100.
47. Rektorova, I., et al., Striatal dopamine transporter Imaging correlates with depressive symptoms 
and Tower of London task performance in Parkinson’s disease. Movement Disorders, 2008. 23(11): 
p. 1580-1587.
48. Boileau, I., et al., Decreased binding of the D-3 dopamine receptor-preferring ligand C-11 -()-PHNO 
in drug-nave Parkinsons disease. Brain, 2009. 132: p. 1366-1375.
49. Sourani, D., et al., The habenula couples the dopaminergic and the serotonergic systems: 
application to depression in Parkinson’s disease. European Journal of Neuroscience, 2012. 36(6): 
p. 2822-2829.
50. Proulx, C.D., O. Hikosaka, and R. Malinow, Reward processing by the lateral habenula in normal 
and depressive behaviors. Nature Neuroscience, 2014. 17(9): p. 1146-1152.
51. Shabel, S.J., et al., Input to the Lateral Habenula from the Basal Ganglia Is Excitatory, Aversive, and 
Suppressed by Serotonin. Neuron, 2012. 74(3): p. 475-481.
52. Cools, R., K. Nakamura, and N.D. Daw, Serotonin and Dopamine: Unifying Affective, Activational, 
and Decision Functions. Neuropsychopharmacology, 2011. 36(1): p. 98-113.
53. Chamberlain, S.R., et al., Neurochemical modulation of response inhibition and probabilistic 
learning in humans. Science, 2006. 311(5762): p. 861-863.
54. Bari, A., et al., Serotonin Modulates Sensitivity to Reward and Negative Feedback in a Probabilistic 
Reversal Learning Task in Rats. Neuropsychopharmacology, 2010. 35(6): p. 1290-1301.
55. Furr, A., M.D. Lapiz-Bluhm, and D.A. Morilak, 5-HT2A receptors in the orbitofrontal cortex facilitate 
reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment 
in rats. International Journal of Neuropsychopharmacology, 2012. 15(9): p. 1295-1305.
56. Scholl, J., et al., Beyond negative valence: 2-week administration of a serotonergic antidepressant 
enhances both reward and effort learning signals. Plos Biology, 2017. 15(2).
57. Izquierdo, A., et al., The neural basis of reversal learning: an updated perspective. Neuroscience, 
2017. 345: p. 12-26.
58. De Deurwaerdere, P., G. Di Giovanni, and M.J. Millan, Expanding the repertoire of L-DOPA’s actions: 
A comprehensive review of its functional neurochemistry. Progress in Neurobiology, 2017. 151: p. 
57-100.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 107
Dopamine dose-related reversal learning deficits
107
04
59. Herzallah, M.M., et al., Depression Impairs Learning Whereas Anticholinergics Impair Transfer 
Generalization in Parkinson Patients Tested on Dopaminergic Medications. Cognitive and 
Behavioral Neurology, 2010. 23(2): p. 98-105.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 108
chapter
05
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 109
Mechanisms underlying
dopamine-induced risky choice
in Parkinson’s disease with
and without depression (history)
Monique H.M. Timmer, 
Guillaume Sescousse, 
Rianne A.J. Esselink,
Payam Piray, 
Roshan Cools
Computational Psychiatry (2018); 2:11-27
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 110
Abstract
Background: Patients with Parkinson’s disease (PD) are often treated with dopaminergic 
medication. Dopaminergic medication is known to improve both motor as well as certain non-
motor symptoms, such as depression. However, it can contribute to behavioural impairment, 
for example, enhancing risky choice. Here we characterize the computational mechanisms 
that contribute to dopamine-induced changes in risky choice in PD patients with and without 
a depression (history). 
Methods: We adopt a clinical-neuroeconomic approach to investigate the effects of 
dopaminergic medication on specific components of risky choice in PD. Twenty-three healthy 
controls, 21 PD patients with a depression (history) and 22 non-depressed PD patients were 
assessed using a well-established risky choice paradigm. Patients were tested twice; once 
after taking their normal dopaminergic medication (ON) and once after withdrawal of their 
medication (OFF).
Results: Dopaminergic medication increased a value-independent gambling propensity in 
non-depressed PD patients, while leaving loss aversion unaffected. By contrast, dopaminergic 
medication effects on loss aversion were associated with current depression severity and 
with drug effects on depression scores. 
Conclusions: The present findings demonstrate that dopaminergic medication increases a 
value-independent gambling bias in non-depressed PD patients. Moreover, the current study 
raises the hypothesis that dopamine-induced reductions in loss aversion might underlie 
previously observed comorbidity between depression and medication-related side effects 
in PD, such as impulse control disorder. 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by, among other 
things, degeneration of dopaminergic neurons leading to striatal dopamine depletion. PD 
patients exhibit motor and certain non-motor symptoms, which can be alleviated (to some 
extent) by dopaminergic medication. However, the effects of dopaminergic medication on 
cognitive and decision functions are more complex [1]. 
Work with experimental animals, healthy volunteers and PD patients revealed that 
dopaminergic medication enhances risky choice [2-7]. In PD, these side effects can contribute 
to severe psychiatric abnormalities, including drug- and gambling-addiction [8]. However, 
both the nature and extent of these psychiatric abnormalities vary greatly across patients. For 
example, although all patients receive dopaminergic medication, impulse control disorder 
(ICD) occurs only in a subset (~10-15%) [8]. In keeping with this clinical variability, we know that 
there is also large individual variability in the nature and extent of dopaminergic drug effects 
on cognitive and decision functions (e.g. [9]). Here we aimed to characterize the mechanisms 
that contribute to individual variability in medication-induced changes in risky choice in PD. 
To this end, we adopted a controlled medication withdrawal procedure to assess effects of 
dopaminergic medication on a well established risky choice paradigm in PD. 
We asked two specific questions, which were inspired by a number of apparently discrepant 
observations. First, we asked whether the extent to which dopaminergic medication 
increases risky choice in PD depends on the presence of depression (history), a frequent 
non-motor symptom of PD. This question was raised by clinical observations that ICDs are 
often comorbid with depression [10, 11]. Based on this literature, dopamine-induced increases 
in risky choice might be expected to be greater in PD patients with than without a depression 
(history). 
This prediction, however, contrasts with an alternative hypothesis, derived from the 
dopamine overdose account, which states that dopamine-induced deficits reflect 
detrimental overdosing of dopamine levels in relatively unaffected brain regions, such as 
the ventral striatum [12-14]. Based on evidence that depression in PD is accompanied by 
disproportionately reduced ventral striatal dopamine [15-17], we might predict dopamine-
induced increases in risky choice to be greater in non-depressed than depressed PD. Our 
design allowed us to disentangle these two contrasting hypotheses. 
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Our second question was which computational mechanisms contribute to drug-induced 
increases in risky choice. To decompose drug effects on risky choice, we employed a 
computational modelling approach based on prospect theory, one of the more successful 
accounts of decision making under risk [18, 19]. Unlike model-free analyses of choice patterns, 
this model-based approach enabled us to disentangle two different mechanistic hypotheses 
regarding the nature of drug effects. 
The first mechanistic hypothesis was inspired by recent theorizing and empirical evidence 
indicating a key role for striatal dopamine in the relative weighting of reward versus punishment 
on learning and choice [20]. Thus one mechanism by which dopaminergic medication 
may increase risky choice is by attenuating loss aversion, which reflects our tendency to 
weigh losses more than equally sized gains. Loss aversion is one of the core concepts of 
prospect theory [18, 19]. In the domain of learning, studies with healthy volunteers and PD 
patients have demonstrated repeatedly that the balance between learning from reward and 
punishment depends critically on striatal dopamine [21-23]. Increases in dopamine enhance 
reward-based relative to punishment-based learning while decreases in dopamine enhance 
punishment-based relative to reward-based learning. Recent theoretical work extends these 
value-dependent effects from learning to choice [20] and empirical evidence has indeed 
demonstrated that dopaminergic medication in PD alters reward- versus punishment-based 
choice in ways very similar to its effects on learning [24, 25]. Here we aimed to investigate 
whether dopaminergic medication alters risky choice in PD in an analogous manner, by 
increasing the relative weighting of rewards (gains) versus punishments (losses), thereby 
attenuating loss aversion. 
A second mechanism by which dopaminergic medication might affect risky choice is by 
altering the tendency to gamble in a value-independent manner. This is based on recent 
studies with healthy volunteers revealing that levodopa increases risky choice by increasing 
the propensity to gamble regardless of the gamble values at stake [2, 26]. 
To address our two specific questions, we adopted a two-step approach. First, we assessed 
whether dopamine-induced increases in risky choice, as observed previously in non-
depressed PD [6, 7, 21], can best be accounted for by decreases in loss aversion and/or 
increases in a value-independent gambling bias. To this end, we assessed medication effects 
on prospect theory-derived parameters, representing loss aversion and gambling bias, from 
choice patterns on the risky choice task obtained from a psychiatrically clean group of 
PD patients without depression. Second, we assessed whether effects of dopaminergic 
medication on risky choice computations vary as a function of (individual differences in the 
current severity of) depression. 
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Methods
Participants and experimental design
We recruited 23 non-depressed PD patients, 24 PD patients with a depression (history) and 
25 healthy controls. Data from 1 non-depressed PD patient, 3 PD patients with a depression 
(history) and 2 healthy controls were discarded from the analyses (see exclusion). The final 
analysis included 22 non-depressed PD patients, 21 PD patients with a depression (history) 
and 23 healthy controls. 
Patients were recruited from the Parkinson Centre at the Radboud university medical centre, 
the Netherlands. Healthy controls were recruited via advertisement, or were partners or 
acquaintances of patients. Healthy controls and patients were matched for gender, age and 
IQ measured with the NART (Dutch version of the National Adult Reading Test [27]). Patient 
groups were matched in terms of disease severity (measured with the Unified Parkinson’s 
Disease Rating Scale (UPDRS part III) [28]) and used similar amounts of dopaminergic 
medication (LED (Levodopa Equivalent Dose [29]) (Table 1). Written informed consent 
according to the Declaration of Helsinki was obtained from all participants. The study was 
part of a larger project investigating the neurobiological mechanisms of depression in PD 
and was approved by the local ethics committee (CMO region Arnhem - Nijmegen, the 
Netherlands, nr. 2012/43). 
All patients were diagnosed with idiopathic PD according to the UK Brain Bank criteria [30] 
by a neurologist specialized in movement disorders (Prof. B.R. Bloem, Dr. R.A. Esselink, Dr. 
B. Post) and were treated with dopaminergic medication. In the non-depressed group 11 
patients were treated with levodopa, 2 with dopamine receptor agonists and 9 with both. In 
the group of PD patients with a depression (history) 14 patients were treated with levodopa, 
2 with dopamine receptor agonists and 5 with both. Patients were on stable medication 
regimes during the course of the study, except for one patient who used duloxetine – a 
serotonin/noradrenalin reuptake inhibitor prescribed to treat pain - for 4 weeks between 
the two testing days (in this case testing days were separated by 17 weeks). The drug was 
discontinued 4 weeks before the second testing day. Seven patients in the patient group 
with a depression (history) received antidepressants (paroxetine n=3, escitalopram n=1, 
venlafaxine n=1 and nortriptyline n=2). 
Patients were included in the depression (history) group if they met the DSM-IV criteria for any 
of the various depression-related diagnoses in the DSM-IV within a timeframe of five years 
before PD diagnosis up until now. This five-year cut-off was chosen because the incidence 
of depression is significantly higher within the five years before PD diagnosis [31]. These 
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depressive episodes are therefore more likely related to PD pathology. Seven patients were 
diagnosed with a major depressive episode (3 past, 4 current), 12 with a minor depressive 
episode (9 past, 3 current), 1 with a past dysthymic disorder and 1 with a past adjustment 
disorder with depressed mood. Thus note that the patient group with a depression (history) 
consisted of patients with both past (n=14) and current (n=7) depression. This heterogeneity 
allowed us to specifically assess dopaminergic medication effects on risky-choice parameters 
as a function of current depression severity. Indeed, only seven patients were identified as 
being depressed at the time of testing. As such, any conclusions regarding the effects of 
depression across the group of patients with depression (history) should be interpreted 
as reflecting effects of either current or past depression. Psychiatric diagnosis was based 
on structured psychiatric interviews administered during an intake session (MINI-plus [32]). 
General exclusion criteria were clinical dementia (Mini Mental State Examination<24, [33]), 
psychiatric disorders other than depression (bipolar disorder, schizophrenia, ADHD and drug 
or alcohol abuse), neurological comorbidity and hallucinations. Healthy controls were also 
excluded if they had a history of mood or anxiety disorder, obsessive-compulsive disorder 
or used any psychotropic medication. 
Patients were assessed on two occasions, once after taking their normal dopaminergic 
medication (ON) and once after abstaining from their dopaminergic medication for at least 
18 hours (24 hours for slow release dopamine receptor agonists) (OFF). Antidepressants 
were taken on both testing days enabling us to assess specifically dopaminergic medication 
effects on gambling behaviour. The order of ON and OFF sessions was counterbalanced in 
each patient group (Table 1). Healthy controls were only tested once. During testing sessions 
we administered the gambling task described below. Furthermore, on each testing day, 
participants completed the Beck Depression Inventory (BDI [34]) to assess current depressive 
symptoms. Participants were instructed to answer BDI questions according to how they felt 
over the past 24 hours (rather than the past week), enabling us to assess dopaminergic drug 
(withdrawal) effects on depression scores. Patients also completed the QUIP rating scale 
[35] developed to assess ICD symptoms in PD and the UPDRS part III was administered to 
assess clinical motor symptom severity [28]. 
Participants were paid a fixed amount per testing day for participation (healthy controls 
30 Euros; patients 40 Euros) and received an additional amount of money based on task 
performance (between 2-11 Euros per session, see below). 
Task 
Participants played a well-validated gambling task designed to measure loss aversion [36] 
(Figure 1). During this task, participants were presented with 169 mixed gambles (split into 3 
runs) on a computer screen. Each gamble offered a 50/50 percent chance of either gaining 
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or losing varying amounts of money. Potential gains ranged from +€6 to +€30 (increments 
of €2), while potential losses ranged from -€3 to -€15 (increments of €1). This asymmetric 
gain-loss range was chosen in order to maximize statistical power, based on the assumption 
that on average people are twice as sensitive to losses as they are to gains [36]. Each of the 
possible gain-loss pairs (13x13=169) was presented once in randomized order. Participants 
were asked to either accept (play) or reject the gamble by pressing one of two buttons. In 
order to make participants feel that they were gambling with their own money, and thus 
avoid “house money effects” [37], endowments at the beginning of this gambling task were 
earnings from a behavioural experiment immediately preceding the present experiment on 
the same day. Gambles were not resolved during the experiment to exclude trial-by-trial 
behavioural adjustments based on previous earnings. However, to ensure that participants 
would take each gamble seriously, at the end of the experiment, 3 gambles were randomly 
selected and played for real money. 
+24
-10
Accept     Reject
+24
-10
Accept     Reject
Response deadline 4 sec.
Gain/Loss Matrix
+6   Potential Gain   +30
-1
5 
   
Po
te
nt
ia
l L
os
s  
  -
3
Figure 1. Task overview. Participants played a gambling task designed to measure loss aversion. 
During this task participants were presented with 169 mixed gambles, each offering 50/50 percent 
change of either gaining or losing varying amounts of money. Gains ranged from +€6 to +€30 
(increments of €2), losses ranged from -€3 to -€15 (increments of €1) (see gain/loss matrix). Each 
possible gain/loss pair was presented once in randomized order. Participants were asked to either 
accept (play) or reject the gamble within  a maximum time of 4 sec.  
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Analysis
Model
We used a model-based approach to analyze participant’s choice behaviour. This procedure 
involved fitting a theoretical model of decision making to behavioural data in order to quantify 
specific aspects of choice behaviour. One of the most popular accounts of decision making 
under risk is prospect theory [18]. We sought to understand the effects of dopaminergic 
medication and depression in PD by assessing how these factors modulate the parameters 
obtained from a model based on prospect theory. Within that framework, the subjective utility 
of each gamble (SUG) can be approximated by the following equation: 	
	
SUG	=	pGain	*	Gain	-	pLoss	*Loss	*	λ	
 
 
Where pGain is the gain probability, pLoss the loss probability, Gain the gain value of the gamble 
and Loss the (absolute) loss value of the gamble. The relative weighting of gains and losses 
is reflected in the loss aversion parameter λ. If λ>1, then losses are overvalued relative to 
gains: a person is loss averse. If λ<1, then gains are overvalued relative to losses: a person 
is loss seeking. If λ=1, gains and losses are valued equally: a person is gain-loss-neutral.
A softmax function was used to estimate the probability of gamble acceptance based on 
the subjective value of the gamble:
 
𝑝𝑝(𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔	𝑔𝑔𝑎𝑎𝑎𝑎𝑔𝑔𝑝𝑝𝑎𝑎𝑔𝑔𝑎𝑎𝑎𝑎𝑔𝑔) = 	
/
/0123(45678)
  
 
 
This function includes two other parameters; an inverse temperature parameter (μ) and a 
constant parameter (c). The constant parameter (c) reflects a value-independent gambling 
bias toward or away from gambling. If c>0, there is a tendency to accept gambles regardless 
of their subjective utility. If c<0, there is a tendency to reject gambles regardless of their 
subjective utility. The inverse temperature parameter reflects consistency of choice behaviour. 
If μ=0, choices are random, whereas if μ is highly positive or negative, there is consistency 
in choice behaviour, with a positive μ representing higher gamble acceptance with higher 
gain and lower loss value (and vice versa for negative μ). Model parameter were constrained 
as follows: from 0 to 10 for the loss aversion parameter (λ) and the inverse temperature 
parameter (μ) and from -10 to 10 for the value-independent gambling bias parameter (c). We 
anticipated μ to be positive, consistent with a utility maximization strategy, where participants 
accept more gambles when gain values increase and loss values decrease. None of the 
parameters obtained in our participants reached these boundaries (except for the two 
patients who were excluded from the analysis, see exclusion).
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The model that we fitted to the data assumes a linear valuation of gains and losses, 
in contrast to the curvilinear value function of prospect theory. This is a common and 
reasonable simplifying assumption given the relatively narrow range of gains and losses 
used in this protocol. We also assumed no subjective transformation of probabilities as 
described in prospect theory and thus assumed equal weights for the 0.5 probability of 
gains and losses [36, 38]. 
Exclusion
We assessed whether participants’ choices were influenced by gain and loss values in an 
expected manner, i.e. whether participants were utility maximizers (accepting more gambles 
with increasing gain values and accepting fewer gambles with increasing loss values). 
Inspection of the individual response patterns revealed that two participants (1 patient with 
a depression (history) and 1 non-depressed patient) did not meet this a priori assumption, 
suggesting a lack of understanding of task instructions. In both cases this was during the first 
testing day. In one case the response pattern revealed that the participant accepted more 
gambles when gain values decreased and loss values increased, thereby unintentionally 
trying to minimize earnings. During debriefing this participant realized that he had made a 
mistake. The responses of the other participant were suggestive of random choice behaviour. 
In both cases, these observations were confirmed by negative temperature parameters (μ) 
obtained from the model. These two patients were excluded from further analyses. Moreover, 
two healthy controls were excluded from further analyses because of a lifetime history of 
depression, while two PD patients with a depression (history) were excluded because they 
failed to finish the study leading to incomplete datasets.
Model fitting and comparison
We used a hierarchical Bayesian fitting procedure to fit the model to participants’ choices 
as described by Huys and colleagues [39, 40]. This method estimates the mean and 
variance of model parameters across all subjects and sessions. These parameters then 
serve to define a normal a priori distribution for finding individual values of parameters 
for each subject and session (i.e. posterior parameters). We hypothesized the a priori 
distributions of the relevant parameters (the loss aversion parameter (λ) and the gambling 
bias parameter (c)) to be different for patients and healthy controls. Therefore, we first fitted 
the model to patient data only. Note that any differences in posterior parameters between 
patient groups and medication sessions cannot be attributed to parameter regularization 
employed during fitting, because individual parameters from both patient groups and 
both drug sessions were obtained using the same a priori distribution [40]. To compare 
PD patients with healthy controls, we fitted the model to healthy control and patient data 
together (separately for each drug session).
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The hierarchical Bayesian fitting procedure is an iterative algorithm. In every iteration, 
individual parameters are optimized based on the data and current estimation of the group 
mean and variance. We used a Laplace approximation for defining a normal approximation 
of individual posteriors, in which the maximum a posteriori values were found using 
nonlinear optimization methods (MATLAB optimization toolbox, fmincon routine, interior-
point algorithm). The group mean and variance are then updated according to obtained 
individual posteriors (see [40] for equations), which serve as group mean and variance in 
the next iteration. The iterative updating of group- and individual- parameters continues 
until changes in parameters are very small (i.e. a convergence criteria satisfied). Importantly, 
convergence is guaranteed in this algorithm [41]. 
A Bayesian model comparison was conducted to compare the model with 3 parameters 
(λ, μ and c) with a slightly simpler model, where we forced c to be zero, thereby reducing 
the number of free parameters. This model assumed that subjects do not exhibit a value-
independent bias toward or away from gambling. A Bayesian model comparison assessed 
which model best captured participants’ choices by computing model evidence by balancing 
model fits and model complexity [42, 43]. A procedure was employed that penalizes 
complexity by marginalizing over both group and individual parameters using Laplace 
approximation and Bayesian information criterion, respectively. The negative log-mode 
evidence (NLME) was computed as:
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where                                               nD nq Q S m N || nH m2 is the set of choice data for the nth participant,                                           nD nq Q S m N || nH m2is the fitted individual parameter 
for nth participant,                                               nD nq Q S m N || nH m2and         n n || n 2 are the mean and variance for the group distribution, respectively, 
                                              
nD nq Q S m N || nH m2 is the number of free parameters of the model,                                               nD nq Q S m N || nH m2is the number of participants and                                               nD nq Q S m N || nH m2 
is the determinant of the Hessian matrix of the log-posterior function at                                               nD nq Q S m N || nH m2. The first term 
on the right hand-side of the equation refers to how well the model predicts data. The sum 
of the next three terms together is the penalty due to individual parameters. The last term 
represents the penalty approximated for                                               nD nq Q S m N || nH m2  (mean and variance together) group parameters 
using Bayesian information criterion [42]. The model with the lowest NLME is the best model. 
Statistical analysis
First, we examined whether dopaminergic medication modulated loss aversion and/or 
gambling bias parameters in non-depressed PD patients. Subsequently, we compared 
medication effects on these parameters between non-depressed PD patients and PD 
patients with a depression (history). Finally, we compared patients’ data with those of 
age-matched controls, each group and drug session separately. Since loss aversion and 
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gambling bias parameters were non-normally distributed (Shapiro-Wilk, p<0.05) we used 
two-tailed Wilcoxon signed-rank tests to assess within-subject differences and Mann 
Whitney tests to assess between-group differences. Depression scores and proportion 
of accepted gambles, which were normally distributed, were analyzed with a mixed 
ANOVA with drug as within-subject and group as between-subject factor. Two-tailed 
Pearson correlations were used for normally distributed data and two-tailed Spearman 
correlations for non-normally distributed data. Furthermore, for non-normally distributed 
data we reported medians and their standard error. Standard errors of the median were 
computed using bootstrapping [44]. By resampling with replacement of the original group 
sample, we created 105 new group samples. The standard error of the median was then 
defined as the standard deviation of all bootstrapped samples. 
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Results
Risky choice and drug effects in non-depressed PD patients
Patient and disease characteristics are presented in Table 1. Median parameters obtained 
from the model (per group and medication session) are presented in Table 2. Individual 
endowments at the beginning of the experiment varied between participants (Table 1), as 
these were earnings from a previous experiment performed the same day. However, there 
was no significant main effect of drug on earnings. 
Using prospect theory-based analysis, we assessed the computational mechanisms 
contributing to risky choice. The full model including a constant parameter (c) (reflecting 
a gambling response bias irrespective of the value of gambles) provided a better account 
of participants’ choices than did a model without this parameter, indicated by a lower log-
model evidence (in patients: 4102 compared with 4374 for the model where (c) was forced 
to be zero, in healthy controls: 1099 compared with 1131 for the model where (c) was forced 
to be zero). Therefore, reported results are based on parameters obtained from the full 
model. First, we assessed medication effects on model parameters derived from risky choice 
patterns in non-depressed PD patients.
Analysis of the value-independent gambling bias parameter (c) revealed negative parameters 
during both drug sessions (Table 2), indicating a tendency to avoid gambling irrespective 
of the value of the gambles. Dopaminergic medication significantly increased the value-
independent gambling propensity in non-depressed PD patients (Z=-2.65, p=0.008) (Figure 
2). There was no effect of dopaminergic medication on loss aversion (λ) (Z=-1.54, p=0.12) and 
no effect on the inverse temperature parameter (µ) (Z=-0.18, p=0.86). Moreover, there were 
no effects of medication dose (LED) and no session order effects. 
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Table 1. Group characteristics
  PD with a depression 
(history)
Non-depressed PD Healthy controls
  n = 21 n = 22 n = 23
Gender, men 13 13 14
Age, years 58.5 (5.8) 61.0 (7.6) 60.9 (5.9)
NART-IQ 96.2 (11.6) 97.0 (15.5) 100.7 (13.7)
MMSE 28.5 (1.4) 28.6 (1.3) 28.8 (1.2)
Hoehn & Yahr 1.6 (0.4) 1.8 (0.5) -
UPDRS - III (OFF)
Disease duration, years
22.7 (9.6)
5.1 (3.5)
22.2 (6.5)
4.5 (2.2)
-
-
LED mg/day 551 (248) 627 (275) -
LED agonists mg/day 71 (122) 103 (129) -
BDI (OFF) 9.9 (6.1) 4.0 (2.3) 3.1 (2.1)
Current ICD 4 1 -
First session ON 11 9 -
Days between sessions 23 (27) 21 (20) -
Endowment OFF session 11.20 (1.08) 10.52 (1.69) 11.36 (1.76)
Eondowment ON session 11.28 (1.25) 11.26 (1.42) -
PD = Parkinson’s disease, NART-IQ = Dutch version of the National Adult Reading Test, MMSE = 
Mini Mental State Examination, UPDRS = Unified Parkinson’s Disease Rating Scale, LED = Levodopa 
Equivalent Dose, BDI = Beck Depression Inventory, ICD = impulse control disorder.
Values represent numbers or mean (standard deviation)
Table 2. Model parameters per group and drug session
  OFF session ON session
Gambling response bias (c)
PD with a depression (history)
Non-depressed PD
Healthy controls
Loss aversion (λ)
PD with a depression (history)
Non-depressed PD 
Healthy controls
Inverse temperature (µ)
PD with a depression (history)
Non-depressed PD
Healthy controls
-1.73 (14.9)
-2.71 (9.4)
-0.65 (11.1)
1.51 (3.0)
1.01 (3.2)
1.37 (2.8)
0.93 (2.1)
0.89 (1.5)
1.06 (2.1)
-1.30 (13.8)
-1.05 (8.9)
-
1.19 (2.7)
1.16 (2.6)
-
0.94 (1.9)
1.09 (2.2)
-
PD = Parkinson’s disease. Values represent median (range) 
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Figure 2. Drug effects on value-independent gambling bias. Median value-independent gambling bias 
parameter (c) per session (OFF session in dark grey, ON session in light grey) in non-depressed PD 
patients. For illustration purposes, we also added the bars for PD patients with a depression (history) 
(OFF and ON sessions) and healthy controls (OFF session). Error bars represent standard errors of 
the median. **p<0.01
Effect of depression (history) in PD
Subsequently, we compared non-depressed PD patients and PD patients with a 
depression (history). Again, individual endowments at the beginning of the task varied 
between participants (Table 1). There was no significant main effect of group or drug and 
no group*drug interaction on these earnings. 
Analyses of the value-independent gambling bias parameter (c) revealed a near significant 
group*drug interaction (U=156, p=0.07), indicating that dopaminergic medication tended 
to increase a value-independent gambling propensity to a greater extent in non-
depressed compared with PD patients with a depression (history). While the medication 
had a clear effect on value-independent gambling propensity in non-depressed PD 
patients as reported above, it had no effect in PD patients with a depression (history) 
(Z=-.087, p=0.9). The main effect of drug failed to reach significance (Z=-1.78, p=0.08). 
There was no main effect of group (U=199, p=0.44). There was no significant correlation 
between drug effects on value-independent gambling bias and current depression 
severity (BDI score).
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 123
Mechanisms underlying dopamine-induced risky choice
123
05
Analyses of the loss aversion parameter (λ) revealed a significant group*drug interaction 
(U=149, p=0.046). PD patients with a depression (history) exhibited greater drug-induced 
decreases in loss aversion than non-depressed PD patients. However, the simple main 
effects of drug were not significant. There was a near-significant simple main effect of group 
in the OFF state; patients with a depression (history) tended to be more loss-averse than 
non-depressed patients (U=151, p=0.052). During the ON state there was no simple main 
group effect (U=215, p=0.70). There was no overall main effect of group (U=191, p=0.33) and 
no overall main effect of drug (Z=-0.21, p=0.84) (Figure 3) 
To visualize drug and group effects on loss aversion, we plotted, for each group and 
drug session separately, the degree to which the ratio of rejecting to accepting gambles 
increased as a function of increases in potential losses (raw data) (Figure 4). To control 
for effects of other factors, such as general drug effects on gambling rate, we plotted the 
ratio of rejecting to accepting gambles as a function of relative loss differences between 
pairs of trials, while effects of different gains were averaged out. A steeper slope indicates 
greater loss sensitivity. From this Figure 4 it is clear that dopaminergic medication had 
contrasting effects on loss aversion in non-depressed PD patients and PD patients with 
a depression (history).
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Figure 3. Drug effects on loss aversion. Median loss aversion parameter (λ) per group (non-depressed 
PD patients and PD patients with a depression (history)) and drug session (OFF session in dark grey, 
ON session in light grey). For illustration purposes, we also added the bar for healthy controls (OFF 
session). Error bars represent standard errors of the median. *p<0.05
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Figure 4. Loss sensitivity. The ratio of the number of rejected gambles divided by the number of 
accepted gambles in log-space (y-axis) as a function of the relative loss averaged across different 
gain values (x-axis) per group and per drug session. A steeper slope indicates greater loss sensitivity. 
Medication effects on loss aversion were predicted by current OFF state depression severity 
(rho(41)=-.348, p=0.022). This correlation was due to greater drug-induced decreases in loss 
aversion in patients with higher current OFF-state depression scores (Figure 5A). Moreover, 
drug effects on current depression scores correlated significantly with drug effects on loss 
aversion (rho(41)=-.384, p=0.011), indicating greater drug-induced decreases in loss aversion 
in patients with greater drug-induced decreases in depression scores. This correlation was 
strong in patients with a depression (history) (rho(19)=-.592, p=0.005), but not significant in 
the non-depressed patients (rho(20)=-.021, p=0.93) and significantly different between groups 
(Fisher r-z transformation, z=-2.01, p=0.044) (Figure 5B).
There were no main effects of drug (Z=-.31, p=0.75) or group (U=225, p=0.88) and there was 
no significant group*drug interaction (U=226, p=0.90) on the inverse temperature parameter 
(µ). There were no effects of LED, no session order effects and no effects of current ICD 
status on model-parameters (value-independent gambling bias, loss aversion and inverse 
temperature parameter). 
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Mixed ANOVA of depression scores (BDI) demonstrated a significant group*drug interaction 
(F(1,41)=4.19, p=0.047). Post-hoc paired sample t-test revealed that this interaction was due 
to a significant drug-induced decrease in depression scores in patients with a depression 
(history) (t20)=2.19, p=0.041) but not in non-depressed patients (t(21)=-.60, p=0.56). There was 
also a main effect of group (F(1,41)=17.26, p<0.001), indicating significantly higher depression 
scores in patients with a depression (history). There was no main effect of drug. 
Five patients exhibited at least one ICD as assessed with the QUIP rating scale (1 non-depressed 
patient and 4 patients with a depression (history)). None of them exhibited gambling addiction. 
Comparison with healthy controls
Relative to controls, non-depressed PD patients showed a significantly lower value-
independent gambling bias during the OFF session (U=111, p=0.001), but not during the 
ON session (U=177, p=0.08). This is consistent with the significant effect of medication in 
the non-depressed PD group, mentioned above. Relative to controls, PD patients with a 
depression (history) showed a significantly lower value-independent gambling bias during 
the ON session (U=151, p=0.033), but not during the OFF session (U=160, p=0.06). Note 
however that, within this patient group, there was no significant medication effect on the 
value-independent gambling bias parameter. 
Relative to controls, median loss aversion parameter estimates were quite low in patients. 
However, direct comparisons with controls revealed that this reduction was significant only 
in non-depressed PD patients OFF medication (U=150, p=0.019). The median loss aversion 
parameter from non-depressed patients ON medication (U=169, p=0.056) and from PD 
patients with a depression (history) OFF (U=228 p=0.75) or ON medication (U=176, p=0.12) did 
not differ from that of controls. There were no differences in terms of the inverse temperature 
parameter (μ) between controls and either group of PD patients (ON and OFF medication).
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Figure 5. Correlations between (drug effects on) loss aversion and depression. A Correlation between 
scores on the Beck Depression Inventory during the OFF session (x-axis) and drug effects on loss 
aversion (λ) on the y-axis (ON session score minus OFF session score) across PD patients with and without 
a depression (history) (rho(41)=-.348, p=0.022). B Correlation between drug effects on depression scores 
on the x-axis (BDI OFF session score minus ON session score) and drug effects on loss aversion (λ) on 
the y-axis (ON session score minus OFF session score) (rho (41)=-.384, p=0.011). Patients with a depression 
(history) are marked in red (rho(19)=-.592, p=0.005) and non-depressed patients in blue (rho(20)=-.021, 
p=0.93). This correlation was significantly different between groups (Fisher r-z transformation, z=-2.01, 
p=0.044). Patients who screened positive for having an ICD are marked with a yellow border.   
Proportion of accepted gambles
In addition to the computational parameters underlying risky choice, we analyzed the 
proportion of accepted gambles, which is a compound measure of risky choice. The proportion 
of accepted gambles in PD patients with a depression (history) was 53.6% OFF medication 
and 57.9% ON medication. In non-depressed PD patients this was 56.3% OFF medication and 
60.2% ON medication. The proportion of accepted gambles in healthy controls was 62.2%. 
Mixed ANOVA in PD patients revealed no significant group*drug interaction (F(1,41)=0.01, 
p=0.94) and no main effect of group (F(1,41)=0.31, p=0.58) or drug (F(1,41)=2.32, p=0.136). The 
correlation between drug-induced increases in gamble acceptance and depression scores 
OFF medication failed to reach significance (r(41)=0.273, p=0.077). There was no significant 
correlation between LED and drug-induced increases in gamble acceptance (r(41)=0.171, 
p=0.27). Comparison of patients with healthy controls (each patient group and drug session 
separately) revealed no significant differences in gamble acceptance. 
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Discussion
The present study revealed two key findings. First, the data demonstrate that dopaminergic 
medication increases a value-independent gambling bias in non-depressed PD patients, as 
it does in healthy controls [2, 26]. This provides the third piece of converging evidence for 
dopamine-induced increases in gambling bias and reinforces the construct validity of this 
finding, also generalizing it across experimental paradigm and across underlying theoretical 
framework. Indeed, dopamine-induced increases in a value-independent gambling bias has 
now been shown using computational model-based analyses grounded in reinforcement 
learning theory [2], mean-variance theory [26] and prospect theory [18]. Second, the present 
data indicate that dopaminergic medication reduces loss aversion to a greater degree in PD 
patients with higher current depression ratings. The finding that dopamine modulates the 
relative weighting of gains versus losses during risky choice concurs generally with current 
theories about striatal dopamine’s role in valuation and choice [20] and raises the hypothesis, 
to be addressed in future studies, that dopamine-related reductions in loss aversion might 
underlie previously observed comorbidity between depression and medication-related side 
effects in PD, such as ICDs. 
The present study illustrates the power of a computational model-based approach to analyze 
choice data. Indeed, the present study would have failed to reveal any of the effects on risky 
choice, if we had not taken into account the prior theoretical insight that the proportion of 
accepted gambles on tasks such as the one used here is a function of multiple parameters, 
including a value-independent gambling bias and loss aversion. Our observation raises the 
possibility that dopamine-induced increases in risky choice as measured previously using 
other tasks in non-depressed PD (i.e. the Cambridge gamble task and the Game of Dice task) 
[3, 6, 7], also reflect increases in a value-independent gambling bias. 
Two previous studies have reported dopamine-induced changes in a value-independent 
gambling bias [2, 26]. Both studies involved administration of an acute dose of levodopa 
to healthy volunteers and both reported enhanced attraction to gambling for gains. Unlike 
[2], we show that the gambling bias extends to gambles that mixed gains and losses, 
suggesting that the effect is not only value-, but also valence-independent. As has been 
suggested previously [2, 26, 45, 46], the nonspecific attraction to gambling might arise 
from an exploration bonus associated with surprising outcomes that potentiates information, 
sensation- and novelty seeking [47, 48]. 
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Based on the dopamine overdose hypothesis [13], we considered the hypothesis that 
dopamine’s effects on gambling (biases) might be greater in non-depressed PD patients, with 
putatively intact ventral striatal dopamine levels, than in patients with a depression (history), 
with putatively greater striatal dopamine deficiency. In fact the comparison with controls 
suggested that non-depressed PD patients exhibited an abnormally reduced gambling bias 
when OFF medication, rather than abnormally enhanced gambling bias when ON medication. 
This clearly is not consistent with the overdose hypothesis, although it should be noted that 
our design was not optimized for comparing patients with controls, who were tested only 
once in the absence of medication. Perhaps more importantly, although there was a statistical 
trend for a group*drug interaction, with marginally greater drug effects on value-independent 
gambling bias for non-depressed than (previously) depressed patients, this effect did not 
actually reach significance. Thus we provide no support for the hypothesis that medication 
effects on gambling (bias) are greatest in patients with less affected dopamine levels. Of 
course, the current study does not exclude the possibility that dopamine-induced increases 
in gambling bias are absent in PD patients with more severe current depression. 
Dopaminergic medication decreased loss aversion to a greater extent in PD patients with a 
depression (history) than in non-depressed PD patients. However, the simple main effects of 
drug were non-significant. This could reflect the heterogeneity of our sample of depressed 
patients. Indeed, a weakness of the current study is, that we included PD patients with present 
as well as past depression. However, it did allow us to investigate effects of current depression 
severity on mechanisms of risky choice. Correlation analyses revealed that dopamine-induced 
decreases in loss aversion were related to current depression severity and to effects of 
dopamine on depressive symptoms. Patients with the highest current depression scores and 
the greatest beneficial effect of dopaminergic medication on depression scores also exhibited 
the greatest dopamine-induced decrease in loss aversion. This finding concurs with clinical 
evidence indicating that PD patients who exhibit more severe depressive symptoms are at 
increased risk for having ICD [11], although a strong link between (dopamine-induced decreases 
in) loss aversion and ICD has yet to be established [49, 50]. 
The effect of medication on the gambling bias in the non-depressed PD patients represents 
a conceptual replication, and accordingly we have considerable confidence in the 
reproducibility of the effect, also given that it remained significant after correcting for the 
multiple contrasts [(i) ON versus OFF in the non-depressed group and (ii) non-depressed 
patients versus patients with a depression (history)]. Conversely, the effect of depression on 
loss aversion was marginally significant, particularly when taking into account the fact that 
multiple comparisons were conducted. Accordingly, we recommend that future studies aim 
to replicate this effect of depression on loss aversion. 
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To conclude, the present findings suggest that previously observed increases in risky 
choice in (non-depressed) PD patients on dopaminergic medication might reflect a value-
independent change in a gambling bias. Moreover, the present study raises the hypothesis, 
to be addressed in future studies, that dopamine-induced reductions in loss aversion might 
underlie previously observed comorbidity between depression and medication-related side 
effects in PD, such as ICD. 
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Abstract 
Motor and cognitive deficits in Parkinson’s disease (PD) have been argued to reflect 
motivational deficits. In prior work, however, we have shown that motivation for cognitive 
control is paradoxically potentiated rather than impaired in Parkinson’s disease. This is 
particularly surprising given the fact that Parkinson’s disease is often accompanied by 
depression, a prototypical disorder of motivation. To replicate our previous finding and 
assess the effects of depression, we investigated performance of PD patients with (n=22) 
and without depression (history) (n=23) and age-matched healthy controls (n=23) on a task 
specifically designed to measure the effect of reward motivation on task-switching. We 
replicated previous findings by showing contrasting effects of reward motivation on task-
switching in PD patients and age-matched healthy controls. While the promise of high versus 
low reward improved task-switching in PD, it tended to impair task-switching in age-matched 
healthy controls. There were no effects of a depression (history) diagnosis in PD patients. 
These findings reinforce prior observations that Parkinson’s disease is accompanied by 
enhanced incentive motivation of cognitive control and highlight the potential of incentive 
motivational strategies for overcoming cognitive deficits in Parkinson’s disease. 
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterized 
by severe dopamine depletion in the striatum, as well as abnormalities in other 
neuromodulatory systems. It is accompanied primarily by motor symptoms, such as 
bradykinesia and motor rigidity, but many patients also exhibit significant dopamine-
dependent cognitive deficits. Dopamine-dependent cognitive deficits, for example in 
task-switching and working memory, are seen even in the early stages of the disease, 
and in a manner that is independent from dementia [1-3].
Consistent with an original characterization of PD as a paralysis of the will, the motor 
deficits, in particular bradykinesia, have been argued to reflect a motivational deficit 
[4]. For example, Mazzoni and colleagues demonstrated that, although PD patients can 
display motor behaviour that matches that of healthy controls in both speed and accuracy, 
they performed motor actions with lower probability [5]. This finding indicated that the 
movement slowing characteristic of PD reflects a motivational or cost-benefit decision 
deficit rather than a pure motor deficit [6]. This concurred with subsequent optimal 
control theory-based work, suggesting that the main determinant of the movement deficit 
in PD is reduced optimization of motor effort [7]. This motor motivation hypothesis, 
which implies that PD patients do not “want” to move, rather than not being able to 
move was further strengthened by a series of recent studies with PD patients, showing 
reduced reward sensitivity of both speed and accuracy of motor decisions [8], but see 
[9], as well as decreased willingness to exert motor effort [10-12]. In keeping with the 
well-known implication of dopamine in motivation and cost/benefit decision making [13-
16], the latter studies confirmed that the willingness to exert motor effort depends on 
dopaminergic medication status, with patients exhibiting reduced motor motivation in 
the OFF medication state compared with the ON medication state [10-12]. 
An open question is whether PD is also accompanied by reduced motivation for cognitive 
control. Based on the above-reviewed literature on motor motivation in PD, one might 
expect that PD patients also exhibit reduced reward sensitivity of performance on 
cognitive control tasks. However, there is little evidence for reduced cognitive motivation 
and, if anything, the reverse pattern is observed. While Harsay and colleagues [17] 
reported no effects of PD on the reward sensitivity of performance on an antisaccade 
task, Aarts and colleagues [18] in fact showed that relative to age- and IQ-matched 
controls, PD patients, who were tested OFF their normal dopaminergic medication, 
exhibited significantly enhanced reward sensitivity of task-switching. Critically, this effect 
co varied with dopamine cell loss, as indexed by (123)I-FP-CIT binding in the striatum 
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measured with SPECT (Single Photon Emission Computed Tomography) [18]: Dopamine 
cell loss in the dorsal striatum (i.e. posterior putamen) correlated positively with the 
degree to which the promise of a monetary reward reduced task-switching costs, so 
that PD patients with the greatest striatal dopamine depletion exhibited the greatest 
beneficial effect of reward on task-switching. 
This finding is not only paradoxical in light of the above-mentioned theories that consider 
PD to be a disorder of the will [4, 5, 10], but also in light of several other observations in 
PD. First, impaired cognitive control (i.e. task-switching deficit) is a core feature of PD [19-
24]. Second, many PD patients suffer from non-motor symptoms that are associated with 
motivational deficits, such as depression and apathy [25, 26] and depression (non-PD) 
has been shown to be associated with decreased reward motivation during effort-based 
decision-making [27, 28] and diminished behavioural as well as neural (striatal) responses 
to incentive cues [29-32]. And lastly, ample evidence implicates striatal dopamine in 
reward motivation, which is severely depleted in PD [14, 16, 33, 34]. 
However, the finding does concur remarkably well with another recent finding showing a 
similar negative correlation between an index of striatal dopamine, dopamine synthesis 
capacity as measured with 6-[(18)F]-fluoro-L-m-tyrosine Positron Emission Tomography 
(FMT-PET), and motivated cognitive control in young healthy volunteers [35]. In these 
healthy controls, higher striatal dopamine in dorsal striatum (i.e. left caudate nucleus) was 
associated with greater detrimental effects of reward motivation on cognitive control, this 
time measured in terms of Stroop interference control. This finding in healthy volunteers 
casts our earlier observation in PD patients in a new light. The PD work showed that 
reward motivation potentiates cognitive control in people with severely depleted levels of 
dopamine in the dorsal striatum, which we interpreted at the time as (over)compensation 
in the relatively intact ventral striatal dopamine neurons [18]. However, the more recent 
finding of reward motivation undermining cognitive control in high-dopamine controls 
[35] rather seems to suggest a linearly negative relationship between dopamine and 
motivated cognition, with Parkinson’s disease patients on the left side of the curve and 
high-dopamine controls on the right. 
Given the renewed relevance of this observation in PD patients, also in light of recent 
renewed interests in motivational and value-based accounts of control [36-39], we aimed 
here, first, to replicate our finding that effects of reward motivation on task-switching 
are potentiated in a novel sample of non-depressed PD patients. Moreover, in line with 
the proposed key role for dopamine, we also assessed whether this effect depends on 
dopaminergic medication state by comparing performance of patients when they were in 
their ON and OFF states. Furthermore, we aimed to address whether reward motivational 
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enhancement of task-switching in PD is abolished in PD patients with depression (history), 
following prior work showing reduced reward sensitivity in depression [28, 31, 40, 41], 
or whether this increased motivated cognition is intact, given equally or even more 
diminished dopamine levels in the striatum of PD patients with depression [42-46], but 
see [47, 48]. To this end, we assessed PD patients with and without depression (history) 
and healthy controls using a task similar to that used in previous studies [18, 49]. All 
patients were tested twice, ON and relatively OFF dopaminergic medication. 
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Materials and methods
Participants
Twenty-four PD patients with depression (history), 23 non-depressed PD patients and 
25 healthy controls were recruited. Data from 2 healthy controls were discarded from 
the analysis because of a lifetime depression history. Furthermore, two PD patients 
with depression (history) failed to complete the study, leading to incomplete datasets. 
Reported analyses include 22 PD patients with and 23 PD patients without depression 
(history) and 23 healthy controls. Based on a power calculation for which we used 
GPower software [50], a minimum of 18 participants per group was estimated sufficient 
to show a significant effect (with power of 0.80, α error probability of 0.05 and a medium 
effect size (f=0.25)).  
Patients were recruited from the Parkinson Centre at the Radboud University Medical Centre, 
Nijmegen, Netherlands. Healthy controls were recruited via advertisement or were partners 
or acquaintances of participating patients. The three groups were matched for age, gender 
and IQ measured with the NART (Dutch version of the National Adult Reading Test, [51]) (Table 
1). Patient groups were also matched for disease severity measured with the UPDRS-III [52], 
disease duration (years) and amounts of dopaminergic medication (levodopa equivalent 
dose, [53]) (Table 1). The study was approved by the local ethics committee (CMO regio 
Arnhem - Nijmegen, The Netherlands, nr. 2012/43) and written informed consent according 
to the Declaration of Helsinki was obtained from all participants. Participants were paid for 
participation according to the institutional guidelines.
All patients were diagnosed with idiopathic Parkinson’s disease according to the UK 
Brain Bank criteria [59]. Diagnosis were made by a neurologist specialized in Movement 
Disorders (Prof. B.R. Bloem, Dr. R.A. Esselink, or Dr. B. Post). All patients were treated with 
dopaminergic medication: levodopa (depressed PD group n=15, non-depressed PD group 
n=11), dopamine receptor agonists (depressed PD group n=2, non-depressed PD group n=2) 
or a combination of both (depressed PD group n=5, non-depressed PD group n=10). Eight 
patients in the depressed PD group received antidepressants (paroxetine n=3, escitalopram 
n=1, venlafaxine n=1, nortriptyline n=2, citalopram n=1). Patients were selected for the 
depressed PD group if they met the DSM-IV criteria for a major (n=7) or minor depressive 
episode (n=13), dysthymic disorder (n=1) or adjustment disorder with depressed mood (n=1) 
within the five years before PD diagnosis or during their disease course up until now. Seven 
patients were diagnosed with current depression, the other patients with past depression. 
PD-patients with a past depression were included in the depressed group, because impaired 
reward motivation (and underlying striatal dysfunction) has also been shown in individuals 
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at risk of depression, putatively reflecting an underlying vulnerability trait [60]. Psychiatric 
diagnosis was established via structured psychiatric interviews (MINI-plus, [61]) conducted 
during an intake session. The timeframe of five years was chosen because the incidence 
of depression is higher within the five years before PD diagnosis and therefore presumably 
related to PD pathology [62]. 
Table 1. Patient and control group characteristics
 
Non-depressed PD 
(n=23)
PD with depression 
(history) (n=22)
Healthy controls                    
(n=23)
Gender, men 14 14 14
Age, years 61.0 (±7.4) 58.4 (±5.7) 60.9 (±5.9)
NART-IQ 97.0 (±15.1) 95.7 (±11.5) 100.7 (±13.7)
Handedness, Right 18 18 20
Response hand, Right 14 7 12
MMSE 28.5 (±1.3) 28.4 (±1.4) 28.8 (±1.2)
BDI 4.1 (±2.3) 9.6 (±6.1)*** 3.1 (±2.1)
AS 9.0 (±4.4) 13.6 (±3.9)*** 8.6 (±2.9)
STAI 28.4 (±4.5) 37.0 (±7.0)*** 26.8 (±3.6)
UPDRS - III 21.8 (±6.7) 23.1 (±9.6)
Disease duration, years 4.5 (±2.2) 5.0 (±3.5)
LED 618.3 (±272.8) 547.7 (±242.4)
First session ON 13 11  
*** PD patients with depression (history) differed significantly from both non-depressed and healthy 
controls (p<0.001). 
PD = Parkinson’s disease, NART = National Adult Reading Test [51], MMSE = Mini Mental State 
Examination [54], BDI = Beck Depression Inventory [55], AS = Apathy Scale [56], STAI = Spielberg 
State Trait Anxiety Inventory [57], UPDRS – III = Unified Parkinson’s Disease Rating Scale, motor part 
[58], LED = levodopa equivalent dose. LED was calculated, pooling different drugs according to the 
following formula: regular levodopa x1 + slow release levodopa x0.7 + ropinirol x20 + pramipexole 
x100 + [regular levodopa dose+ (slow release levodopa x0.7)] x0.2 if taking entacapone [53]. 
General exclusion criteria were any other neurological or psychiatric disorders (bipolar 
disorder, schizophrenia, ADHD, drugs and/or alcohol abuse) and clinical dementia assessed 
with a Mini Mental State Examination (cut off of <24, [54]). Healthy controls were also 
excluded if they had a history of a mood or anxiety disorder or if they used any psychotropic 
medication. 
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General procedures
This experiment was conducted as part of a larger project investigating the neurobiological 
mechanisms of depression in Parkinson’s disease. Patients and healthy controls were first 
scheduled for an intake session to obtain informed consent and check for in- and exclusion 
criteria. Measurements in healthy controls were obtained once, while measurements in PD 
patients were obtained twice; once while using their regular dopaminergic medication (ON) 
and once after withdrawal of their dopaminergic medication for at least 18 hours (24 hours 
for slow release dopamine receptor agonists) (practically defined OFF). The order of ON and 
OFF sessions was randomized such that approximately half of the patients, in both patient 
groups, were first tested ON medication (depressed PD group n=11, non-depressed PD group 
n=13) and the other half first tested OFF medication (depressed PD group n=11, non-depressed 
PD group n=10). Testing days were on average 22 days apart (SD 27.0) in the depressed 
PD group and 21 days (SD 19.8) in the non-depressed PD group. Patients were on stable 
medication regimes during the course of the study, except for one patient in the depressed PD 
group who was shortly treated for pain (4 weeks) with duloxetine in between the two testing 
days. This medication was discontinued 4 weeks before the second testing day. Patients who 
received antidepressants were asked specifically to take this medication on both testing days 
to assure that within subject differences between testing days are attributed to dopaminergic 
manipulation only. All testing days started in the morning between 8:30 and 10:30 am.  
Task
Participants performed a well-established pre-cued task-switching paradigm designed to 
measure effects of reward motivation on task-switching identical to one employed previously 
[18]. Participants were presented a series (240 in total) of incongruent Stroop-like arrow-word 
targets (either the word “left” in a right pointing arrow or the word “right” in a left pointing 
arrow). On each trial they were asked to respond either to the direction of the arrow or to the 
direction of the word by pressing a left or right button. Patients responded with their least 
affected hand, which was not always the dominant hand. Therefore, we asked some healthy 
controls (randomly) to respond with their non-dominant hand as well. This was matched 
between groups (Table 1). Half of the trials were repeat trials and half of the trials were switch 
trials (switch from arrow to word target or vise versa). Furthermore, half of the trials - repeat 
and switch - were preceded by a high reward (10 cents) cue and the other half by a low 
reward (1 cent) cue, indicating the amount of money participants could obtain by responding 
correctly and in time. The order of trials was pseudo-randomized. All participants were 
familiarized with the task directly preceding the experiment and performed 2 practice blocks. 
Response deadlines - separately for arrow, word, repeat and switch trials - were individually 
determined based on performance on 24 trials performed directly after practice and before 
the start of the experiment. Patients performed these practice blocks on both testing days 
and response deadlines were adjusted based on performance on that specific day. 
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Analyses
Reaction times (RTs) and error rates (proportion of errors per trial type) were analyzed. For 
statistical purposes, RTs were log transformed to maximize homogeneity of variance between 
groups. An arcsine transformation (2 arcsin√x) was applied to error rates. Untransformed 
data are shown in Table 2 as a function of group and medication session.
First, we assessed whether there were any drug effects in PD patients by means of an 
analysis of variance (ANOVA) with the within-subject factors DRUG (ON, OFF), REWARD 
(high, low) and TRIAL-TYPE (switch, repeat). Subsequently, in the absence of a medication 
effect, we averaged patient's error rates and reaction times across the two drug sessions 
and compared these measurements with measurements obtained in healthy controls by 
means of a mixed ANOVA with REWARD (high, low) and TRIAL-TYPE (switch, repeat) as 
within-subject factors and GROUP (nondepressed PD, depressed PD and healthy control) as 
a between-subject factor. When the overall mixed ANOVA revealed a significant interaction 
with GROUP as a factor, we performed subsequent mixed ANOVA’s to compare the GROUPS 
separately breaking-down this interaction. In these cases, the factor GROUP comprises only 
2 levels. For the overall interaction we use “GROUP(3)” (referring to 3 within-subject levels) 
and when breaking-down the overall interaction comparing 2 groups, we use “GROUP(2)” 
(referring to 2 within-subject levels). Statistical inference was set at a threshold of p<0.05. 
Partial Eta squared (ηp2) is reported as measure of effect size.  
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Table 2. Raw (untransformed) data on the rewarded task-switching paradigm
Error rates (%)
OFF ON
  Low 
reward
High 
reward
Reward 
benefit
Low 
reward
High 
reward
Reward 
benefit
Non-depressed PD
Repeat 11.0 (2.4) 10.7 (2.4) 0.004 (0.012) 5.9 (1.0) 6.8 (1.1) -0.009 (0.010)
Switch 13.3 (2.2) 11.1 (2.0) 0.022 (0.011) 10.0 (1.5) 7.1 (1.1) 0.029 (0.010)
PD with depression (history)
Repeat 5.4 (0.9) 5.6 (1.0) -0.002 (0.009) 5.7 (1.3) 5.8 (0.9) -0.000 (0.008)
Switch 8.8 (1.2) 8.4 (1.1) 0.004 (0.011) 9.1 (1.4) 7.9 (1.4) 0.012 (0.013)
Healthy controls
Repeat 7.2 (1.8) 6.3 (1.6) 0.009 (0.008)
Switch 8.4 (1.5) 10.2 (2.0) -0.18 (0.011)      
Reaction times (ms)
OFF ON
Low 
reward
High 
reward
Reward 
benefit
Low 
reward
High 
reward
Reward 
benefit
Non-depressed PD
Repeat 510.4 (24.6) 506.6 (26.3) 3.8 (4.7) 558.5 (25.4) 544.1 (25.0) 14.4 (4.4)
Switch 530.4 (30.2) 514.4 (28.3) 16.1 (5.7) 570.0 (28.0) 563.7 (29.5) 6.3 (5.3)
PD with depression (history)
Repeat 563.7 (27.6) 547.7 (27.0) 16.0 (4.3) 558.3 (33.5) 540.6 (32.8) 17.7 (3.9)
Switch 574.9 (30.8) 571.8 (32.1) 3.1 (4.8) 565.6 (34.2) 564.9 (38.6) 0.6 (5.7)
Healthy controls
Repeat 505.4 (24.1) 500.4 (24.2) 5.0 (4.5)
Switch 520.6 (26.8) 519.8 (26.0) 0.8 (5.2)      
Values represent mean proportion of incorrect responses in % and mean response times in ms 
(standard errors of the mean). PD = Parkinson’s disease. 
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Results
Effect of reward motivation on task switching 
Error rates
In PD patients, there was no significant main effect of DRUG and none of the interaction 
effects with DRUG as a factor were significant (Supplement, Table S1). Therefore, we averaged 
patient’s error rates across the two drug sessions and compared these measurements with 
measurements obtained in healthy controls. 
There was no main effect of REWARD (F(2,65)=0.71, p=0.40, ηp2=0.011). We did observe a 
significant main effect of TRIAL-TYPE (F(2,65)=45.18, p<0.001, ηp2=0.410), indicating that all 
subjects made more errors on switch compared with repeat trials. This was not different 
between PD patients (depressed and nondepressed) and healthy controls (TRIAL-TYPE x 
GROUP(3): F(2,65)=0.61, p=0.55, ηp2=0.018). 
Consistent with our previous study [18], we observed that PD patients exhibited greater 
beneficial effects of reward motivation on task-switching than healthy controls evidenced 
by a significant 3-way interaction between TRIAL-TYPE, REWARD and GROUP(3) 
(F(2,65)=5.11, p=0.009, ηp2=0.136) (Figure 1). This beneficial effect of reward motivation 
on task-switching did not differ between PD patients with and without depression 
(history), evidenced by a non-significant TRIAL-TYPE x REWARD x GROUP(2) interaction 
when comparing PD patients with and without depression (history) (F(1,43)=0.62, p=0.43, 
ηp2=0.014). Both PD groups showed a greater beneficial effect of reward motivation on 
task-switching than healthy controls (comparison of non-depressed PD with healthy 
controls, F(1,44)=7.84, p=0.008, ηp2=0.151; comparison of depressed PD patients with 
healthy controls, F(1,43)=4.76, p=0.035, ηp2=0.100). Breakdown of this interaction revealed 
greater beneficial effects of reward motivation on switch trials in patients (from both 
patient groups) than in healthy controls (REWARD x GROUP(3) interaction on switch trials, 
F(2,65)=5.22, p=0.008, ηp2=0.138 (comparison of non-depressed PD with healthy controls, 
F(1,44)=9.91, p=0.003, ηp2=0.184; comparison of PD patients with a depression (history) 
and healthy controls, F(1,43)=4.62, p=0.037, ηp2=0.097). No such interaction was observed 
for repeat trials (REWARD x GROUP(3) interaction on repeat trials, F(2,65)=0.64, p=0.53, 
ηp2=0.019). Post-hoc paired samples t-tests revealed that non-depressed PD patients 
made significantly fewer errors on high-reward switch trials compared with low-reward 
switch trials (t(22)=2.90, p=0.008, d=0.618). No such effect was observed in depressed PD 
patients (t(21)=1.24, p=0.23, d=0.259). Conversely, healthy, age-matched controls tended 
to make more errors on high-reward switch trials compared with low-reward switch trials 
(t(22)=-1.79, p=0.087, d=-0.373). There was no TRIAL-TYPE x GROUP(3) interaction for low-
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reward trials (F(2,65)=0.887, p=0.42, ηp2=0.027), but on high-reward trials, switch costs 
were lower for PD patients than healthy controls (TRIAL-TYPE X GROUP(3): F(2,65)=3.34, 
p=0.042, ηp2=0.093). 
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Figure 1. Effects of reward motivation on task-switching. Average switch cost [switch-repeat] on error 
rates on low (blue squares) and high reward trials (red squares) in non-depressed PD patients, PD 
patients with a depression (history) and healthy controls. Black lines represent the (positive and negative) 
standard error of the mean. Individual data points are plotted in grey dots. PD = Parkinson’s disease. 
Previously, we have shown that effects of reward motivation are more readily observed on 
the most established task-set (i.e. the arrow task) [18]. Therefore, we performed an extra 
analysis including TASK (i.e. arrow or word) as additional within-subject factor. In patients, 
in terms of error rates, there was no significant DRUG x REWARD x TRIAL-TYPE x TASK x 
GROUP(2) interaction (F(1,43)=1.88, p=0.18, ηp2=0.042) and no significant DRUG x REWARD 
x TRIAL-TYPE x TASK interaction (F(1,43)=0.11, p=0.74, ηp2=0.003). Therefore, to compare 
patient data with healthy control data, we averaged patient data across drug sessions. 
Comparison of depressed patients, non-depressed patients and healthy controls revealed 
no differences in terms of the effect of task (i.e. arrow or word) on reward motivated cognitive 
control, indicated by a non-significant interaction between REWARD, TRIAL-TYPE, TASK and 
GROUP(3) (F(2,65)=0.01, p=0.99, ηp2=0.000).
To assess whether the beneficial effect of reward motivation on task-switching in PD patients 
varied as a function of current depression severity, we correlated the effect of reward 
motivation (low-high reward) on switch-cost (switch-repeat) with the BDI score during the OFF 
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session. This analysis revealed that reward motivational enhancement of task-switching in 
the PD group as a whole did not vary as a function of current depression severity (r(45)=0.152, 
p=0.32). Additional subgroup analyses (comparison of currently depressed patients with 
never depressed patients and of patients who suffer(ed) from mild depressive symptoms with 
patients who suffer(ed) from a major depressive episode) can be found in the supplement. 
Reaction times
There was no main effect of DRUG and no significant interactions with DRUG as a factor in PD 
patients (Supplement, Table S1). There was a near significant GROUP(2) by DRUG interaction 
(F(1,43)=4.00, p=0.052, ηp2=0.085). However, breakdown of this interaction revealed no 
significant drug effect on reaction times in neither PD group (non-depressed PD p=0.07, 
depressed PD p=0.47). Moreover, all interactions of interest with drug as a factor were not 
significant. Therefore, we averaged patient’s reaction times across the two drug sessions 
and compared these measurements with measurements obtained in healthy controls.
Comparison of PD patients with and without a depression (history) and healthy controls 
revealed a significant main effect of REWARD (F(2,65)= 20.55, p<0.001, ηp2=0.240), indicating 
faster reaction times on high versus low reward trials across all three groups. There was 
also a significant main effect of TRIAL-TYPE (F(1,65)=45.01, p<0.001, ηp2=0.409), indicating 
slower reaction times on the more demanding switch than repeat trials in all three groups. 
There were no significant interactions with GROUP(3) as a factor, indicating that PD patients 
with and without depression (history) and healthy controls did not differ in terms of reaction 
times (Supplement, Table S2). 
Again, we performed an extra analysis including TASK (i.e. arrow or word) as additional 
within-subject factor. In patients, in terms of reaction times, there was no significant DRUG x 
REWARD x TRIAL-TYPE x TASK x GROUP(2) interaction (F(1,43)=0.73, p=0.40, ηp2=0.017) and no 
significant DRUG x REWARD x TRIAL-TYPE x TASK interaction (F(1,43)=1.47, p=0.23, ηp2=0.033). 
Therefore, to compare patient data with healthy control data, we averaged patient data 
across drug sessions. Comparison of depressed patients, nondepressed patients and 
healthy controls revealed no differences in terms of the effect of task (i.e. arrow or word) 
on reward motivated cognitive control, indicated by a non-significant interaction between 
REWARD, TRIAL-TYPE, TASK and GROUP(3) (F(2,65)=0.00, p=0.99, ηp2=0.000).
There were no significant correlations between behavioural findings in terms of reaction 
times and current depression severity. Again, additional subgroup analyses can be found 
in the supplement. 
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In sum, PD patients with and without depression (history) showed reward motivational 
enhancement of task-switching in terms of error rates, whereas reward motivation, if anything, 
impaired task-switching in matched healthy controls. We did not observe any differences 
between PD with and without depression (history) patients and healthy controls in terms of 
reaction times and there were no effects of medication.
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Discussion
The present study replicates previous findings by demonstrating reward motivational 
enhancement of task-switching in terms of error rates in PD patients compared with healthy 
controls [18]. In addition, we extend previous findings by showing that reward motivational 
enhancement of task-switching in PD is unaltered by depression (history). 
The finding that reward motivation has contrasting effects on task-switching in patients 
with PD and healthy controls is a direct replication of our previous study with the exact 
same paradigm [18] and strengthens our belief in the observation that PD is accompanied 
by enhanced beneficial impact of incentive on cognitive control. The hypothesis that the 
potentiation of cognitive motivation in PD patients, observed here and in our previous study, 
reflects dopamine deficiency is supported by the observation in that previous study that 
effects correlated with dopamine cell loss in dorsal striatum. Moreover, it is also strengthened 
by our previous study in healthy volunteers, in which higher baseline dopamine synthesis 
capacity was associated with greater detrimental effects of reward motivation on cognitive 
control [35]. 
One potential caveat that we considered is the possibility that there was more dynamic 
range for reward motivation to impact performance in PD patients than in controls. In other 
words, it is easier to potentiate performance if it is impaired to begin with. However, this 
was not the case. There was no task-switching deficit in PD patients compared with controls 
in the low-reward trials. Therefore, we can exclude that potential confound. Of course this 
observation does raise a different question: Why did the present study not reveal a task-
switching deficit in PD, as did previous studies [19-24, 63], but see [64]? One possibility 
is that the current task was not optimized for detecting such task-switching deficits [64], 
although we have previously used the exact same task to demonstrate subtle but significant 
deficits [18, 49]. More likely, is the possibility that any task-switching deficit was remedied 
by the reward context in which trials were presented. While the presence of an incentive 
potentiated performance disproportionally on the switch trials, it is possible that any benefit 
generalized to the repeat trials (relative to a non-rewarded context). 
A striking feature of our current and previous data is that, in age-matched healthy controls, 
reward motivation tended to impair rather than enhance task-switching. As such, the age-
matched control group resembled if anything the younger volunteers from the prior study 
with higher striatal dopamine synthesis capacity [35]. This is in line with recent reports that 
ageing is accompanied by upregulated striatal dopamine synthesis capacity [65]. 
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One aspect of our results that is surprising in the context of the previous PET and SPECT 
studies using this paradigm is the failure to find an effect of dopaminergic medication. There 
was no effect of dopaminergic medication on task-switching or on the interaction between 
reward motivation and task-switching in our PD patients. The absence of a main effect of 
dopaminergic medication on task-switching is particularly unexpected given prior evidence 
for beneficial effects of dopaminergic medication on task-switching in PD [19, 21, 63, 64, 66]. 
Moreover, the association between the incentivization of cognitive control and indices of 
striatal dopamine transmission in previous studies [18, 35] renders the absence of an effect 
of dopaminergic medication on this task remarkable. After all, we would have expected 
any dopamine-dependency to surface in terms of an effect of medication withdrawal. We 
remain puzzled about this lack of effects, and speculate that this reflects either a suboptimal 
withdrawal procedure (given that the used compounds have long half-lives) or individual 
genetic differences, as shown previously in a study with the same paradigm to assess 
dopaminergic drug effects in ADHD [67, 68].
PD patients with depression (history) showed similar reward motivational enhancement 
of task-switching as did non-depressed PD patients. Thus the beneficial effect of reward 
motivation on cognitive control is potentiated even in (previously) depressed PD patients. 
This might be surprising given decreased reward motivation in depression [27-32]. One 
potential caveat of the present study is the heterogeneity of the patient group with depression 
(history): This group included patients with past and present depression and sample sizes 
of the subgroups were too small to make meaningful direct comparisons between groups 
with current and past depression. As such, we can only conclude that a depression history 
in Parkinson’s disease does not alter reward motivational enhancement of cognitive control. 
The question whether a current depression diminishes incentive motivation for cognitive 
control should be addressed in future work. 
The finding of enhanced incentive motivation for cognitive control replicated here is perhaps 
reminiscent of the phenomenon of ‘paradoxical kinesia’. Nevertheless, it contrasts with 
previous studies showing reduced motivation for physical effort in PD [10-12], although these 
have focused primarily on intrinsic motivation (value-based choice to exert effort). Studies 
investigating extrinsic (incentive) motivation for physical effort in PD are still scarce, but 
suggest similar effects [11]. It will be interesting to compare, in future work, the effect of PD 
on extrinsic and intrinsic motor and cognitive motivation. 
Which mechanism might underlie the effect of PD on incentivizing cognitive control? One 
possibility, inspired by opportunity cost accounts of tonic dopamine’s role in motivating vigor 
(physical effort) [6] as well as cognitive control [37, 69], is that increases in tonic dopamine 
might correspond with increases in a net average reward rate of the environment against 
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which rewards are compared. A separate, but relevant line of evidence concerns the 
phenomenon of adaptive coding of reward [70, 71] and studies indicating that a potential 
reward is subjectively more valuable in a reward-poor environment [72-75]. As such, one 
possible explanation of the present findings is that PD patients, whose tonic dopamine level 
and putative corresponding average reward rate is excessively low, evaluate a reward as 
relatively more valuable than healthy controls, making them more likely to engage in a high-
demand task when a reward is at stake. To test this hypothesis, instantaneous and average 
reward rate should be manipulated in an orthogonal manner, as has been done previously 
for testing the dopamine-dependent opportunity cost account of physical vigor [76, 77]. 
In sum, we replicated findings of reward motivational enhancement of cognitive control in 
PD patients and extended these findings to PD patients with concurrent depression. These 
findings suggest that PD patients might benefit from incentive motivational strategies to 
overcome their cognitive deficits associated with the disease. 
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Supplement
Table S1. Drug effects in patients with Parkinson’s disease
Error rates
DRUG
DRUG x GROUP 
DRUG x REWARD
DRUG x REWARD x GROUP
DRUG x TRIAL-TYPE 
DRUG x TRIAL-TYPE x GROUP 
DRUG x REWARD x TRIAL-TYPE
DRUG x REWARD x TRIAL-TYPE x GROUP
F(1,43)=3.27, p=0.078, ηp2=0.071
F(1,43)=2.66, p=0.110, ηp2=0.058
F(1,43)=0.00, p=0.973, ηp2=0.000
F(1,43)=0.46, p=0.502, ηp2=0.011
F(1,43)=0.51, p=0.823, ηp2=0.001
F(1,43)=0.46, p=0.503, ηp2=0.011
F(1,43)=1.01, p=0.322, ηp2=0.023
F(1,43)=0.07, p=0.789, ηp2=0.002
Reaction times
DRUG
DRUG x GROUP 
DRUG x REWARD
DRUG x REWARD x GROUP
DRUG x TRIAL-TYPE 
DRUG x TRIAL-TYPE x GROUP 
DRUG x REWARD x TRIAL-TYPE
DRUG x REWARD x TRIAL-TYPE x GROUP
F(1,43)=1.46, p=0.234, ηp2=0.033
F(1,43)=4.00, p=0.052, ηp2=0.085
F(1,43)=0.10, p=0.759, ηp2=0.002
F(1,43)=0.01, p=0.913, ηp2=0.000
F(1,43)=0.01, p=0.921, ηp2=0.000
F(1,43)=0.26, p=0.615, ηp2=0.006
F(1,43)=2.47, p=0.123, ηp2=0.054
F(1,43)=2.14, p=0.151, ηp2=0.047
Table S2. Analysis of reaction times in PD patients with and without a depression (history) and controls
GROUP
REWARD  x GROUP 
TRIAL-TYPE x GROUP
REWARD x TRIAL-TYPE x GROUP
F(2,65)=0.87, p=0.422, ηp2=0.026
F(2,65)=2.13, p=0.127, ηp2=0.062
F(2,65)=0.48, p=0.623, ηp2=0.014
F(1,43)=1.26, p=0.291, ηp2=0.037
PD = Parkinson’s disease
Subgroup analysis 
We performed subgroup analyses comparing error rates in currently depressed patients 
(n=7) with error rates in never depressed patients (i.e. the non-depressed patient group). 
This comparison revealed no differences, evidenced by a non-significant 3-way interaction 
between TRIAL-TYPE, REWARD and GROUP (F(1,28)=0.58, p=0.45, ηp2=0.02). 
However, when comparing reaction times between patients with a current depression and 
never depressed patients, we did observe a significant 3-way interaction between TRIAL-
TYPE, REWARD and GROUP (F(1,28)=0.7.19, p=0.012, ηp2=0.204)). Break-down of this interaction 
revealed a significant TRIAL-TYPE x REWARD interaction in the currently depressed patients 
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(F(6)=14.36, p=0.012, ηp2=0.705)), but not in the never depressed patients (F(22)=0.07, p=0.80, 
ηp2=0.03)). Post-hoc paired samples t-tests in currently depressed patients revealed that 
reward significantly decreased reaction times on repeat trials (t(6)=3.86, p=0.008, d=0.17). No 
such effect was observed on switch trials (t(6)=0.02, p=0.98, d=0.00).
We also performed subgroup analyses comparing patients who suffer(ed) from mild 
depressive symptoms (n=15) with patients who suffer(ed) from a major depressive episode 
(n=7). These analyses revealed no significant differences in terms of error rates (non-
significant 3-way interaction between TRIAL-TYPE, REWARD and GROUP (F(1,20)=0.75, p=0.40, 
ηp2=0.04)) and no significant differences in terms of reaction times (non-significant 3-way 
interaction between TRIAL-TYPE, REWARD and GROUP (F(1,20)=0.00, p=0.98, ηp2=0.00).
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Summary and discussion
This thesis focuses on depression in Parkinson’s disease, one of the most frequent non-
motor symptoms with a tremendous negative impact on the quality of life of patients and their 
caregivers. With the presented studies, I aimed to elucidate the neurocognitive mechanisms 
contributing to depression in Parkinson’s disease, ultimately aiming to improve adequate 
recognition, treatment and eventually prevention of depression in Parkinson’s disease. 
One chapter is devoted explicitly to improving recognition and treatment of depression 
in Parkinson’s disease in current clinical practice (chapter 2). The other chapters aimed 
to enhance our knowledge of the mechanisms contributing to depression in Parkinson’s 
disease, with a focus on the role of dopamine and reward (and punishment) processing 
across the three cognitive domains most commonly associated with dopamine functioning; 
learning (chapter 3 and 4), decision making (chapter 5) and motivation (chapter 6). 
Below I will provide a short summary of the main findings of this thesis. Then I will discuss 
the findings in light of three overarching concepts, namely: (1) depression in Parkinson’s 
disease - a neurocognitive disorder reflecting, among other things, (ventral) striatal dopamine 
deficiency; (2) the role of (striatal) dopamine in the effects of dopaminergic medication on 
cognition in Parkinson’s disease; and (3) the dopamine overdose hypothesis to account for 
paradoxical cognitive effects of medication in Parkinson’s disease. I will end this chapter by 
discussing the weaknesses and strengths of the studies followed by a paragraph discussing 
future perspective and challenges. 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 164
Chapter 7
164
Summary of the findings
In chapter 2, I provided an overview of the diagnostic pitfalls that contribute to the 
underdiagnosis and undertreatment of depression in Parkinson’s disease in current clinical 
practice. Moreover, I provided the reader with helpful diagnostic clues and tools, an overview 
of the basic pathophysiology of depression in Parkinson’s disease and a broad spectrum of 
treatment options, aiming to improve recognition and treatment of depression in Parkinson’s 
disease in current clinical practice, ultimately aiming to improve the quality of life of patients 
and their caregivers.
Chapters 3 and 4 focused on the domain of learning. In chapter 3, I investigated reward 
and punishment reversal learning and associated neural signalling in patients with 
Parkinson’s disease with and without a depression (history). Patients were assessed ON 
and OFF dopaminergic medication. Previous studies consistently showed that dopaminergic 
medication shifts the balance between reward- and punishment-based learning [1, 2]. 
However, there is discrepancy in extant literature with respect to the integrity of reward and- 
punishment-based learning in patients OFF medication. This study showed that a depression 
(history) in Parkinson’s disease is accompanied by impaired reward (versus punishment) 
reversal learning and an attenuation in the differential striatal BOLD response to unexpected 
reward versus unexpected punishment. Surprisingly, no effect of dopaminergic medication 
on reversal learning or associated striatal BOLD signal was observed. I concluded that 
impairments in reversal learning from reward versus punishment and associated striatal 
signalling depend on the presence of (a history of) depression in Parkinson’s disease. 
Moreover, these findings highlight the importance of taking into account depression (history) 
when investigating reward (versus punishment) learning in Parkinson’s disease.  
In chapter 4, I investigated, in a very large sample of patients with Parkinson’s disease, 
whether current depression severity mediates an observed link between dopaminergic 
medication dose and reversal learning impairment. It is well-known that dopaminergic 
medication in Parkinson’s disease can improve as well as impair cognitive functions. The 
dopamine overdose hypothesis states that dopaminergic medication specifically impairs 
cognitive functions associated with brain regions with relatively intact dopamine levels, such 
as the ventral striatum [3-5]. Depression in Parkinson’s disease is hypothesized to reflect 
ventral striatal dopamine deficiency. As such, I hypothesized that detrimental effects of 
dopaminergic medication on reversal learning - a task that critically implicates ventral striatal 
dopamine - would be restricted to non-depressed patients. Consistent with the overdose 
hypothesis, I showed that higher amounts of dopaminergic medication are associated 
with greater impairments in reversal learning. Critically, and in contrast to our hypothesis, 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 165
Summary and discussion
165
07
mediation analyses revealed that this association is greatest in patients who exhibit the 
highest depression scores. I concluded that patients with Parkinson’s disease and concurrent 
depression are more vulnerable to the detrimental effects of high dopaminergic medication 
dose on reversal learning than non-depressed patients. These findings highlight the need 
for stricter monitoring of cognitive side effects with dopaminergic treatment in depressed 
patients.
Dopaminergic medication has often been argued to enhance risky choice in patients with 
Parkinson’s disease [6, 7]. In chapter 5, which focused on decision making rather than 
learning, I assessed dopaminergic medication effects during risky choice in patients with 
Parkinson’s disease with and without a depression (history). Critically, I adopted a prospect 
theory based approach to investigate the computational mechanisms that might contribute to 
enhanced risky choice. The study revealed two key findings. First, dopaminergic medication 
increased a value-independent gambling bias in non-depressed patients with Parkinson’s 
disease, as it does in healthy controls [8, 9], providing converging evidence for dopamine-
induced increases in a general tendency to gamble. Second, dopaminergic medication 
reduced loss aversion to a greater degree in patients with higher current depression ratings, 
raising the hypothesis that dopamine-induced reductions in loss aversion might underlie 
previously observed co morbidity between depression and medication-related side effects 
in Parkinson’s disease, such as impulse control disorder.
In chapter 6, I shift my attention from the domains of learning and decision making to 
the domain of motivation. Specifically, I investigated effects of reward motivation on 
cognitive control. I replicated previous paradoxical findings of greater reward motivational 
enhancement of task-switching in patients with Parkinson’s disease relative to healthy 
controls [10]. Moreover, I extend previous findings by showing that reward motivational 
enhancement of task-switching in Parkinson’s disease is unaltered by a depression (history) 
diagnosis. I did not observe an effect of dopaminergic medication on reward motivation 
for task-switching. These findings reinforce prior observations that Parkinson’s disease 
is accompanied by enhanced incentive motivation of cognitive control and highlight the 
potential of incentive motivational strategies for overcoming cognitive deficits in Parkinson’s 
disease. 
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Discussion
Depression in Parkinson’s disease - a neurocognitive 
disorder reflecting, among other things, (ventral) striatal dopamine deficiency 
As outlined in the introduction, depression is considered a neurocognitive disorder. The 
cognitive neuropsychological model of depression assigns a causal role to negative affective 
biases in the development, maintenance and treatment of depression [11-13]. These negative 
affective biases are observed across various aspects of cognition. I focused on (aberrant) 
reward (and punishment) processing across the three cognitive domains most commonly 
associated with dopamine, namely learning, decision making and motivation. Reward (and 
punishment) processing has critically implicated striatal dopamine and is therefore very likely 
to contribute to depression in Parkinson’s disease. 
Depression (without Parkinson’s disease) has been associated with an imbalance in the 
impact of reward and/or punishment on learning and choice. For example, in the domain of 
learning it has been shown that individuals with depression exhibit both an enhanced impact 
of punishment as well as a reduced impact of reward [14-16]. In the domain of risky choice, 
depressed individuals have been shown to exhibit faster learning to avoid risky responses 
than controls [17] and to exhibit decision strategies that aim to minimize losses rather than 
maximize gains [18, 19]. In chapter 3 and chapter 5, I extended these findings to depression 
in Parkinson’s disease by showing that a depression (history) in Parkinson’s disease is 
accompanied by an imbalance in the impact of reward versus punishment on learning and 
risky choice respectively. Specifically, in chapter 3 I showed impaired reward-based (versus 
punishment-based) learning in patients with a depression (history) compared with non-
depressed patients. This impairment in reward learning was associated with an attenuation 
in the differential striatal response to unexpected reward versus unexpected punishment, 
suggesting that abnormal striatal signalling, the key region affected by Parkinson’s disease, 
is also implicated in depression-related deficits in Parkinson’s disease. In chapter 5, I showed 
that patients with a depression (history) compared with non-depressed patients tended to 
exhibit enhanced loss aversion during risky choice (i.e. weigh potential losses more heavily 
than potential gains), although this latter finding has to be interpreted with caution as it failed 
to reach significance. Together the findings from chapter 3 and chapter 5 support the idea 
that a depression (history) in Parkinson’s disease is associated with negative affective biases, 
in line with the cognitive neuropsychological model of depression. 
As outlined in the introduction, depression in Parkinson’s disease is conceptualized to 
reflect a (ventral) striatal dopamine deficient state. Note however, that other systems, such 
as the noradrenergic and serotonergic system, also play key roles [20-22]. The ‘dopamine 
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hypothesis’ of depression in Parkinson’s disease is based on several observations; (1) 
patients with Parkinson’s disease frequently experience depressive symptoms during OFF 
periods [23, 24], (2) dopaminergic medication has an antidepressant effect [25, 26] and (3) 
depressed patients with Parkinson’s disease have reduced striatal dopamine transporter 
binding compared with non-depressed patients, reflecting more severe degeneration of 
presynaptic dopaminergic neurons, especially in ventral striatal regions ([21, 27-29], but see 
[30, 31]). It is well-known that the balance between learning from reward and punishment 
critically depends on (ventral) striatal dopamine [1, 2, 32] and recent theoretical and empirical 
work has extended these value-dependent effects from learning to choice [33-35]. High 
striatal dopamine has been associated with enhanced reward-based relative to punishment-
based learning/choice, whereas low striatal dopamine has been associated with impaired 
reward-based relative to punishment-based learning/choice. The findings of impaired 
reward-based (versus punishment-based) learning and a tendency towards enhanced loss 
aversion during risky choice in patients with a depression (history) in chapter 3 and chapter 5 
respectively, might thus reflect striatal dopamine deficiency. Indeed, in chapter 3 I showed 
that this reward learning impairment in patients with depression (history) is accompanied by 
aberrant striatal signalling (albeit in a dopaminergic medication-independent manner, see 
discussion section - dopaminergic modulation of cognitive function). Moreover, in chapter 5, 
I showed that enhanced loss aversion in depression was only observed during the OFF 
medication state, but not during the ON medication state, suggesting that dopaminergic 
medication attenuates this negative bias (although this study does not speak to the neural 
locus of these effects). These findings are in line with the hypothesis that depression in 
Parkinson’s disease is a neurocognitive disorder that reflects (ventral) striatal dopamine 
deficiency. However, future research is necessary to substantiate this concept.
The findings in chapter 3 and chapter 5 are compatible with the cognitive neuropsychological 
model of depression. However, the finding of enhanced reward motivation for cognitive 
control in patients with Parkinson’s disease irrespective of depression (chapter 6) is 
surprising. Especially given observations that depression (without Parkinson’s disease) is 
associated with reduced reward motivation [36-39]. One possible explanation is that the 
heterogeneity of our depressed patient group, which included patients with past and present 
depression, undermined the power to find an effect. However, previous literature has shown 
that reward motivational deficits in patients with depression extend to non-depressed 
individuals who are at risk of depression [40], but see [38]. Another possibility is, that the 
depression-related motivation deficit is not sufficiently large to overrule the dorsal striatal 
depletion-related potentiation of motivated cognition common in both depressed and non-
depressed Parkinson’s disease patients. Previous work showed that beneficial or detrimental 
effects of reward motivation on cognitive control depend on baseline striatal dopamine 
levels. High striatal dopamine levels have been associated with detrimental effects of reward 
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motivation on cognitive control, whereas low striatal dopamine levels have been associated 
with beneficial effects of reward motivation on cognitive control [10, 41]. This hypothesis 
is supported by the findings in chapter 6. In this chapter I showed reward motivational 
enhancement of task-switching in subjects with low dopamine levels (i.e. patients with 
Parkinson’s disease) and, if anything, detrimental effects of reward motivation on task-
switching in healthy controls. Due to the severe dopaminergic degeneration in Parkinson’s 
disease it is possible that additional effects of depression on dopaminergic signalling will 
only have a relatively small impact on this aspect of cognition. However, although very 
speculative, we cannot exclude the possibility that enhanced reward motivation for cognitive 
control in depression is a more generalizable construct. Previous studies in depression 
(without Parkinson’s disease) only assessed the effect of reward motivation on approach 
behaviour [36, 37, 42, 43] and physical effort-based decision-making in depression (without 
Parkinson’s disease) [38, 39]. Studies assessing reward motivation for cognitive control 
in depression (without Parkinson’s disease) are lacking. For future studies, it would be 
interesting to compare reward motivation for mental effort (cognitive control) and physical 
effort in patients with and without depression ánd with and without Parkinson's disease. 
Dopaminergic modulation of cognitive function
As outlined in the introduction, effects of dopaminergic medication on cognitive function 
are complex and depend on the underlying neurocircuitry. Studies in Parkinson’s disease 
showed that dopaminergic medication specifically improves performance on cognitive 
tasks that are associated with the dorsal, severely dopamine depleted (cognitive) cortico-
striatal circuit, such as task-set switching and working memory, but impairs performance on 
cognitive tasks that are associated with the ventral (limbic) cortico-striatal circuit, such as 
reversal learning and risky choice. The latter has been hypothesized to reflect detrimental 
overdosing of still relatively intact dopamine in the ventral (limbic) cortico-striatal circuit [3-
5]. Additionally, cognitive functions associated with the dorsal cortico-striatal circuit can be 
influenced by cognitive functions associated with the ventral cortico-striatal circuit, due to 
the spiralling nature of these anatomical loops [44, 45]. As outlined before, depression in 
Parkinson’s disease has been conceptualized to reflect, in part, ventral striatal dopamine 
deficiency. This led to various hypotheses with respect to dopaminergic medication effects 
that were tested in this thesis; (1) dopaminergic medication would impair performance on 
cognitive tasks associated with the ventral cortico-striatal circuit, but only in non-depressed 
patients (with presumably intact ventral striatal dopamine levels), (2) by contrast, performance 
on cognitive tasks associated with the ventral cortico-striatal circuit would be impaired 
in patients with depression (and presumably low ventral striatal dopamine levels) when 
tested OFF medication, and (3) dopaminergic medication would remedy these deficits in 
depressed patients. These hypothesis were tested using a reward and punishment reversal 
learning task in chapter 3, the reversal stages of the intradimensional/extradimensional 
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set-shifting paradigm in chapter 4 and a risky choice task in chapter 5. In chapter 6 I 
assessed dopaminergic medication effects using a reward motivated cognitive control task, 
thought to involve interactions between ventral and dorsal cortico-striatal circuits (see [44]. 
Moreover, dopaminergic medication effects were predicted to be valence-specific, shifting 
the balance in the impact of reward and/or punishment, enhancing reward-based relative 
to punishment-based learning and choice (in chapter 3 and chapter 5 respectively). Also 
an alternative hypothesis was considered: based on clinical observations that depression 
and medication-related impulse control disorder are often comorbid [46], the possibility 
that dopaminergic drug effects on risky choice would be restricted to depressed patients 
was considered (chapter 5). Finally, apart from an effect on loss aversion, also an effect 
on a value-independent gambling bias was considered. This followed from a recent set of 
observations in healthy controls showing that levodopa increases risky choice by increasing 
the propensity to gamble in a value-independent manner [8, 9] (chapter 5).  
While I had good grounds to hypothesize that all cognitive tasks employed throughout 
this thesis were dopamine sensitive, the actual effects of dopaminergic medication were 
somewhat mixed. Whereas I did observe expected (detrimental) effects of dopaminergic 
medication (dose) on reversal learning in chapter 4 and on risky choice in chapter 5, there 
were no effects of dopaminergic medication on valence specific reversal learning and 
reward motivated cognitive control in chapter 3 and chapter 6 respectively. How can this 
be explained? 
As outlined before, dopaminergic medication in Parkinson’s disease can impair 
performance on cognitive tasks associated with the relatively intact ventral (limbic) 
cortico-striatal circuit, such as reversal learning and risky choice [3, 5, 47]. The finding 
reported in chapter 4 that increasing dopaminergic medication dose is associated with 
greater reversal learning impairment is another converging piece of evidence. These 
(detrimental) effects of dopaminergic medication on learning have repeatedly been 
shown to be valence-specific [1, 2, 48, 49]. As such, I was particularly surprised by the 
absence of a drug effect on valence-specific reversal learning in chapter 3. I considered 
the possibility of an inadequate medication withdrawal procedure, especially of the long-
acting dopamine receptor agonists. The risky choice paradigm was the last task that 
subjects performed on each testing day, and as such medication withdrawal effects were 
potentially greater on this task. This could explain why there were effects of dopaminergic 
medication on the risky choice paradigm, but not on the valence-specific reversal learning 
paradigm and the reward motivated cognitive control paradigm. However, the pattern of 
performance that I observed on the valence-specific reversal learning task in chapter 3 
was consistent with patterns previously observed in an OFF medication state rather than 
an ON state pattern [2, 48, 50, 51]. Therefore, although I cannot exclude the possibility of 
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an inadequate medication withdrawal procedure completely, this explanation is not likely. 
Another possible explanation is related to the specific types of dopaminergic medication 
and their effect on the dopaminergic system. The two main classes of dopaminergic agents 
that are used to treat patients with Parkinson’s disease are dopamine receptor agonists 
and levodopa. Although both types of medication share similar mechanisms of action, 
there are some subtle (but maybe very relevant) differences. First, whereas levodopa 
presumably affects phasic more than tonic dopamine, dopamine receptor agonists 
specifically mimic tonic dopamine [52, 53]. Secondly, the affinity for the specific classes 
of dopamine receptors slightly differs. Whereas levodopa acts to enhance endogenous 
dopamine and acts on both D1 and D2 type dopamine receptors, dopamine receptor 
agonists have a preference for the D2 type dopamine receptors [53]. Phasic dopamine 
bursts in response to an unexpected reward and phasic dopamine dips in response to 
an unexpected punishment serve as teaching signals. However, tonic dopamine levels 
determine the system’s sensitivity to these teaching signals. A certain minimum level of 
tonic dopamine is necessary to reach the threshold to respond to phasic dopamine bursts 
signalling a reward and vice versa, too high tonic dopamine levels prevent phasic dopamine 
dips to lower dopamine levels sufficiently to respond adequately to signal a punishment 
(or reward omission). Indeed, computational [54] as well as experimental work [1, 55] has 
shown that the impairing effects of dopaminergic medication on learning are specific to 
the punishment condition. Following this line of reasoning, it is possible that effects of 
dopaminergic medication on learning are more easily induced by the administration and/
or withdrawal of dopamine receptor agonists than levodopa. Indeed, impairing effects of 
dopaminergic medication on punishment learning have been shown primarily with the 
use of dopamine receptor agonists [1, 55]. In contrast to previous studies, in my patient 
sample only a small proportion of patients used dopamine receptor agonists, potentially 
explaining the absence of a drug effect on valence specific reversal learning in chapter 
3. But does this explain why there was an association between dopaminergic medication 
dose (which is a compound measure of all types of dopaminergic medication) and reversal 
learning impairment as described in chapter 4? Hypothetically yes. First of all, the sample 
size in which I observed this effect was very large, as such the power to find an effect was 
much larger. Moreover, it is very likely that the presynaptic reuptake capacity of dopamine 
(derived from levodopa) decreases with increasing Parkinson’s disease severity due to 
more severe degeneration of presynaptic dopaminergic neurons. If reuptake is limited, 
then increases in levodopa medication dose would (eventually) lead to increases in tonic 
dopamine levels and subsequent impairment in (punishment) learning. This still leaves 
two questions. Why was there an effect of dopaminergic medication on risky choice in 
chapter 5? And why was there no effect of dopaminergic medication on reward motivated 
cognitive control in chapter 6? 
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To start with the latter, there are several possible explanations. First of all, it is possible 
that the effect the task aimed to measure, i.e. the interaction between ventral and dorsal 
cortico-striatal cognitive function, is not dopamine sensitive. However, this is not very 
likely. Ample evidence exists for a role of striatal dopamine in reward motivated cognitive 
control (for a review see [44]). Moreover, previous studies in Parkinson’s disease did find 
an effect of dopaminergic medication on the interaction between reward motivation and 
physical effort [56-58]. Another potential explanation is that the effect of dopaminergic 
medication on reward motivated cognitive control depends on genetic variants, e.g. in the 
dopamine transporter (DAT) gene. Studies in healthy individuals and patients with ADHD 
showed that dopaminergic medication effects on reward motivated cognitive control, 
assessed with the exact same paradigm, depend on polymorphisms in the DAT gene [59, 
60]. Polymorphisms in this gene putatively affect synaptic (i.e. tonic) striatal dopamine 
levels [61, 62]. Although this has not been tested in Parkinson’s disease yet, it is possible 
that dopaminergic medication effects on reward motivated cognitive control depend on 
individual genetic variation in the dopamine pathway. Lastly, in the discussion section 
of chapter 6 I raised the hypothesis that specifically tonic dopamine levels might be 
important for motivated cognitive control. This hypothesis was inspired by opportunity 
cost accounts of tonic dopamine’s role in motivating vigor (physical effort) [63] as well as 
cognitive control [64, 65] and states that tonic dopamine levels presumably reflect a net 
average reward rate of the environment against which rewards are compared. If tonic 
dopamine levels are low, a reward is subjectively more valuable (and worth the effort), 
whereas when tonic dopamine levels are high, a reward is subjectively less valuable. Such 
a hypothesis indirectly implies that specifically manipulations of tonic striatal dopamine 
levels could affect the effect of reward motivation on physical effort and/or cognitive 
control. As outlined above, it is possible that the dopaminergic manipulation in the present 
study was ineffective to affect tonic striatal dopamine levels sufficiently.
But then, what was the nature of the dopaminergic medication effect that I observed on 
risky choice in chapter 5? In chapter 5 I used a computational approach to disentangle 
the mechanisms by which dopaminergic medication increases risky choice and found 
that dopaminergic medication increased a value-independent gambling bias in non-
depressed patients. This finding is in line with previous findings in healthy controls showing 
that levodopa increases a value-independent gambling propensity and as such further 
strengthens this concept [8, 9]. The mechanism underlying this effect, however, so far 
remains unclear. Following other people, I speculate that this nonspecific attraction to 
gambling might arise from an exploration bonus associated with surprising outcomes that 
potentiates information, sensation- and novelty seeking [8, 9, 66-68], but this issue clearly 
requires further research. 
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The overdose hypothesis 
Several of the hypotheses tested in this thesis were grounded in work that led to the 
development of the overdose hypothesis. According to this hypothesis, dopaminergic 
medication doses necessary to remedy the severely dopamine depleted dorsal cortico-
striatal circuit and associated motor and cognitive function, might detrimentally overdose 
relatively intact dopamine levels in the ventral cortico-striatal circuit and impair associated 
cognitive function [3, 5]. Based on this hypothesis I expected that detrimental effects of 
dopaminergic medication would be restricted to patients with putatively intact ventral striatal 
dopamine levels (i.e. the non-depressed patients). However, in chapter 4 and in chapter 5, 
I observed that (detrimental) effects of dopaminergic medication were in fact greater in 
patients with higher current depression ratings. In chapter 4 I showed that detrimental 
effects of dopaminergic medication dose on reversal learning were mediated by current 
depression severity. Patients with the highest current depression ratings exhibited the 
greatest detrimental effects of dopaminergic medication on reversal learning. In chapter 5 
I showed that patients with the highest current depression ratings exhibit the greatest 
dopamine-induced decreases in loss aversion (although in this experiment it did not actually 
have consequences for risky choice, which might represent a less sensitive behavioural 
outcome measure). In clinical practice, detrimental (overdosing) effects of dopaminergic 
medication have been argued to underlie dopamine-induced impulse control disorders [7, 
69]. Intriguingly, in large clinical samples it has been shown that higher current depression 
severity is one of the strongest predictors of exhibiting an impulse control disorder [46, 
70, 71]. This suggests that detrimental (overdosing) effects of dopaminergic medication 
on cognition are seemingly more likely to occur in patients with concurrent depression. 
How to reconcile this enhanced vulnerability to detrimental (assumed overdosing) effects 
of dopaminergic medication in depression with evidence suggesting that depression in 
Parkinson’s disease reflects (ventral) striatal dopamine deficiency? The exact mechanisms 
remain to be established. One possibility is that depression is accompanied by impaired auto-
regulation of striatal dopamine levels. Tonic dopamine levels in the striatum are regulated 
by auto-regulatory mechanisms, such as the dopamine D2/D3 auto-receptor and the 
presynaptic dopamine transporter (DAT). Depression in Parkinson’s disease is accompanied 
by decreased striatal DAT [21, 27-29] and decreased D2/D3 receptor availability [72]. As such, 
the hypodopaminergic state of depression in Parkinson’s disease might well be accompanied 
by deficient auto-regulatory mechanisms, rendering depressed patients more susceptible to 
overdosing effects. An alternative possibility, given the implication of serotonin in depression, 
is that the detrimental effects of dopaminergic medication reflect maladaptive interaction 
between dopaminergic medication and deficient serotonin transmission. This maladaptive 
interaction can occur both at the cellular as well as the neuronal network level [73-76]. 
At the cellular level at least two mechanisms seem to play a role: (i) Striatal serotonergic 
neurons can convert levodopa, the dopamine precursor, to dopamine [77]. And (ii) serotonin 
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transporters have affinity for dopamine reuptake, especially when dopamine transporters 
(DAT) are scant, such as in Parkinson’s disease [78]. These “compensatory” mechanisms lead 
to aberrant striatal dopamine release via serotonergic neurons which has been argued to 
contribute to the development of dyskinesias in Parkinson’s disease – the motor analogue 
of detrimental “overdosing” by dopaminergic medication [69, 76, 79-81]. At the neuronal 
network level, the serotonergic and dopaminergic systems are tightly coupled. Dopaminergic 
neurons in the ventral tegmental area, the substantia nigra, the nucleus accumbens and 
the caudate nucleus receive dense serotonergic projections [74, 76, 82]. Ample evidence 
exists that serotonin regulates striatal (tonic) dopamine, mainly via tonic inhibition [82-87]. 
As such, putative changes in the serotonergic system in depression can indirectly affect the 
dopaminergic system and its reaction to dopaminergic medication. In this light it should also 
be discussed that serotonergic acting agents, such as SSRIs (serotonin reuptake inhibitors) 
which are frequently used in depression, potentially interact with dopaminergic medication 
effects on cognition. This should be taken into account when investigating dopaminergic 
medication effects on cognition. Unfortunately, in the study described in chapter 4 data 
regarding the use of antidepressants was lacking, therefore, I was unable to control for 
this. In the study described in chapter 5, I used non-parametric statistics making it hard 
to control for other factors, such as the use of antidepressants. This is a potential caveat 
of both studies (see also “Methodological weaknesses and strengths). Future research is 
necessary to elucidate whether a maladaptive interaction between dopaminergic medication 
and aberrant serotonin transmission plays a role in the enhanced vulnerability of depressed 
patients to the detrimental (assumed overdosing) effects of dopaminergic medication on 
cognition in Parkinson’s disease. 
In sum, together with previous observations from clinical practice, our findings suggest 
that specifically patients with a dysfunctional ventral striatum (i.e. patients who suffer from 
depression), and not patients with a putatively intact ventral striatum, are more vulnerable to 
experience detrimental (or overdosing) effects of dopaminergic medication. These findings 
highlight the need for stricter monitoring of detrimental effects of dopaminergic medication 
on cognition in patients with Parkinson’s disease and concurrent depression. 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 174
Chapter 7
174
Methodological weaknesses and strengths
As every other research project, the studies described in this thesis have their strengths 
and weaknesses. There are several general limitations related to the studies described in 
chapter 3, chapter 5 and chapter 6. First of all, the design of these studies was not optimized 
to compare patient data with healthy control data as healthy controls were only assessed 
once and patients twice (ON and OFF medication). In chapter 3 and chapter 6, due to the 
absence of a drug effect in patients, I was able to compare patient data with healthy control 
data by averaging patient data across the two drug sessions. However, specifically in chapter 
5, where I observed effects of dopaminergic medication, I had to compare ON and OFF data 
of patients separately with healthy control data, which led to multiple comparisons. Moreover, 
healthy control data were obtained from a separate fitting procedure with different priors 
than patient data. As such, the comparisons of patients’ data with healthy control data should 
be interpreted with caution. A second limitation of the design was the heterogeneity of the 
depressed patient group, which included both patients with past and present depression. 
This heterogeneity led to interpretation difficulties, making it hard to make solid statements 
about whether differences observed between non-depressed patients and patients with 
a depression (history) reflected state (i.e. current depression) or trait (i.e. depression 
vulnerability) effects. And lastly, reflecting clinical practice, the patient sample described in 
chapters 3, 5 and 6, used different types of dopaminergic medication. This heterogeneity 
might have contributed to the mixed effects of dopaminergic medication I observed 
throughout these chapters (see also above). With respect to the study described in chapter 
4, several limitations should be acknowledged. First of all, patients were only assessed ON 
dopaminergic medication. As such, I could only perform correlation analyses assessing 
the effect of dopaminergic dose on cognitive function, rather than comparing ON and OFF 
effects in an within-subject design. Moreover, previous studies revealed that dopaminergic 
medication specifically impairs punishment-learning [2, 3]. The task employed in chapter 4 
lacked the possibility to disentangle whether detrimental effects of dopaminergic medication 
were valence-specific, leaving this question open for further research. The other caveat of 
the study described in chapter 4 is the lack of data regarding the use of antidepressants in 
depressed patients. As outlined above, I cannot exclude the possibility that the observed 
detrimental effects of dopaminergic medication on reversal learning in depressed patients 
reflect a maladaptive interaction between dopaminergic medication and deficient serotonin 
transmission. Future studies assessing dopaminergic medication effects on cognition in 
depression in Parkinson’s disease should take into account (and/or control for) the use of 
serotonergic acting agents. 
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There are also strengths to acknowledge of the work presented in this thesis. One key 
strength of the work presented in this thesis is the complementariness of the described 
studies in chapter 3, 4, 5 and 6, which are all based on the same general concepts, namely: 
(1) the concept that depression in Parkinson’s disease is a neurocognitive disorder that 
reflects, among other things, (ventral) striatal dopamine deficiency; (2) the role of (striatal) 
dopamine in the effects of dopaminergic medication on cognition in Parkinson’s disease; 
and (3) the dopamine overdose hypothesis to account for paradoxical cognitive effects of 
medication in Parkinson’s disease. This enabled me to interpret effects of a depression 
(history) diagnosis and dopaminergic medication on (valence-specific) cognition in a broader 
perspective. Another strength, although also a weakness (see above), is the heterogeneity of 
the depressed patient group in the studies described in chapter 3, 5 and 6. Specifically this 
heterogeneity allowed me to assess the effects of depression severity on (dopaminergic drug 
effects) on cognition. A clear strength of the work presented in chapter 4 is the very large 
sample size, which increases the confidentiality and reproducibility of the observed findings. 
And lastly, while the work in chapter 3, 4, 5 and 6 contributes to enhanced understanding of 
mechanisms contributing to depression in Parkinson’s disease, ultimately aiming to improve 
adequate diagnosis, treatment and maybe even prevention of depression in Parkinson’s 
disease in the future, the work presented in chapter 2 contributes to improving adequate 
recognition and treatment of depression in Parkinson’s disease in current clinical practice, 
enhancing quality of life in patients and caregivers of patients who currently suffer from 
depression. 
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Future perspectives and challenges
In this thesis I have investigated the role of dopamine and reward (and punishment) 
processing across various aspects of cognition in depression in Parkinson’s disease. The 
work contributes to elucidating the mechanisms underlying depression in Parkinson’s 
disease. However, a lot still remains unknown. First of all, as outlined above, the mixed 
effects of the dopaminergic withdrawal procedure on the various tasks throughout this 
thesis presumably reflect the different types of dopaminergic medication that patients 
used. Levodopa and dopamine receptor agonists putatively affect various aspects of 
reward processing in a different manner, due to subtle difference in mechanisms of action. 
As such, future research should take into account these different types of dopaminergic 
medication (and their presumed mechanism of action) when investigating reward processing 
(in Parkinson’s disease). Secondly, the work presented in this thesis suggests that dopamine 
sensitive negative affective biases play a role in depression in Parkinson’s disease. The study 
in chapter 3 revealed that Parkinson’s disease patients with a depression (history) have 
impaired reward (versus punishment) reversal learning and the study in chapter 5 revealed 
a tendency towards enhanced loss aversion in depressed patients. Whereas the latter was 
shown to be dopamine sensitive, the (surprising) absence of a drug effect on valence-specific 
reversal learning in chapter 3 still leaves us with the question whether impairments in reward 
learning in depression in Parkinson’s disease are dopamine sensitive (maybe only to dopamine 
receptor agonists?). And subsequently, whether dopamine-induced changes in loss aversion 
and/or reward learning are the underlying mechanism via which dopaminergic agents exert 
their antidepressant effect. This raises the question whether the antidepressant effect, and 
the putative underlying mechanism of action, of levodopa and dopamine receptor agonists 
is comparable. Thus far, no clinical trials have been done comparing the effect of levodopa 
and dopamine receptor agonists on depression in Parkinson’s disease. Thirdly, the work 
presented in this thesis suggests that Parkinson’s disease patients who suffer from depression 
are more likely to experience detrimental effects of dopaminergic medication on cognition 
(see chapter 4 and 5). Future research is necessary to substantiate this and to elucidate 
the mechanisms underlying these detrimental effects. I proposed a presynaptic, disturbed 
auto-regulatory mechanism to account for this. However, also post-synaptic changes and 
effects of other neurotransmitter systems on dopamine’s neurotransmission are likely to play 
a role. To disentangle this, requires extensive (big data) research, for instance via assessing 
effects of different pharmacological manipulations (modulating different neurotransmitter 
systems) on various aspects of cognition combined with nuclear neuroimaging techniques 
(that enable us to investigate neurotransmitter synthesis capacity, reuptake capacity, etc) 
and neurogenetics (assessing effects of different neurotransmitter reuptake transporter and 
receptor phenotypes). Finally, the greatest challenge is to bridge the gap between cognitive 
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neuroscience and clinical practice. The work presented in chapter 3, 4, 5 and 6 contributes 
to enhancing our knowledge of (dopamine’s role) in various reward processes and how this 
is affected by depression in Parkinson’s disease. This, however, does not directly help to 
improve treatment of (or prevent) depression in patients with Parkinson’s disease. However, 
in the future, neuroscience might help to predict treatment response early in the course 
of treatment; predicting who will benefit from what type of medication to treat depression 
as well as predicting possible adverse events, such as detrimental (“overdosing”) effects 
on cognition. Indeed, a few studies in depressed individuals (without Parkinson’s disease) 
revealed that the response to antidepressants based on affective processing biases before 
commencement of treatment could be predicted based on neural activity (as measured with 
fMRI) during the processing of negative stimuli [88, 89]. Moreover, behaviourally, it has been 
shown that the effect of antidepressants after 6 weeks of treatment could be predicted by 
its effect on affective processing after only 2 weeks of treatment [90]. Although evidence 
is still scarce and more research is needed, these studies show promising results of how 
clinical practice might benefit from neuroscience in the future.   
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Box 1. Apathy
One other frequent symptom of both Parkinson’s disease and depression which should be 
discussed in light of the findings presented in this thesis is apathy. The prevalence of apathy 
in Parkinson’s disease varies between 20 and 60%, depending on disease severity (increasing 
with increasing disease severity) [91, 92]. Apathy can occur in isolation, but is also a well-known 
accompaniment of depression. The key difference between apathy and depression is the 
lack of suffering in apathetic patients. For a comprehensive review on apathy in Parkinson’s 
disease, please see [92]. 
The definition of apathy has changed over time, but one common feature is apathy as a 
disorder of motivation [93-95]. As outlined in the introduction, the mesocorticolimbic dopamine 
system plays a key role in (incentive) motivation. As such, is it not surprising, that also apathy, 
like depression in Parkinson’s disease, has been linked to abnormalities in this neurocircuitry 
[20, 94]. For instance, degeneration of dopaminergic neurons in the ventral striatum have been 
shown to correlate with apathy severity in patients with Parkinson’s disease [21]. Moreover, 
structural imaging in Parkinson’s disease patients revealed that apathy was associated with 
more pronounced nucleus accumbens atrophy [96] and nuclear neuro-imaging revealed that 
apathetic Parkinson’s disease patients exhibit decreased responsiveness to monetary gains 
in an extensive circuit grossly overlapping the ventral cortico-striatal circuit [97]. Finally, like 
depression, also apathy can be seen during OFF periods in patients with Parkinson’s disease 
and motor fluctuations [23].  
While the research in this thesis aimed to investigate the neurocognitive mechanisms 
underlying depression in Parkinson’s disease, it is possible that some of the findings reflect 
apathy (as feature of depression). I measured apathy (during the ON state) in patients with 
Parkinson’s disease using the apathy scale - the recommended scale to assess apathy in 
Parkinson’s disease [98]. Not surprisingly, apathy scores and depression scores correlated 
(r(43)=.387, p=0.009). It would be interesting in future work to assess which aspects of cognition 
are specifically related to apathy and which to depression.  
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 179
Summary and discussion
179
07
References
1. Cools, Altamirano, and D’Esposito, Reversal learning in Parkinson’s disease depends on medication 
status and outcome valence. Neuropsychologia, 2006. 44(10): p. 1663-1673.
2. Frank, M.J., L.C. Seeberger, and R.C. O’Reilly, By carrot or by stick: Cognitive reinforcement learning 
in Parkinsonism. Science, 2004. 306(5703): p. 1940-1943.
3. Cools, R., et al., Enhanced or impaired cognitive function in Parkinson’s disease as a function of 
dopaminergic medication and task demands. Cerebral Cortex, 2001. 11(12): p. 1136-1143.
4. Swainson, R., et al., Probabilistic learning and reversal deficits in patients with Parkinson’s 
disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. 
Neuropsychologia, 2000. 38(5): p. 596-612.
5. Gotham, A.M., R.G. Brown, and C.D. Marsden, Frontal cognitive function in patients with Parkinsons 
Disease ON and OFF levodopa. Brain, 1988. 111: p. 299-321.
6. Weintraub, D., et al., Impulse Control Disorders in Parkinson Disease A Cross-Sectional Study of 
3090 Patients. Archives of Neurology, 2010. 67(5): p. 589-595.
7. Voon, V., A.R. Mehta, and M. Hallett, Impulse control disorders in Parkinson’s disease: recent 
advances. Current Opinion in Neurology, 2011. 24(4): p. 324-330.
8. Rigoli, F., et al., Dopamine Increases a Value-Independent Gambling Propensity. 
Neuropsychopharmacology, 2016. 41(11): p. 2658-2667.
9. Rutledge, R.B., et al., Dopaminergic Modulation of Decision Making and Subjective Well-Being. 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015. 35(27): p. 
9811-22.
10. Aarts, E., et al., Aberrant reward processing in Parkinson’s disease is associated with dopamine 
cell loss. Neuroimage, 2011.
11. Roiser, J.P., R. Elliott, and B.J. Sahakian, Cognitive mechanisms of treatment in depression. 
Neuropsychopharmacology, 2012. 37(1): p. 117-36.
12. Harmer, C.J., G.M. Goodwin, and P.J. Cowen, Why do antidepressants take so long to work? A 
cognitive neuropsychological model of antidepressant drug action. British Journal of Psychiatry, 
2009. 195(2): p. 102-108.
13. Clark, L., S.R. Chamberlain, and B.J. Sahakian, Neurocognitive Mechanisms in Depression: 
Implications for Treatment, in Annual Review of Neuroscience. 2009. p. 57-74.
14. Murphy, F.C., et al., Neuropsychological impairment in patients with major depressive disorder: the 
effects of feedback on task performance. Psychological Medicine, 2003. 33(3): p. 455-467.
15. Robinson, O.J., et al., Ventral Striatum Response During Reward and Punishment Reversal Learning 
in Unmedicated Major Depressive Disorder. Am J Psychiatry, 2011.
16. Taylor Tavares, J.V., et al., Neural basis of abnormal response to negative feedback in unmedicated 
mood disorders. Neuroimage, 2008. 42(3): p. 1118-26.
17. Smoski, M.J., et al., Decision-making and risk aversion among depressive adults. Journal of 
Behavior Therapy and Experimental Psychiatry, 2008. 39(4): p. 567-576.
18. Cella, M., S. Dymond, and A. Cooper, Impaired flexible decision-making in major depressive 
disorder. Journal of Affective Disorders, 2010. 124(1-2): p. 207-210.
19. Maddox, W.T., et al., Depressive symptoms enhance loss-minimization, but attenuate gain-
maximization in history-dependent decision-making. Cognition, 2012. 125(1): p. 118-124.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 180
Chapter 7
180
20. Martens, K.A.E. and S.J.G. Lewis, Pathology of behavior in PD: What is known and what is not? 
Journal of the Neurological Sciences, 2017. 374: p. 9-16.
21. Remy, P., et al., Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation 
in the limbic system. Brain, 2005. 128: p. 1314-1322.
22. Paulus, W. and K. Jellinger, The neuropathological basis of different clinical subgroups of Parkinsons 
Disease. Journal of Neuropathology and Experimental Neurology, 1991. 50(6): p. 743-755.
23. Classen, J., et al., Nonmotor fluctuations: phenotypes, pathophysiology, management, and open 
issues. Journal of Neural Transmission, 2017. 124(8): p. 1029-1036.
24. Richard, I.H., A.W. Justus, and R. Kurlan, Relationship between mood and motor fluctuations in 
Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001. 13(1): p. 35-41.
25. Barone, P., et al., Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s 
disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, 2010. 9(6): p. 573-
580.
26. Seppi, K., et al., The Movement Disorder Society Evidence-Based Medicine Review Update: 
Treatments for the Non-Motor Symptoms of Parkinson’s Disease. Movement Disorders, 2011. 26: 
p. S42-S80.
27. Weintraub, D., et al., Striatal dopamine transporter imaging correlates with anxiety and depression 
symptoms in Parkinson’s disease. Journal of Nuclear Medicine, 2005. 46(2): p. 227-232.
28. Vriend, C., et al., Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT 
binding in the caudate nucleus. J Neurol Neurosurg Psychiatry, 2013.
29. Rektorova, I., et al., Striatal dopamine transporter Imaging correlates with depressive symptoms 
and Tower of London task performance in Parkinson’s disease. Movement Disorders, 2008. 23(11): 
p. 1580-1587.
30. Felicio, A.C., et al., Higher dopamine transporter density in Parkinson’s disease patients with 
depression. Psychopharmacology, 2010. 211(1): p. 27-31.
31. Ceravolo, R., et al., Mild affective symptoms in de novo Parkinson’s disease patients: relationship 
with dopaminergic dysfunction. European Journal of Neurology, 2013. 20(3): p. 480-485.
32. van der Schaaf, M.E., et al., Establishing the dopamine dependency of human striatal signals during 
reward and punishment reversal learning. Cereb Cortex, 2014. 24(3): p. 633-42.
33. Smittenaar, P., et al., Decomposing effects of dopaminergic medication in Parkinson’s disease on 
probabilistic action selection - learning or performance? European Journal of Neuroscience, 2012. 
35(7): p. 1144-1151.
34. Shiner, T., et al., Dopamine and performance in a reinforcement learning task: evidence from 
Parkinson’s disease. Brain, 2012. 135: p. 1871-1883.
35. Collins, A.G.E. and M.J. Frank, Opponent Actor Learning (OpAL): Modeling Interactive Effects of 
Striatal Dopamine on Reinforcement Learning and Choice Incentive. Psychological Review, 2014. 
121(3): p. 337-366.
36. Henriques, J.B. and R.J. Davidson, Decreased responsiveness to reward in depression. Cognition 
& Emotion, 2000. 14(5): p. 711-724.
37. Knutson, B., et al., Neural responses to monetary incentives in major depression. Biological 
Psychiatry, 2008. 63(7): p. 686-692.
38. Yang, X.H., et al., Motivational deficits in effort-based decision making in individuals with 
subsyndromal depression, first-episode and remitted depression patients. Psychiatry Research, 
2014. 220(3): p. 874-882.
39. Treadway, M.T., et al., Worth the ‘EEfRT’? The Effort Expenditure for Rewards Task as an Objective 
Measure of Motivation and Anhedonia. Plos One, 2009. 4(8).
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 181
Summary and discussion
181
07
40. Olino, T.M., et al., Reduced reward anticipation in youth at high-risk for unipolar depression: A 
preliminary study. Developmental Cognitive Neuroscience, 2014. 8: p. 55-64.
41. Aarts, E., et al., Dopamine and the cognitive downside of a promised bonus. Psychological science, 
2014. 25(4): p. 1003-9.
42. Henriques, J.B., J.M. Glowacki, and R.J. Davidson, REWARD FAILS TO ALTER RESPONSE BIAS IN 
DEPRESSION. Journal of Abnormal Psychology, 1994. 103(3): p. 460-466.
43. Stoy, M., et al., Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated 
depressed patients normalizes after treatment with escitalopram. Journal of Psychopharmacology, 
2012. 26(5): p. 677-688.
44. Aarts, E., M. van Holstein, and R. Cools, Striatal dopamine and the interface between motivation 
and cognition. Frontiers in Psychology, 2011. 2.
45. Haber, S.N., J.L. Fudge, and N.R. McFarland, Striatonigrostriatal pathways in primates form an 
ascending spiral from the shell to the dorsolateral striatum. Journal of Neuroscience, 2000. 20(6): 
p. 2369-2382.
46. Joutsa, J., et al., Impulse control disorders and depression in Finnish patients with Parkinson’s 
disease. Parkinsonism & Related Disorders, 2012. 18(2): p. 155-160.
47. Cools, R., et al., L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in 
patients with Parkinson’s disease. Journal of Psychopharmacology, 2003. 17(3): p. A57-A57.
48. Bodi, N., et al., Reward-learning and the novelty-seeking personality: a between- and within-
subjects study of the effects of dopamine agonists on young Parkinsons patients. Brain, 2009. 
132: p. 2385-2395.
49. Moustafa, A.A., et al., A Role for Dopamine in Temporal Decision Making and Reward Maximization 
in Parkinsonism. Journal of Neuroscience, 2008. 28(47): p. 12294-12304.
50. Kobza, S., et al., Dissociation between Active and Observational Learning from Positive and 
Negative Feedback in Parkinsonism. Plos One, 2012. 7(11).
51. Palminteri, S., et al., Pharmacological modulation of subliminal learning in Parkinson’s and Tourette’s 
syndromes. Proceedings of the National Academy of Sciences of the United States of America, 
2009. 106(45): p. 19179-19184.
52. Koller, W.C. and M.C. Rueda, Mechanism of action of dopaminergic agents in Parkinson’s disease. 
Neurology, 1998. 50(6): p. S11-S14.
53. Martins, D., M.A. Mehta, and D. Prata, The “highs and lows” of the human brain on dopaminergics: 
Evidence from neuropharmacology. Neuroscience and Biobehavioral Reviews, 2017. 80: p. 351-371.
54. Frank, M.J., Dynamic dopamine modulation in the basal ganglia: A neurocomputational account of 
cognitive deficits in medicated and nonmedicated Parkinsonism. Journal of Cognitive Neuroscience, 
2005. 17(1): p. 51-72.
55. van Eimeren, T., et al., Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: 
A Trigger for Pathological Gambling in Parkinson’s Disease? Neuropsychopharmacology, 2009. 
34(13): p. 2758-2766.
56. Chong, T.T.J., et al., Dopamine enhances willingness to exert effort for reward in Parkinson’s 
disease. Cortex, 2015. 69: p. 40-46.
57. Le Bouc, R., et al., Computational Dissection of Dopamine Motor and Motivational Functions in 
Humans. Journal of Neuroscience, 2016. 36(25): p. 6623-6633.
58. Porat, O., et al., Asymmetric dopamine loss differentially affects effort to maximize gain or minimize 
loss. Cortex, 2014. 51: p. 82-91.
59. van Holstein, M., et al., Human cognitive flexibility depends on dopamine D2 receptor signaling. 
Psychopharmacology (Berl), 2011. 218(3): p. 567-78.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 182
Chapter 7
182
60. Aarts, E., et al., Reward modulation of cognitive function in adult attention-deficit/hyperactivity 
disorder: a pilot study on the role of striatal dopamine. Behavioural Pharmacology, 2015. 26(1-2): 
p. 227-240.
61. Fuke, S., et al., The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects 
gene expression. The pharmacogenomics journal, 2001. 1(2): p. 152-6.
62. Heinz, A., et al., Genotype influences in vivo dopamine transporter availability in human striatum. 
Neuropsychopharmacology, 2000. 22(2): p. 133-139.
63. Niv, Y., et al., Tonic dopamine: opportunity costs and the control of response vigor. 
Psychopharmacology, 2007. 191(3): p. 507-20.
64. Boureau, Y.L., P. Sokol-Hessner, and N.D. Daw, Deciding How To Decide: Self-Control and Meta-
Decision Making. Trends in Cognitive Sciences, 2015. 19(11): p. 700-710.
65. Kurzban, R., et al., An opportunity cost model of subjective effort and task performance. Behavioral 
and Brain Sciences, 2013. 36(6): p. 661-679.
66. Kakade, S. and P. Dayan, Dopamine: generalization and bonuses. Neural Networks, 2002. 15(4-6): 
p. 549-559.
67. Friston, K.J., et al., The anatomy of choice: active inference and agency. Frontiers in Human 
Neuroscience, 2013. 7.
68. Norbury, A., et al., Dopamine Modulates Risk-Taking as a Function of Baseline Sensation-Seeking 
Trait. Journal of Neuroscience, 2013. 33(32): p. 12982-12986.
69. Voon, V., et al., Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: 
an update. Lancet Neurology, 2017. 16(3): p. 238-250.
70. Voon, V., et al., Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study. 
Annals of Neurology, 2011. 69(6): p. 986-996.
71. Pontone, G., et al., Clinical features associated with impulse control disorders in Parkinson disease. 
Neurology, 2006. 67(7): p. 1258-1261.
72. Boileau, I., et al., Decreased binding of the D-3 dopamine receptor-preferring ligand C-11 -()-PHNO 
in drug-nave Parkinsons disease. Brain, 2009. 132: p. 1366-1375.
73. Jaunarajs, K.L.E., et al., Potential mechanisms underlying anxiety and depression in Parkinson’s 
disease: Consequences of L-DOPA treatment. Neuroscience and Biobehavioral Reviews, 2011. 
35(3): p. 556-564.
74. Proulx, C.D., O. Hikosaka, and R. Malinow, Reward processing by the lateral habenula in normal 
and depressive behaviors. Nature Neuroscience, 2014. 17(9): p. 1146-1152.
75. Shabel, S.J., et al., Input to the Lateral Habenula from the Basal Ganglia Is Excitatory, Aversive, and 
Suppressed by Serotonin. Neuron, 2012. 74(3): p. 475-481.
76. De Deurwaerdere, P., G. Di Giovanni, and M.J. Millan, Expanding the repertoire of L-DOPA’s actions: 
A comprehensive review of its functional neurochemistry. Progress in Neurobiology, 2017. 151: p. 
57-100.
77. Arai, R., et al., Immunohistochemical evidence that central serotonin neurons produce dopamine 
from exogenous L-dopa in the rat, with reference to the involvement of aromatic L-amino-acid-
decarboxylase. Brain Research, 1994. 667(2): p. 295-299.
78. Kannari, K., et al., Reuptake of L-DOPA-derived extracellular dopamine in the striatum with 
dopaminergic denervation via serotonin transporters. Neuroscience Letters, 2006. 402(1-2): p. 
62-65.
79. Politis, M., et al., Serotonergic mechanisms responsible for levodopa-induced dyskinesias in 
Parkinson’s disease patients. Journal of Clinical Investigation, 2014. 124(3): p. 1340-1349.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 183
Summary and discussion
183
07
80. Rylander, D., et al., Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced 
Dyskinesia. Annals of Neurology, 2010. 68(5): p. 619-628.
81. Carta, M., et al., Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia 
in Parkinsonian rats. Brain, 2007. 130: p. 1819-1833.
82. Boureau, Y.L. and P. Dayan, Opponency Revisited: Competition and Cooperation Between 
Dopamine and Serotonin. Neuropsychopharmacology, 2011. 36(1): p. 74-97.
83. Esposito, E., V. Di Matteo, and G. Di Giovanni, Serotonin-dopamine interaction: an overview, in 
Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance, G. DiGiovanni, 
V. DiMatteo, and E. Esposito, Editors. 2008. p. 3-6.
84. Navailles, S., et al., In vivo evidence that 5-HT2C receptor antagonist but not agonist 
modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. 
Neuropsychopharmacology, 2004. 29(2): p. 319-326.
85. De Deurwaerdere, P., et al., Constitutive activity of the serotonin2c receptor inhibits in vivo 
dopamine release in the rat striatum and nucleus accumbens. Journal of Neuroscience, 2004. 
24(13): p. 3235-3241.
86. Herve, D., et al., Opposite changes in dopamine utilization in the Nucleus Accumbens and the 
frontal-cortex after electrolytic lesion of the median Raphe in the rat. Brain Research, 1981. 216(2): 
p. 422-428.
87. Herve, D., et al., Increased utilatzation of dopamine in the Nucleus Accumbens but not in the 
cerebral-cortex after dorsal Raphe lesion in the rat. Neuroscience Letters, 1979. 15(2-3): p. 127-133.
88. Chen, C.H., et al., Brain imaging correlates of depressive symptom severity and predictors of 
symptom improvement after antidepressant treatment. Biological Psychiatry, 2007. 62(5): p. 407-
414.
89. Davidson, R.J., et al., The neural substrates of affective processing in depressed patients treated 
with venlafaxine. American Journal of Psychiatry, 2003. 160(1): p. 64-75.
90. Tranter, R., et al., The effect of serotonergic and noradrenergic antidepressants on face emotion 
processing in depressed patients. Journal of Affective Disorders, 2009. 118(1-3): p. 87-93.
91. den Brok, M., et al., Apathy in Parkinson’s disease: A systematic review and meta-analysis. 
Movement Disorders, 2015. 30(6): p. 759-769.
92. Pagonabarraga, J., et al., Apathy in Parkinson’s disease: clinical features, neural substrates, 
diagnosis, and treatment. Lancet Neurology, 2015. 14(5): p. 518-531.
93. Marin, R.S., Apathy – a neuropsychiatric syndrome. Journal of Neuropsychiatry and Clinical 
Neurosciences, 1991. 3(3): p. 243-254.
94. Chong, T.T.J. and M. Husain, The role of dopamine in the pathophysiology and treatment of apathy. 
Progress in Brain Research, 2016. 229: p. 389-426.
95. Starkstein, S.E. and A.F.G. Leentjens, The nosological position of apathy in clinical practice. Journal 
of Neurology Neurosurgery and Psychiatry, 2008. 79(10): p. 1088-1092.
96. Carriere, N., et al., Apathy in Parkinson’s Disease Is Associated With Nucleus Accumbens Atrophy: 
A Magnetic Resonance Imaging Shape Analysis. Movement Disorders, 2014. 29(7): p. 897-903.
97. Lawrence, A.D., I.K. Goerendt, and D.J. Brooks, Apathy blunts neural response to money in 
Parkinson’s disease. Social Neuroscience, 2011. 6(5-6): p. 653-662.
98. Leentjens, A.F.G., et al., Apathy and Anhedonia Rating Scales in Parkinson’s Disease: Critique and 
Recommendations. Movement Disorders, 2008. 23(14): p. 2004-2014.
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 184
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 185
Appendix
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 186
01
Appendix
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 187
Nederlandse samenvatting 
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 188
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 189
Nederlandse samenvatting / Dutch summary
189
A
Nederlandse samenvatting 
De ziekte van Parkinson is een veel voorkomende hersenziekte. Bij de ziekte van 
Parkinson sterven de dopamine producerende cellen in de substantia nigra af, wat leidt 
tot een dopamine tekort in het striatum – een groep hersenkernen diep in de hersenen. 
Door dit dopamine tekort ontstaan de motore verschijnselen die de ziekte van Parkinson 
kenmerken, zoals traagheid en stijfheid. Naast problemen met het bewegen ervaren 
veel patiënten ook niet-motorische problemen, waaronder psychische veranderingen. 
Depressie is één van de meest voorkomende niet-motorische problemen van de ziekte 
van Parkinson en heeft een enorme invloed op de kwaliteit van leven van patiënten en 
hun naasten. 
Welke hersenmechanismen een rol spelen bij het ontstaan van depressieve klachten bij de 
ziekte van Parkinson is nog niet volledig bekend. De onderzoeken in dit proefschrift richten 
zich op depressie bij de ziekte van Parkinson, waarbij de focus ligt op cognitieve (denk) 
processen die een rol spelen bij depressie en waarvan bekend is dat de neurotransmitter 
dopamine een belangrijke rol speelt. 
Hoe wij informatie verwerken hangt sterk samen met hoe wij ons voelen. Mensen die last 
hebben van een depressieve stemming verwerken informatie op een verstoorde manier. 
De verwerking van negatieve informatie is versterkt, terwijl de verwerking van positieve 
informatie verminderd is. Dit worden negatieve affectieve biases genoemd. Deze negatieve 
affectieve biases bij depressie worden gezien op verschillende cognitieve vlakken, zoals 
bij het herkennen van emoties, het emotionele geheugen en het verwerken van straf en 
beloning tijdens bijvoorbeeld leer- en besluitvormingsprocessen. Er wordt gedacht dat 
negatieve affectieve biases een belangrijke rol spelen bij het ontstaan, het in standhouden 
en het behandelen van een depressie. Specifiek dopamine in het striatum - het gebied waar 
bij mensen met de ziekte van Parkinson een tekort aan dopamine ontstaat - speelt een 
belangrijke rol bij het verwerken van beloning (en straf). De onderzoeken in dit proefschrift 
richten zich daarom specifiek op de rol van dopamine in relatie tot verstoorde verwerking 
van beloning (en straf) bij depressie bij de ziekte van Parkinson. Hierbij ligt de focus op drie 
cognitieve domeinen waarbij striataal dopamine een belangrijke rol speelt, namelijk leren, 
besluitvorming en motivatie.   
In hoofdstuk 2 vindt u een overzichtsartikel waarin de diagnostische valkuilen worden 
beschreven die bijdragen aan de onderdiagnostiek en onderbehandeling van depressie 
bij de ziekte van Parkinson. Daarnaast vindt u in dit hoofdstuk praktische tips die helpen 
bij de diagnostiek van depressie bij mensen met de ziekte van Parkinson, een overzicht 
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van de pathofysiologie en een breed spectrum aan behandelopties. Allen met als doel om 
depressie bij de ziekte van Parkinson in de klinische praktijk beter te kunnen herkennen 
en behandelen.
Hoofdstuk 3 en 4 richten zich met name op het domein leren. In hoofdstuk 3 heb ik leren van 
straf en beloning (specifiek reversal learning) en geassocieerde hersenactiviteit onderzocht 
bij patiënten met de ziekte van Parkinson met en zonder (voorgeschiedenis van) depressieve 
klachten. Patiënten werden onderzocht met (ON) en zonder dopaminerge medicijnen (OFF). 
Daarbij heb ik gebruik gemaakt van functionele MRI. Meerdere onderzoeken hebben reeds 
aangetoond dat dopaminerge medicatie de balans tussen leren van beloning versus straf 
verschuift. Dopaminerge medicatie verhoogt de gevoeligheid voor beloning en vermindert de 
gevoeligheid voor straf. Echter, er zijn discrepanties in de literatuur hoe Parkinson patiënten 
leren van beloning versus straf zonder medicatie (OFF). De studie in hoofdstuk 3 toont aan 
dat Parkinson patiënten met een depressie (in de voorgeschiedenis) slechter zijn in het 
leren van beloning (versus straf). Deze verminderde beloningsgevoeligheid gaat gepaard 
met een kleiner verschil in striatale hersenactiviteit in reactie op een onverwachte beloning 
versus een onverwachte straf. Ik zag geen effect van dopaminerge medicatie. Deze studie 
toont daarmee aan dat slechter leren van beloning (versus straf) en geassocieerde striatale 
hersenactiviteit bij patiënten met de ziekte van Parkinson afhangt van de aanwezigheid 
van (een voorgeschiedenis van) depressieve klachten. Daarnaast onderstrepen deze 
resultaten het belang van het in ogenschouw nemen van depressieve klachten wanneer 
men onderzoek doet naar leren van beloning (versus straf) bij patiënten met de ziekte van 
Parkinson.
In hoofdstuk 4 heb ik, in een zeer groot cohort van patiënten met de ziekte van Parkinson, 
onderzocht of de associatie tussen de hoeveelheid dopaminerge medicatie en een verstoring 
in reversal learning wordt gemedieerd door de ernst van huidige depressieve klachten. 
Het is bekend dat dopaminerge medicatie cognitieve functies zowel kan verbeteren als 
verslechteren. Volgens de dopamine overdosis hypothese verslechtert dopaminerge 
medicatie met name cognitieve functies die geassocieerd zijn met hersenengebieden met 
nog relatief intacte dopamine levels, zoals het ventrale deel van het striatum. Gedacht wordt 
dat een dopamine tekort in het ventrale striatum bijdraagt aan het ontstaan van depressieve 
klachten bij de ziekte van Parkinson. Op basis hiervan veronderstelde ik dat een dopamine-
geinduceerde verslechtering in reversal learning, een taak waarbij ventraal striataal 
dopamine een belangrijke rol speelt, beperkt zou moeten blijven tot niet-depressieve 
patiënten. In lijn met de overdosis hypothese, tonen de resultaten dat een hogere dosis 
dopaminerge medicatie inderdaad geassocieerd is met het maken van meer fouten op 
een reversal learning taak. Echter, in tegenstelling tot onze hypothese, toonde de mediatie 
analyse dat deze associatie juist het sterkste is bij patiënten die het hoogst scoren op een 
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depressieschaal. Hieruit concludeerde ik dat patiënten met de ziekte van Parkinson en een 
actuele depressie, ten opzichte van niet-depressieve patiënten, gevoeliger zijn voor de 
negatieve effecten van hogere doseringen dopaminerge medicatie op reversal learning. 
Deze bevindingen onderstrepen het belang van het stricter monitoren van cognitieve 
bijwerking van dopaminerge medicatie bij depressieve patiënten. 
In hoofdstuk 5 heb ik mijn aandacht verschoven van leren naar besluitvormingsprocessen. 
Dopaminerge medicatie wordt vaak verondersteld risicovol keuzegedrag te vergroten bij 
patiënten met de ziekte van Parkinson. In hoofdstuk 5 heb ik effecten van dopaminerge 
medicatie op risicovol keuzegedrag bij patiënten met de ziekte van Parkinson met en 
zonder (voorgeschiedenis van) depressieve klachten met elkaar vergeleken. Hierbij heb ik 
gebruik gemaakt van een computationeel model om te onderzoeken welke computationele 
mechanismen mogelijk bijdragen aan risicovol keuzegedrag. Het gebruikte model is 
gebaseerd op prospect theorie - een invloedrijke theorie welke ons keuzegedrag beschrijft 
en waarbij het concept verlies aversie een belangrijke rol speelt. Mensen wegen verliezen 
veel zwaarder dan dat ze eenzelfde waardestijging waarderen. De studie in hoofdstuk 
5 toont twee belangrijke observaties. Ten eerste, dopaminerge medicatie verhoogt een 
waarde-onafhankelijke gok bias bij niet depressieve patiënten met de ziekte van Parkinson, 
zoals ook reeds eerder bij gezonde mensen is aangetoond. Met andere woorden, 
dopaminerge medicatie vergroot de neiging om te gokken ongeacht de waarde van de 
gok. En ten tweede, dopaminerge medicatie vermindert verlies aversie in een sterkere 
mate bij Parkinson patiënten met hogere depressiescores. Deze bevinding roept de vraag 
op of een dopamine-geinduceerde vermindering van verlies aversie onderliggend is aan de 
eerder geobserveerde relatie tussen depressie en medicatie-geinduceerde impuls controle 
stoornissen bij patiënten met de ziekte van Parkinson. 
In hoofdstuk 6 heb ik mij gericht op het cognitieve domein motivatie. Specifiek heb ik 
onderzoek gedaan naar de effecten van het vooruitzicht van een beloning (reward 
motivation) op cognitieve controle. Als maat voor cognitieve controle heb ik het switchen 
tussen verschillende cognitieve taken gebruikt. Dit switchen tussen verschillende taken is 
een cognitief proces wat bij de ziekte van Parkinson vaak al vroeg in het beloop van de 
ziekte is aangedaan. In hoofdstuk 6 repliceer ik de eerder gevonden paradoxale bevinding 
van een verhoogd effect van reward motivation op cognitieve controle bij patiënten met de 
ziekte van Parkinson ten opzichte van gezonde proefpersonen. Het vooruitzicht van een 
hoge (versus lage) beloning verbetert het switchen tussen cognitieve taken bij Parkinson 
patiënten, terwijl het vooruitzicht van een hoge (versus lage) beloning het switchen tussen 
cognitieve taken bij gezonde proefpersonen juist lijkt te verslechteren. Ik zag geen effect van 
een depressie diagnose (in de voorgeschiedenis) bij patiënten met de ziekte van Parkinson. 
Deze bevindingen versterken eerder gevonden observaties dat de ziekte van Parkinson 
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gepaard gaat met een verhoogd effect van reward motivation op cognitieve controle en 
onderstreept daarmee de mogelijkheden van het gebruik van reward motivation als strategie 
om cognitieve beperkingen door de ziekte van Parkinson tegen te gaan. 
Samenvattend dragen de onderzoeken in dit proefschrift bij aan een beter begrip van welke 
rol dopamine speelt bij het verwerken van beloning (en straf) op verschillende cognitieve 
domeinen in relatie tot depressie bij de ziekte van Parkinson. Verder onderzoek zal nodig 
zijn om depressie bij Parkinson uiteindelijk volledig te begrijpen en hopelijk daarmee beter 
te kunnen behandelen. 
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stage en dat het zo ontzettend goed klikte. Ik wil je ontzettend bedanken voor alle gezellige 
momenten die we samen hebben gehad. Katrien, het begon allemaal met een broek op de 
middelbare school. En wat hebben we nadien veel mooie momenten meegemaakt, onze 
studententijd, vakanties, etc. Ik ben blij dat we, na een periode van wat minder contact, 
elkaar nu weer regelmatig zien. Eugenie, alweer meer dan 20 jaar geleden leerden wij 
elkaar op de atletiekbaan in Apeldoorn kennen. Vele jaren later kan ik wel zeggen dat er van 
daaruit een echt bijzondere en waardevolle vriendschap is ontstaan. Ontzettend bedankt 
dat je altijd voor me klaar staat, voor je luisterende oor en je nuchtere kijk op de dingen. Ik 
ben blij dat je als paranimf naast me staat op deze bijzondere dag. 
Mijn familie
Lieve Christiaan, ik ben blij dat jij mijn grote broer bent! Lieve Frank, als kleine broertje heb 
je mij altijd graag geplaagd en dat doe je nog steeds. Nu plaag ik je even terug, bedankt 
dat je mijn kleine broertje bent! Lieve Nienke, het is fijn om jou als schoonzus te hebben. 
Bedankt voor je enthousiasme en gezelligheid, en ook een goed gesprek op zijn tijd. Mijn 
lieve nichtje Marlou en mijn pas geboren neefje Fynn, wat een boel vrolijkheid en plezier 
brengen jullie onze familie! 
Lieve pap en mam, jullie staan altijd voor me klaar. Bedankt voor jullie onvoorwaardelijke 
liefde en steun! 
Lieve Ewout, ik ben nog steeds iedere dag dankbaar dat ik jou heb mogen ontmoeten. 
Bedankt dat je bent wie je bent en dat je altijd voor me klaar staat. Voor alle liefde en rust 
die je me brengt. Ik hoop dat we nog lang samen mogen genieten. Enne, had ik al een keer 
gezegd dat ik van je hou?
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About the author
Monique Timmer was born on January 30th 1982 in Apeldoorn, the Netherlands. After 
finishing pre-university school cum laude (De Heemgaard, Apeldoorn), she studied medicine 
at the Utrecht University, Utrecht, the Netherlands. During her final clinical internship at the 
Geriatrics department, she first came into contact with patients with Parkinson’s disease 
and cognitive complaints. This was where here interest in this complex disease was 
triggered. After finishing her medical training, she decided that neurology, with a focus on 
neurodegenerative diseases, was the specialization that suited her best. In 2008 she started 
her neurology training at the Radboud UMC, Nijmegen, the Netherlands. In 2011 she met 
Prof. Roshan Cools who was at that time working on a grant application together with Dr. 
Rianne Esselink, neurologist at the Radboud UMC, to investigate cognition and depression in 
Parkinson’s disease. This topic immediately fascinated her and by the end of 2011 she started 
as a PhD student in Prof. Roshan Cools group at the Donders Institute for Brain, Cognition 
and Behaviour in Nijmegen, where she investigated the neurocognitive mechanisms of 
depression in Parkinson’s disease. The results of this research are reported in this thesis. 
During her PhD, she combined research with her neurology training. After finishing her 
neurology training in 2016, she started a two-year clinical fellowship in movement disorders 
at the Radboud UMC. Since October 2018 she is working as a neurologist at the Radboud 
UMC and Parkinson Centre Nijmegen.  
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 210
05
Appendix
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 211
Donders Graduate School
for Cognitive Neuroscience
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 212
529302-L-sub01-bw-Timmer
Processed on: 4-3-2019 PDF page: 213
Donders Graduate School for Cognitive Neuroscience
213
A
Donders Graduate School
for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established 
the Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially 
recognised as a national graduate school in 2009. The Graduate School covers training at 
both Master’s and PhD level and provides an excellent educational context fully aligned with 
the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in biology, 
physics, psycholinguistics, psychology, behavioral science, medicine and related disciplines. 
Selective admission and assessment centers guarantee the enrolment of the best and most 
motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.
Positions outside academia spread among the following sectors: 
- specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology,
- specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, 
- higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of research 
and development. Fewer graduates stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT sector 
and management position in pharmaceutical industry. In general, the PhDs graduates almost 
invariably continue with high-quality positions that play an important role in our knowledge 
economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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